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Abstract 
The biopharmaceutical market shows a high annual growth, and the major contributors for this 
success are antibody molecules. The purification of high added value biological molecules is an 
important step in the manufacturing process of any biopharmaceutical, being currently focused on 
packed-bed chromatography, which does not cope with the high titers and working volumes obtained 
upstream. A new trend in downstream processing explores Anything But Chromatography (ABC) 
methodologies, including precipitation and crystallization techniques, as well as magnetic fishing. 
This work aims at developing a new ABC method - magnetic precipitation - which combines 
crystallization and affinity magnetic separation in a single step providing simultaneous protein 
purification and concentration.  
Firstly, the potential of small synthetic affinity ligands for protein capture was shown with the 
development of an affinity chromatographic adsorbent for human serum albumin capture. Secondly, 
the potential of affinity magnetic fishing in protein capture from complex mixtures was shown with 
affinity-functionalized magnetic particles targeting hen egg white lysozyme and antibodies from 
complex media, such as human serum plasma. As a first step to further investigate the potential of 
combining affinity magnetic particles in other ABC processes, we studied the influence of these 
particles in protein crystal growth as nucleation agents. As a proof-of-concept, functionalized and 
non-functionalized magnetic particles were used as additives in protein crystallization. A rational 
design for magnetic particles functionalization was achieved, having magnetic particles functionalized 
with affinity-triggering molecules for the crystallization of the target proteins - hen egg white lysozyme, 
bovine trypsin and green fluorescent protein from Aequorea victoria. The presence of functionalized 
magnetic particles did not hamper crystal growth nor the resolution of the diffracting crystal. The new 
magnetic crystallization method can overcome some protein crystallization difficulties, but also has 
the potential to be integrated in protein purification methods involving crystallization/precipitation 
steps. Finally, crystallization and magnetic fishing methods were used in synergy for antibody 
purification. A screening of precipitation conditions in the presence of magnetic particles 
functionalized with an affinity ligand for antibodies were tested against human plasma and 
mammalian cells supernatant. Affinity driven magnetic precipitation enabled crude extract 
fractionation and antibody recovery in the elution fraction with high purity and recovery yield, up to 
99% and 97%, respectively. 
This work shows the development of a new method using crystallization and magnetic particles - 
magnetic precipitation, with the potential implications to be implemented and integrated as a platform 
to improve protein crystal for X-ray diffraction or as a step in a protein’s purification pipeline. 
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Resumo 
O mercado biofarmacêutico apresenta um dos maiores crescimentos anuais, e os principais 
contribuintes para esse sucesso são as moléculas de anticorpos. A purificação de moléculas 
biológicas de alto valor de mercado é uma etapa importante no processo de produção de qualquer 
biofarmacêutico, sendo a sua purificação atualmente focada na cromatografia em coluna, que não 
consegue trabalhar com as elevadas concentrações e volumes obtidos a montante no processo de 
produção de biofármacos. Uma nova tendência no processo de purificação de biofármacos explora 
as metodologias Tudo Exceto Cromatografia (TEC), incluindo técnicas de precipitação e 
cristalização, bem como a captura magnética. 
Este trabalho tem como objetivo desenvolver um novo método TEC combinando 
cristalização/precipitação e captura magnética por afinidade - precipitação magnética - 
proporcionando simultaneamente purificação e concentração de proteínas. 
Em primeiro lugar, foi demonstrado o potencial da utilização de ligandos de afinidade sintéticos 
com o desenvolvimento de um adsorvente cromatográfico de afinidade para captura de albumina 
soro humano. Em segundo lugar, foi demonstrado o potencial de partículas magnéticas 
funcionalizados com um ligando de afinidade para capturar lisozima de clara de ovo e anticorpos de 
uma mistura proteica complexa, como plasma de soro humano. Como primeiro passo para investigar 
o potencial de combinar partículas magnéticas de afinidade em outros processos TEC, estudamos a 
influência destas partículas no crescimento de cristais de proteínas, como agentes de nucleação. 
Como prova de conceito, partículas magnéticas funcionalizadas e não funcionalizadas foram 
utilizadas como aditivos na cristalização proteínas. O design racional da funcionalização das 
partículas magnéticas foi conseguido, tendo as partículas funcionalizadas moléculas com afinidade 
para as proteínas alvo – lisozima de clara do ovo de galinha, tripsina bovina e proteína fluorescente 
verde de Aequorea victoria. A presença de partículas magnéticas funcionalizadas não afetou a 
cristalização das proteínas nem a prejudicou a resolução de difração do cristal. O novo método de 
cristalização magnética pode permitir a possibilidade de superar algumas dificuldades de 
cristalização de proteínas, mas também tem o potencial de ser integrado em métodos de purificação 
de proteínas que envolvam etapas de cristalização / precipitação.  
Finalmente, a cristalização e separação magnética foram dois métodos explorados em sinergia 
para purificação de anticorpos. Uma triagem das condições de precipitação na presença de 
partículas magnéticas funcionalizados com um ligante de afinidade para anticorpos foi testada contra 
o plasma humano e o sobrenadante de células de mamífero. A precipitação magnética acionada por 
afinidade permitiu o fracionamento do extrato bruto e a recuperação de anticorpos na fração de 
eluição com alto grau de pureza e rendimento, até 99% e 97%, respetivamente. 
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Neste trabalho, o desenvolvimento de um novo método - precipitação magnética tem potenciais 
implicações não apenas como um processo de purificação integrado, mas também como uma 
ferramenta para determinação da estrutura tridimensional de proteínas por cristalografia de raios-X. 
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Background and objectives 
The biopharmaceutical market is the sector of the pharmaceutical industry with the higher growth 
for the past years and it is forecasted to continue its growth for the next five years. In 2018 the 
pharmaceutical market represented $865 billion, of those $219 billion corresponded to the 
biopharmaceutical market [1]. By 2017 more than 50% of the top 10 blockbuster pharmaceuticals 
(more than $1 billion of revenue) corresponded to biopharmaceuticals comprising monoclonal 
antibodies, vaccines and insulin [2]. Monoclonal antibodies (mAbs) represent the greater revenue 
source in the biopharma sector, with 68 mAbs available corresponding to $123 billion of the 
biopharma market [2].  
Since the first biopharmaceutical – Humulin, approved in 1982 – several developments have been 
achieved in the upstream development (e.g. cell line and media upgrading) to improve product titer 
and quality, as well as to increase the production scale [3]. Nonetheless, the downstream processing 
of the biological pharmaceuticals was not able to keep up with the upstream developments, and it is 
currently considered to be the bottleneck in biopharmaceuticals production. Currently, the standard 
methods in downstream process for the purification of biological products are chromatographic 
techniques, mainly affinity chromatography. However, chromatography techniques represent a 
drawback in terms of process scalability and is many times associated with high costs [4].  
New approaches rely in Anything But Chromatography (ABC) methodologies, which include 
magnetic separation, membrane processes, liquid-liquid extraction, precipitation and crystallization 
techniques. ABC techniques aim to overcome some drawbacks of the already implemented 
chromatographic techniques. Such drawbacks come from the process scalability and inability to cope 
with high volumes, since the costs associated with chromatographic techniques scale with the 
upstream volume (e.g. protein A affinity resin: 5000-14,000 €/L resin). ABC techniques are generally 
associated with lower costs (e.g. crystallization/precipitation process:15-140 €/L precipitant) [5].  
From the ABC technologies, crystallization/precipitation has attracted a significant attention in the 
development of downstream processes. These techniques are currently being developed for protein 
purification once they are linked to low operation costs, can cope with the process scales and titers 
in the upstream and comply with the single-use technologies [6,7]. The use of ABC technologies to 
purify proteins with therapeutic market value is already implemented in the downstream train of 
proteins such as insulin (crystallization) [8], human serum albumin [9] or erythropoietin (precipitation) 
[10]. Crystallization, due to its characteristics, is successfully used as a polishing step, to improve 
both protein purity and concentration. As for precipitation, it can be used in an initial purification step, 
to precipitate the target protein or contaminants, or as a final step to further protein purification and 
concentration. 
Currently, crystallization is a challenging technique and research on its application in the 
purification of other high added value proteins, such as mAbs, has been conducted [11]. 
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Concomitantly, magnetic separation has shown potential to be used as an alternative to the traditional 
separation techniques [12]. Furthermore, magnetic separation has been successfully integrated in 
aqueous-two phase systems improving the process performance in terms of protein purity and final 
yield [13]. Implementing the crystallization or precipitation step in any process requires the high-
throughput screening with different combination of precipitants, salts and/or polymers at different 
conditions (e.g. temperature and pH), followed by its scale-up and optimization. For protein 
purification process development, the great impact and innovation comes from the possibility of 
adding additives to the precipitant conditions.  
This PhD thesis aimed to develop a new crystallization method using magnetic particles. The new 
method, named as “Magnetic Precipitation”, finds potential applications as a platform to improve 
crystal quality for X-ray diffraction or as a step in the final protein purification pipeline. The great 
novelty in this work is the combination of the crystallization concept with magnetic particles, that are 
coated and functionalized in a tailor-made fashion towards the protein of interest. 
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Abstract  
The current chromatographic approaches used in protein purification are not keeping pace with the 
increasing biopharmaceutical market demand. With the upstream improvements, the bottleneck shifted 
towards the downstream process. New approaches rely in Anything But Chromatography (ABC) 
methodologies and revisiting former techniques with a bioprocess perspective. Protein crystallization and 
precipitation methods are already implemented in the downstream process of diverse therapeutic biological 
macromolecules, overcoming the current chromatographic bottlenecks. Promising work is being developed 
in order to implement crystallization and precipitation in the purification pipeline of high value therapeutic 
molecules. This review focuses in the role of these two methodologies in current industrial purification 
processes and highlights their potential implementation in the purification pipeline of high value therapeutic 
molecules, overcoming chromatographic holdups. 
 
1.1. The new trend: anything but chromatography 
Recent developments in more efficient fermentation and cell culture technologies led to an improvement 
in biopharmaceutical product titers from an average of 0.2 g/L in 1985 to 2.56 g/L in 2014, although 
monoclonal antibodies (mAbs) titers can reach 27 g/L [3]. This improvement in the upstream of 
biopharmaceuticals production led to a shift in the manufacturing bottleneck towards the downstream 
processing (DSP), which can weight up to 70% of the total production costs [4]. Currently, DSP face several 
challenges, namely the need to (i) deal with the high upstream titers and production volumes, (ii) accomplish 
high purities and yields with a reduced number of unit operations through process integration and 
intensification and (iii) comply with the trend of single-use technology DSP [6,7]. 
For biopharmaceutical products with high added value, DSP design aims to achieve high quality, 
concentration, productivity and yield. DSP trains of biological products usually comprises four main steps: 
recovery, isolation, capture and polishing [4]. The capture and polishing steps are frequently based on 
chromatographic operations with high costs associated with resin price (e.g. 5,000-14,000 €/L [5]) and 
operation costs (e.g. high buffer consumption of 300,000-2,000,000 L/batch). The development of new and 
more efficient upstream processes, leading to higher protein titers, constrains the chromatographic process 
of the capturing step [14]. As a result, new approaches to DSP design are being considered, due to the high 
costs associated. High-throughput (HTP) screenings are used in combination with statistically planned 
experiments (Design of Experiments, DoE) to recognize the influence of different factors, thus narrowing 
down the experimental conditions to be tested. In addition, Quality by Design (QbD) can also be 
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implemented with HTP or DoE [15,16], combining in this way the manufacturing process with product quality, 
while improving process robustness and productivity. 
Considering mAbs DSP, the conserved domains of mAbs led many companies to define a general 
purification process based on a common sequence of unit operations. The heart of the process is the protein 
A chromatography capture step usually followed by two polishing steps composed by ion exchange 
chromatography. Although stable, reliable, and reproducible, protein A chromatography is considered to be 
a productivity bottleneck, requiring several cycles per batch (e.g.1-8 cycles/batch mAb [5]), and being 
particularly expensive. In order to overcome the limitations demonstrated by chromatography such as high 
resin cost, diffusion and capacity limitations, new approaches based on Anything but Chromatography 
(ABC) methodologies are gaining increasing interest [17,18]. Currently, new trends in non-chromatographic 
methodologies for DSP include membrane processes [19], liquid – liquid phase extraction [20], magnetic 
separation [12,21,22], precipitation and crystallization [23]. Non-chromatographic methods aim to reduce or 
even replace chromatographic operations in the purification pipeline, which tends to be hampered by the 
already implemented chromatographic methods that can achieve high yields and purity, despite its 
disadvantages. On the other hand, non-chromatographic methods can cope with the high titers and volume 
feed produced upstream. Within the pool of non-chromatographic methods available, precipitation is being 
applied to the purification of some biopharmaceuticals [24–26], and protein crystallization is a new and 
challenging method that can overcome the current chromatographic challenges [27,28]. Although 
crystallization and precipitation are currently being used for the purification of commercially available 
proteins, such as ovalbumin [29], lipase [30], elastase [31], protease I and II [32] and lactose [33] as revised 
by Miranda et al., 2009, these are still not widely implemented in the industrial biopharmaceutical sector 
despite their potential [35]. 
 
1.2. Understanding protein precipitation and crystallization 
Protein precipitation is based on the premises that a homogenous protein solution is only homogeneous 
up to a certain protein concentration from which a new phase, corresponding to the precipitate formation, 
starts to appear. By changing the environmental conditions, one expects to exceed the protein solubility 
limit, leading to the formation of the new solid phase. Protein crystallization is a form of precipitation in which 
the precipitate is formed in an ordered manner. Protein precipitation is mostly used for low value products. 
However, due to its advantages in DSP, research has been conducted towards high value products, such 
as therapeutic proteins in the biopharmaceutical industry. 
Protein precipitation depends on the solubility of a protein in an aqueous media, which is deeply related 
with the distribution of the hydrophobic and hydrophilic amino acid residues at the protein surface [36]. In a 
time where proteins were considered as colloids, the first protein precipitation experiments were carried by 
Antoine Fourcroy in circa 1789. By this time, Fourcroy was able to precipitate gelatin by boiling various 
Chapter 1: The role of crystallization and precipitation in biopharmaceuticals purification 
- 29 - 
animal by-products and albumin from egg white, blood serum and milk casein by heating, acid or alkaline 
precipitation [37]. The following studies focused on proteins that could be obtained in large quantities, 
namely from blood and egg white. The first studies using precipitation as a means for protein purification 
were developed by Edwin Joseph Cohn during World War II (1939 – 1945). He became famous for the 
separation of blood components by fractional precipitation. The Cohn fractionation process aimed at 
obtaining albumin to be administered to soldiers with blood loss, starting from blood plasma and taking 
advantage of the different solubility among the different plasma proteins [38]. This also showed that a protein 
purified by precipitation had biological activity. Since its discovery, protein precipitation has been used in 
proteins DSP, for purification and concentration purposes [39,40].  
With the development of single-crystal X-ray crystallography, the crystallization of macromolecules 
became one of the most common methods to determine protein structures and understand fundamental 
biochemical pathways or even design new drugs. However, by the time the first protein was crystallized, in 
the first half of the 19th century, crystallization was applied as a purification and biophysical characterization 
method [41,42]. Nonetheless, the interest in crystallization from a purification point of view increased due to 
the low costs associated, the ability to cope with high volumes, and with high concentrations of the target 
molecule. In addition, crystallization in the DSP of biopharmaceuticals has the ability to integrate protein 
purification, stabilization and concentration in one single step. 
Macromolecular crystallization can be performed by four different methods, namely vapor diffusion, 
microbatch, dialysis and free interface diffusion. In the vapor diffusion the protein sample is set to equilibrate 
with a reservoir solution that contains similar precipitant and buffer solution at a higher concentration. In 
batch crystallization, the supersaturated protein sample is mixed with the precipitants in the same mixture 
and then placed in a mineral oil of branched alkanes in the C20+ range allowing little to none water diffusion, 
in this way enabling a controlled evaporation. Crystallization by dialysis, makes use of dialysis membranes 
where ions can pass but not proteins or polymers, in this way slowly supersaturating the protein solution 
leading to crystal formation [43]. Free interface diffusion relies on carefully placing the precipitant solution 
on top of the protein solution in a capillary. Due to the narrow diameter of the capillary, the precipitant and 
protein will slowly inter-diffuse until equilibrium is reached, leading to protein supersaturation [44]. 
Although a rational approach might be drawn the fact is that both precipitation and crystallization 
experiments have a rather empirical design, mainly due to the complexity of the occurring phenomena [45]. 
Currently, there is no comprehensive theory behind the process in order to guide the experimental design. 
Furthermore, the wide range of macromolecules possible to crystallize enhances the complexity of the 
crystallization design. The guidelines for macromolecular crystallization involve a systematic search, 
changing individual parameters that can influence the crystallization process. Once found the set or multiple 
sets of parameters that yield the best precipitate/crystal outcome, an optimization can be performed to 
obtain the best possible crystals, which for crystallography purposes correspond to single, edge-shaped 
crystals.  
Nonetheless, some theories have been proposed to understand protein behavior in an aqueous solution. 
Classical nucleation theory (CNT) aims to calculate the nucleation rate of a particular system, as a 
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theoretical model this is an approximation [46,47]. The phase diagram plots the protein concentration versus 
any adjustable parameter (e.g. temperature, precipitant concentration, salt concentration) (Figure 1.1A). 
These diagrams enlighten the kind of interactions occurring between proteins in a qualitative manner, but 
also in a quantitative way it is possible to recover the enthalpy and entropy values for the protein in the 
aqueous solution [48,49]. 
When designing a crystallization assay it is necessary to know (as well as possible) the target protein 
nature and the interactions which most probably enable crystal formation [11]. Protein nature, i.e. structure 
and amino acid composition, have a great influence in the outcome, e.g. intrinsically disordered proteins 
tend to have more polar or highly charged groups than hydrophobic residues. In addition, a biochemical 
characterization of the target protein also helps designing a target precipitation protocol [50]. Moreover, the 
protein purity and the purification process may also present some challenges if the main goal is X-ray 
diffraction for structure determination [50].  
The variables that have to be considered when designing a crystallization strategy can be divided into 
physical, chemical and biochemical, and range from the precipitant to the environmental vibrations [51]. In 
general, protein concentration, temperature or temperature variation, precipitant concentration, the 
presence/absence of ligands and the salt/buffer used play a greater role than gravity, viscosity or 
electric/magnetic field. 
Ion-ion, ion-dipole, dipole-dipole, salt-bridge, hydrogen bonding, and hydrophobic interactions contribute 
all together to protein stability [36]. Dipolar substances, as water, will compete with dipolar interactions; ions 
may disrupt ionic interactions, hydrophobic substances will seek for the hydrophobic core. The sum of all 
medium modifications, when maintained constant, will lead to a protein rearrangement into a stable 
conformation. Variations of temperature, pH, salt concentration, presence of organic solvents and polymers 
can trigger precipitation processes. For example, a rise in temperature favors the formation of hydrophobic 
interactions at the same time as it weakens dipolar interactions; a decrease in temperature leads to the 
opposite effect. Meanwhile when a protein surface does not have net charge - at its isoelectric point – it 
presents the least surface hydration, with the minimum solubility while in the nondenatured form. It should 
be noted that minimum solubility is not synonymous of insolubility/precipitation, as precipitation requires 
additional perturbations. The addition of salt also plays an important role in protein 
precipitation/crystallization. Along the years, protein precipitation/crystallization appear to follow the 
Hofmeister series [52]. This series ranks the ions according to their relative effect on protein solubility and 
structure stability in an aqueous system [53]. In general, the effect of anions is more pronounced than that 
of cations. The Hofmeister anion series is as follows [53,54]: 
CO32-> SO42- > S2O32- > H2PO4- > F- > Cl- > Br- ~ NO3- > I- > ClO4- > SCN- 
To the left of Cl-, are located the kosmotropic anions, on the other side to the right are the chaotropic anions 
[52,53]. Kosmotrope species are referred to as ‘water structure makers’ for strengthening bulk water 
hydrogen bonding network, these species also stabilize and have a salting-out effect on proteins. On the 
other hand, chaotropic species are cited as ‘water structure breakers’ by weakening the bulk water hydrogen 
bonding network, unlike kosmotropes, chaotropes destabilize and tend to unfold proteins leading to a 
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salting-in effect [52–54]. The concentration of salt used will vary according to the protein under study and 
its surface net charge, size and shape. Organic solvents such as methanol, butanol, ethanol and acetone, 
are commonly used in precipitation studies, all containing both hydrophilic and polar domains. While the 
polar groups compete with water to interact with the protein polar groups, the hydrophobic domains disrupt 
intramolecular interactions, resulting in a solubility decrease triggering protein precipitation. Once again, the 
concentration of the organic solvent will vary according to the protein under study, as for salt precipitation. 
Nonetheless, the use of organic solvents for protein precipitation might lead to protein denaturation; in 
alternative, different polymers can be used. Polymers are frequently used in protein precipitation, the most 
commonly used being polyethylene glycol (PEG), usually 20% (w/v) of PEG with molecular weights greater 
than 4000 Da due to the higher efficacy. In solution, PEG not only attracts water molecules from the protein 
surface [55], but also has an effect in sterically exclude proteins from its hydrodynamic volume [56,57], 
enhancing protein-protein interactions leading to protein precipitation. Although limited by the availability 
and stability of the target protein, different combination of precipitants can be used in an initial screening 
[58,59]. Nowadays, different screenings have been developed and are commercially available (e.g. 
JBScreen Wizard from Jena Bioscience) and some can be developed in-house, usually by macromolecular 
crystallography research labs.  
In biologics DSP, precipitation is presented as an alternative to the current chromatographic methods. 
Precipitation protocols have a low cost associated, and can be performed with high protein titers and 
volume. Moreover, precipitation is a scalable technique proportional to the process volume, regardless of 
its titer, as opposed to the current chromatographic methods that scale stoichiometrically with the reaction 
between molecules in solution, i.e. titer dependent [60]. Currently, precipitation can be performed in batch, 
tubular and continuous stirred tank reactors, giving flexibility to the pharmaceutical industry regarding the 
working mode (batch or continuous) [24,61,62].  
Precipitation conditions can be rationalized according to the interactions predicted to occur between the 
target and the precipitant. However, in many cases the theory cannot be translated into practice, making 
this an intrinsic empirical process due to the great amount of interactions prone to occur. Nonetheless, this 
makes it possible to selectively target the precipitation of a specific protein. On the other hand, contrary to 
crystallization, a protein may precipitate and lose its activity, therefore it becomes more critical to evaluate 
the biological activity of the final product. 
Introducing crystallization in an industrial environment, requires a crystallizer tank (Figure 1.1B), that in 
the pharmaceutical industry tends to work under batch conditions, and a possible pre-conditioning step (e.g. 
buffer exchange), as previously reported [27,28]. For HTP screening of protein crystallization conditions 
robotic techniques are used, namely Oryx systems (from Douglas Instruments, Ltd), mosquito systems (from 
TTP Labtech), Rock Maker systems (from Formulatrix) or Cobra or Phoenix Liquid Handling System (both 
from Art Robbins Instruments). 
Nevertheless, crystallization conditions are established empirically and are not standard for proteins of 
the same family, which is considered a drawback in industry. Although the same interactions (e.g. 
hydrophobic, electrostatic) are known to play an important role in protein crystallization by promoting the 
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correct fold [63] and preserving the protein structure and function [64], the intricacy of all the interactions 
occurring in the crystallization phenomena is such that the behavior of each protein has to be considered 
by itself. On the other hand, this singularity can be advantageous when purifying a macromolecule - 
considering the specificity of the crystallographic conditions for a single protein, it would be beneficial to 








1.3. Established purification processes  
Crystallization and precipitation are two-unit operation implemented in the purification pipeline of some 
therapeutic proteins, due to their advantages comparing with traditional DSP unit operations (e.g. 
chromatography). Crystallization was the first to the employed in insulin purification, while precipitation 
methods are used for the purification of human serum albumin and erythropoietin.  
1.3.1. Insulin 
Insulin is a peptide hormone produced and stored in the pancreas by β-cells as an inactive hexamer, 
active only when in its monomer forms (5.8 kDa) [65]. This hormone is responsible for the uptake of glucose 
from the blood stream, regulating the carbohydrate and lipid metabolisms, and preventing the liver from 
producing glucose. Insulin in administered to patients with diabetes mellitus, a metabolic condition that leads 
 Figure 1.1. (A) Qualitative illustration of a protein crystallization phase diagram. The major paths to 
reach protein crystallization are represented for the four main crystallization methods: (a) microbatch, 
(b) vapor diffusion, (c) dialysis and (d) free interface diffusion. The solubility curve is defined as the 
equilibrium between crystals and protein in the solute at a certain concentration. The supersolubility 
curve separates the condition from which nucleation or precipitation spontaneously occur. (B)
Industrial insulin crystallizer from GEA Group Aktiengesellschaft, kindly provided by Doctor Nadine 
Gerndorf. 
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to high blood sugar levels from long fasting periods in people affected by this condition. Per year 10 tons of 
insulin are produced, representing a global market of $5 billion [66].  
In the 1920s the source of insulin was animal pancreas, the first patient being injected with bovine 
insulin. The first 3-dimensional structure of insulin was unveiled in 1969 by X-ray crystallography in Dorothy 
Hodgkin's laboratory (PDB file: 1INS) [67]. As enlightened by Scott (1934), it is possible to crystallize insulin 
in conjugation with metal ions as zinc [68]. With that in mind, Petersen (1947) patented insulin purification 
using citrate buffer with two zinc ions per unit cell (0.34% zinc) [69]. However, only in 1969 the first patent 
reporting insulin crystallization from an animal source was filed by Eli Lilly, describing what turned out to be 
the 8.2 process, since the major yield (90-95%) was obtained with the addition of 1 M sodium hydroxide to 
a 0.5 M acetic acid and insulin solution, at pH 8.2. After 15 min, crystallization occurred spontaneously [70]. 
Only by 1978, with the development of recombinant DNA technology, Genentech scientists were able to 
produce human insulin in Escherichia coli cells. This lead to Humulin, the first biopharmaceutical molecule 
produced and commercialized by 1982. Since the first insulin crystallization patent at a liter scale, the 
industry evolved to 50,000 liter tanks used nowadays, thus demonstrating the feasibility of integrating 
crystallization in a biopharmaceutical bioprocess. Insulin purification process is represented in Figure 1.2A; 
among the different unit operation is possible to verify that crystallization plays an important role since it is 
introduced for three times in the DSP train. Combining this purification method with recombinant DNA 
technology manufacturers are nowadays able to commercialize the purest insulin formulation, with purity 
higher than 98% [8]. 
1.3.2. Human serum albumin 
Human serum albumin (HSA) is present in the human plasma as a monomer (66 kDa), being the 
most abundant protein in the human plasma at a concentration of 30–50 g/L, and has a serum half-life of 
approximately 20 days [71]. Being the most abundant protein, HSA represents the determining factor in 
maintaining the osmotic pressure exerted by proteins in a blood vessel's plasma (oncotic pressure). In 
addition, due to its ligand binding capacity, HSA has not only the ability to transport (e.g. hormones or fatty 
acids), but also to affect the pharmacokinetics of some drugs increasing the circulation time [72]. HSA is 
also used as a biomarker for different diseases that include cancer, rheumatoid arthritis, ischemia and 
severe acute graft-versus-host disease. As therapeutic agent it is used in treating hypovolemia, shock, 
burns, surgical blood loss, trauma, hemorrhage, acute liver failure, cardiopulmonary bypass, hemodialysis, 
chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia acute respiratory distress 
syndrome [72]. Per year 500 tons of HSA are produced, representing a global market of $1.5 billion [66]. 
In 1940 HSA was first purified by the Cohn fractionation process, for intravenous use as blood 
substitute. In this five step ethanol fractionation process, HSA was recovered in the final fraction with 40% 
ethanol at pH 4.8 [38]. Since then, variations of the Cohn process increased yield and purity. Due to the 
great interest in HSA as a therapeutic agent, many patents regarding its purification have been filed. In 
1979, a patent assigned to Plasmesco AG, reported a purification process inspired in the Cohn method 
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using a heat ethanol/PEG process [9]. In this process a 96% recovery yield and <99% protein purity were 
achieved using 9% (v/v) ethanol, pH 6.5 at 68oC. More recently, in 2014 a patent assigned to GE Healthcare 
Bio-Sciences for plasma proteins fractionation with polyacrylic acid precipitation was issued. In this 
purification scheme, polyacrylic acid precipitation in used as a capture step, prior to the chromatographic 
polishing step, as it is represented in Figure 1.2B. In this case HSA did not precipitate; it was maintained in 
the supernatant, with a recovery yield of 88%. Next, a chromatography step, affinity or ion exchange, was 
performed [73]. 
1.3.3. Erythropoietin 
Erythropoietin, or EPO, is a highly glycosylated protein, it has a molecular weight of 34 kDa and is 
responsible for erythropoiesis in the bone marrow. In the blood, EPO has a half-life of 5 hours [74,75]. As a 
therapeutic agent, it is most commonly used for anemia treatment. EPO is produced by recombinant DNA 
(rDNA) technology, making different pharmaceutical agents with different glycosylation patterns that have 
been approved and are commonly named erythropoiesis-stimulating agents (ESA). Due to these 
modifications, ESA blood half-life may vary from the endogenous EPO, due to an increase in the protein 
stability [75]. Nowadays EPO represents $11 billion of the biopharmaceutical market [76]. 
EPO was first purified by Miyake and co-workers in 1977, in a seven-step purification process, that 
included ethanol precipitation [77]. The overall process consisted of (i) anion exchange chromatography , 
(ii) phenol treatment, (iii) ethanol precipitation, (iv) anion exchange chromatography, (v) cation exchange 
chromatography, (vi) gel filtration and (vii) adsorption chromatography, yielding a final recovery of 21% with 
95% purity [77]. This study enabled further characterization studies, disclosing EPO amino acid sequence 
and coding sequence. In 1985, Lin and co-workers were able to isolate the gene encoding for EPO from a 
genomic phage display library, and produced it in Chinese hamster ovary cells [78]. Later in 1987, Amgen 
conducted a clinical trial using recombinant human EPO in 25 anemic patients with end-stage renal disease 
[79]. With the trade name Epogen, it was approved by the FDA in 1989 and by EMA in 2007. 
The first patent in EPO purification was assigned to Genetics Institute in 1987, with an initial purification 
step by ethanol precipitation, followed by different chromatographic methods [10]. By 2001, a patent 
assigned to Sterrenbeld Biotechnologie North, regards the differential precipitation of contaminant proteins, 
leaving EPO in the supernatant, with 100% recovery yield, followed by a series of chromatographic methods 
for further purification [80]. 
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Figure 1.2. Schematic representation of the unit operations implemented in purification processes including 
crystallization and precipitation. (A) Standard insulin purification. (B) GE Healthcare Bio-Sciences HSA 
polyacrylic acid precipitation. 
 
1.4. Purification processes under development 
Crystallization and precipitation technologies can overcome some bottlenecks of current DSP unit 
operations, namely the capability to work with high process volume and protein titers. Several efforts are 
being made to evaluate their potential in replacing standard purification techniques. Currently, the use of 
crystallization for Apo2L purification is under development. At the same time, the development of both 
crystallization and precipitation techniques for mAbs purification is being intensively studied.  
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1.4.1. Apo2L  
Apo2 ligand or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL), 
belongs to the TNF superfamily. The human full length of this transmembrane protein is composed of 281 
amino acids and folds as a type II transmembrane protein, being a single-span transmembrane protein with 
the C-terminal exposed to the extracellular space [81,82]. The recombinant human soluble Apo2L/TRAIL, 
consisting of the TNF-homologous portion of the extracellular domain of the full length Apo2L/TRAIL protein, 
is a 168 amino acid polypeptide with 19.6 kDa [83]. Apo2L has a potential apoptotic function, identified in 
various cancer cell lines, but no apoptotic function was yet associated in non-cancer cells [82,83]. Therefore, 
Apo2L has the potential to act as a tumor repressor in tumor patients.  
The first Apo2L structure was disclosed in 1999 by X-ray crystallography (PDB file: 1D4V, [81]). The 
small scale crystals were produced using 25% ethylene glycol with 0.1% n-octyl-β-glucoside by vapor 
diffusion [81]. With great potential to be used as a tumor repressing agent, and with the capability to be 
crystallized, in 2010 Genentech patented a new purification process for Apo2L. The crystallization was 
performed after a cation exchange chromatography. The eluted fraction of Apo2L, in low ionic strength 
solution (100 mM - 200 mM NaCl or Na2SO4) was cooled down to 4oC enabling spontaneous crystallization. 
The crystallization occurs with or without anti-solvents (PEG, ethanol, isopropanol, dioxane or methyl 
pentanediol). In both conditions, the protein purity reported is at least 99% with 95% recovery yield [84]. 
1.4.2. mAbs 
Due to their antibody-antigen interaction, mAbs are broadly employed as therapeutic agents, as 
diagnostic tools for in vivo and in vitro analysis, as well as in affinity purification processes [85,86]. As 
therapeutic agents, mAbs are mostly used in oncology and immune disorders, however they are also 
prescribed for infectious, neovascular, haemostasis and host-to-graft diseases [87]. Although different mAbs 
present a high degree of homology, the conserved domains of mAbs led many companies to define a 
general purification process based on a common sequence of unit operations, where the protein A 
chromatography capture step is central (Figure 1.3A) [88]. Even though stable, reliable, and reproducible, 
this methodology is considered to be a productivity bottleneck and especially expensive. The bottlenecks 
associated with protein A chromatography regard low elution pH (2-3) which may lead to ligand leaching 
and mAb precipitation. Since this is a chromatographic method, it is not able to deal with high process titers 
(e.g. 10 g/L) or high volumes. In addition the chromatographic process is performed under low flow-rates. 
On the other hand, this is a stable, reliable, and reproducible method that despite its disadvantages, 
continues to be preferred over other commercially available options due to the high purification achieved, 
great versatility and process standardization. 
Even though currently mAbs crystallization is not yet a common and implemented procedure, the 
hope is that this approach can overcome some of the chromatography bottlenecks (Figure 1.3B and C). In 
order to create a rational approach, several studies try to enlighten mAbs behavior under crystallization 
conditions. In Table 1.1 a summary of the works reported so far in the literature for mAbs purification through 
Chapter 1: The role of crystallization and precipitation in biopharmaceuticals purification 
- 37 - 
crystallization and precipitation were assembled. A systematic analysis of data available for mAb 
crystallization conditions, led to conclude that PEG is a common precipitating agent for crystallization at 
room temperature ) [27,60,64,89,90]. The work of Zang and co-workers [27], first demonstrated the 
feasibility of having a crystallization step in the downstream process of mAbs at a μl scale. In this study, 
IgG4 crude extract was purified by protein A chromatography and dialyzed for buffer exchange with 20 mM 
Tris buffer pH 7.0 before the crystallization step. As precipitant solution, 5% (w/v) PEG 8000, 0.2 M 
Ca(OAc)2, 0.1 M imidazole at pH 7.0 was used and  crystals were obtained after 5 days at room temperature. 
After mAb IgG4 solubilization, the final solution showed 90% of protein purity and 31.3% recovery yield. 
Following this study, Smejkal and co-workers in 2013 [28] were able to crystallize an IgG1 in 1 hour using 
5 mM histidine/acetate buffer, 10 mM NaCl, Tris-base up to pH 6.8 at 4oC. Here, a scale-up from μl to L in 
batch conditions was successfully accomplished, with a final protein purity of 96.9% and 90% recovery yield.  
Albeit precipitation is not a conventional purification step in mAbs DSP, precipitation methods are 
regarded as alternatives. Recent studies show the feasibility of using precipitation as a mAb purification 
method, resulting in a highly pure and concentrated active protein [24,61,62,91]. For example, CaCl2/cold 
ethanol precipitation has attracted attention as it can be performed in a simple equipment as stirred tanks 
and centrifuges. A study from Jungbauer group, demonstrated the possibility of mAb precipitation from 
mammalian cell supernatant with 78% recovery yield and >99% protein purity [61]. A more recent study, 
improved CaCl2/cold ethanol precipitation in a continuous tubular reactor achieving 92% recovery yield [24]. 
As in crystallization, also PEG-based precipitation systems are frequently tested with mAbs. Application of 
high-throughput screening to a rapid identification and selection of PEG precipitation conditions using only 
µl volumes of protein is usually the initial approach in these studies, since it enables a rapid selection from 
a wide range of different conditions [92]. A comparison between batch and continuous PEG precipitation, 
demonstrated that both methods lead to >90% recovery yield and >96% protein purity without changes in 
mAbs secondary structure [62]. Combination of CaCl2/PEG precipitation for direct mAb purification from the 
cell culture supernatant can also be used. The CaCl2 precipitation promotes the high molecular weight 
contaminates to precipitate, while PEG precipitation was used for mAb capture [24]. This method allowed 
80-96% recovery yield. Additionally, the use of linear or branched PEG in mAb precipitation was evaluated, 
showing the feasibility of using both for purification purposes with recovery yield greater than 95% [93]. 
Other concept in purification is affinity precipitation. In this system a protein or peptide with affinity 
towards the mAb is placed in the cell culture supernatant and the precipitation of the complex is promoted 
[40,94–96]. In addition, other precipitants had been used in combination with chromatographic methods, as 
polishing steps for impurity removal from the elution fraction of protein A chromatography [97].  
Chapter 1: The role of crystallization and precipitation in biopharmaceuticals purification 
- 38 - 
 
Figure 1.3. Schematic representation of different purification processes for mAbs using chromatographic 
supports or crystallization/precipitation techniques. (A) Standard mAbs purification by chromatographic 
methods. (B) mAbs purification using crystallization/precipitation techniques [27,28]. (C) Aimed purification 
process for mAbs relying on crystallization/precipitation technique. 
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Table 1.1. Summarized review of purification processes under development using crystallization or precipitation as unit operations in mAbs DSP. 
The mAb class and source where it was produced and any pre-treatment used prior to the crystallization or precipitation is discriminated. The protein 
purity and purification yield are described according to the crystallization or precipitation condition used for purification. ND: Not determined. 
MAb 
class Source Purity
1 Yield2 Crystallization/precipitation conditions Ref. 
IgG 4 CHO cell supernatant, dialyzed 90% 31% 5%(w/v) PEG 8000, 0.2M Ca(OAc)2, 0.1M Imidazole, pH 7.0 [27] 
IgG 1 CHO cell supernatant, dialyzed 
93% 88% 
5 mM histidine/acetate buffer, 10mM NaCl, pH 6.8 [28] 
97% 90% 
IgG 1 CHO cell supernatant, protein A purified 90% 96% 250 mM CaCl2, PEG 20000-PEG 2000 [25] 
IgG 1 CHO cell supernatant, partially purified ND >93% 50 mM citrate buffer, pH 6.0 with 15% (w/w) PEG 4000 [60] 
IgG 1 CHO cell supernatant, protein A purified ND 92% 250 mM CaCl2, 25%(v/v) Ethanol [62] 
IgG 1 
CHO cell supernatant 
99% 84% 
Caprylic acid precipitation: 1% caprylic acid in 100 mM sodium citrate pH 4.5 
PEG precipitation: 14% (w/v) 
PEG 6000 pH 7.0 
[91] 
IgG 1 
> 95% 69% 
Caprylic acid precipitation: 1% caprylic acid in 100 mM sodium citrate pH 4.5 
PEG precipitation: 14% (w/v) 
PEG 6000 pH 7.0 
CaCl2 precipitation: 120-150 mM CaCl2, 300 mM Na2HPO4, 4 mM PO43- pH 8.5 
Cold ethanol precipitation: 25% (v/v) ethanol 
> 95% 59% 
CaCl2 precipitation: 120-150 mM CaCl2, 300 mM Na2HPO4, 4 mM PO43- pH 8.5 
Cold ethanol precipitation: 25% (v/v) ethanol CaCl2 precipitation: 120-150 mM CaCl2, 300 
mM Na2HPO4, 4 mM PO43- pH 8.5 
Cold ethanol precipitation: 25% (v/v) ethanol 
IgG 1 CHO cell supernatant, protein A purified 70-90% > 95% 9-10% (w/v) Branched PEG 600 or Linear PEG 4000/PEG 6000 [93] 
1 Ratio between the target protein concentration and protein concentration. 
2 Percentage of purified protein in terms of initial amount of protein. 
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1.5. Concluding remarks and future trends 
The biopharmaceutical sector has the highest estimated growth rate for the next five years. 
Given this scenario, the biopharmaceutical industry will be faced with a higher production demand in the 
near future. Developments in the USP have already been successfully accomplished, shifting the 
bottleneck towards DSP. Although progresses in better performance of cell culture and growth 
conditions should continue to occur, DSP must explore alternative methods. Crystallization and 
precipitation have the great advantage of scaling-up with the process volume, instead of the process 
titers as in chromatography processes. In Table 1.2 a comparison between protein A chromatography 
and crystallization/precipitation in terms of scaling-up and purification criteria were gathered.  
The implementation of protein crystallization or precipitation in purification processes will 
include, the high-throughput screening of different precipitants, polymers and salts, at different 
conditions (e.g. pH and temperature), followed by a scaling-up of the optimized methods. The great 
innovation in this field of purification may arise from the integration of different and new additives 
enhancing the crystallization efficiency and decreasing the process time [58,59] or the integration of 
affinity molecules to target the biopharmaceutical and promote its selective precipitation [94,95].  
Crystallization and precipitation are two-unit operations already implemented in the downstream 
pipeline of therapeutic proteins. Indeed, crystallization is successfully used as a final polishing step, 
enabling at the same time greater protein purity and concentration [70]. On the other hand, precipitation 
can be performed as an initial capture step, either precipitating the target protein or contaminants, or as 
a final purification and concentration step [73,80].  
In order to be considered as alternatives to the current and well implemented chromatographic 
steps in therapeutic protein purification, a method has to be able to handle high volume and protein titer, 
be scalable, and economically viable at an industrial scale. In this regard, both techniques are able to 
cope with the biopharmaceutical industry demands.  
 
Table 1.2. Comparison between protein A chromatography and crystallization/precipitation unit 
operation in mAbs DSP regarding scaling-up and purification criteria. 
 Protein A chromatography Crystallization/Precipitation 
Capacity 40-60 g IgG/L resin Up to 150 g IgG/L precipitant 
Scale-up Process volume Stoichiometrically 
Cost 5,000-14,000 €/L resin 15-140 €/L precipitant 
Yield >95% >90% 
Purity >95% >95% 
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Abstract 
Human serum albumin (HSA) in an important therapeutic agent and disease biomarker, with an 
increasing market demand. By proteins and drugs that bind to HSA as inspiration, a combinatorial library of 
64 triazine-based ligands was rationally designed and screened for HSA binding at physiological conditions. 
Two triazine-based lead ligands (A3A2 and A6A5), presenting more than 50% HSA bound and high 
enrichment factors, were selected for further studies. Binding and elution conditions for HSA purification 
from human plasma were optimized for both ligands. The A6A5 adsorbent yielded a purified HSA sample 
with 98% purity at 100% recovery yield under mild binding and elution conditions. 
 
2.1. Introduction 
Human serum albumin (HSA) is the most abundant protein in the human plasma (30–50 g/l), with a 
serum half-life of approximately 20 days [71]. HSA plays a role in maintaining the osmotic pressure exerted 
by plasma proteins in a blood vessel, and in acting as carrier of several compounds, namely hormones or 
fatty acids. It also behaves as a drug carrier influencing drug pharmacokinetics by increasing the circulation 
time [72]. As a therapeutic agent, HSA is used to treat several conditions such as hypovolemia, shock, 
surgical blood loss and trauma. HSA can also be used as a disease biomarker for cancer or severe acute 
graft-versus-host disease [72]. HSA has an enormous biopharmaceutical potential, and it can be found 
alone [98], fused or in complex with other relevant proteins [99,100]. HSA market is about 15% of the global 
plasma protein market, which reaches over 20$ Billion [101].  
Currently, HSA purification requires multiple unit operation steps, which may include precipitation [73], 
heat-shock fractionation [102], and chromatography (e.g. ion-exchange chromatography and hydrophobic 
interaction chromatography) [103,104]. The first reported HSA purification scheme was the Cohn 
fractionation process in 1940, to produce a blood substitute for patients with blood loss [38]. Nonetheless, 
affinity chromatography is still a method of choice for protein purification. There are several commercially 
available affinity-based resins for HSA capture. The first available resin for HSA purification was the 
Cibacron Blue F3G-A, an adsorbent based on a sulfonated triazine dye [105], which yields heterogeneous 
samples with low purity [106,107]. The use of triazine scaffold, an analogue of the blue dye, attracted 
attention in the late 80´s. It provides an effective strategy to develop novel adsorbents for specific targets 
as they are inexpensive, stable and customized [108,109]. In fact, different triazine based synthetic ligands 
have been so far developed for different targets including immunoglobulins [22,110], insulin [111], and viral 
particles [112].  
In this work, a rationally designed solid-phase combinatorial library based on triazine scaffold was de 
novo designed and assessed for the discovery of new affinity adsorbents towards HSA capture and 
purification.  
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2.2. Materials and methods 
2.2.1. Chemicals 
All used chemicals were at least 98% pure and solvents were pro-analysis grade. The chromatographic 
materials, cross-linked agarose (SepharoseTM CL-6B) acquired from GE Healthcare (Uppsala, Sweden), 
Captiva 96-well filtration block and empty columns (0.8 cm x 6.5 cm) from Agilent Technologies (California, 
USA), 96-well UV-star® half area microplates from Greiner (Kremsmünster, Austria) and 96-well transparent 
microplates flat-bottom from Sarstedt (Nümbrecht, Germany). 
2.2.2. Synthesis of the combinatorial libraries 
For the synthesis of the triazine combinatorial library, SepharoseTM CL-6B was epoxyactivated and 
aminated as described in [113], yielding 20 μmol of epoxy/g of moist agarose. The amine content was 
quantified by the Kaiser test yielding 10 μmol of NH2/g of moist agarose [22]. The combinatorial library 
comprised a total of 64 ligands, each ligand was obtained by nucleophilic substitution of triazine chlorine 
atoms by different amines [109,114]. Every ligand consisted of a different combination of the amines as 
presented in Table 2.1. 
2.2.3. Combinatorial library screening with HSA 
The screening of the combinatorial library started with the regeneration and equilibration of the resins in 
96-well filtration blocks (250 mg of resin/well). Resins were regenerated with 250 μl of regeneration buffer 
(0.1 M NaOH in 30% (v/v) isopropanol) followed by 3 x 750 μl of distillated water per well. The equilibration 
step was conducted by adding 15 x 750 μl of equilibration buffer (10 mM sodium phosphate, 150 mM sodium 
chloride (PBS), pH 7.4) per well, until the absorbance measured at 280 nm was lower than 0.005. Once 
equilibrated, 250 μl of pure 0.25 mg/ml HSA (Sigma-Aldrich) solution in PBS at pH 7.4 or pH 6.0, was loaded 
into each well of the blocks, and incubated for 1 hour at 25 ºC with orbital shaking (200 RPM). The 
functionalized resins were then washed with the corresponding buffer, PBS at pH 7.4 or at pH 6.0 (8 x 250 
μl). Total protein quantification was performed using QuantiProTM BCA assay kit (Sigma-Aldrich) and the 
HSA binding percentage to each adsorbent calculated according to Equation 2.1: 
% Binding (w/w) =
μg HSA bound
μg HSA loaded
×100                   Equation 2.1 
The same procedure was repeated for the re-screening of the most promising ligands. The best ligands 
were re-synthesized and tested for binding to human IgG (hIgG) (product name: Gammanorm®, 
Octapharma) and HSA, both loaded at 0.25 mg/ml in each well and tested in triplicates. For the adsorbents, 
the enrichment factor was calculated according to Equation 2.2: 
Enrichment factor = 
% HSA bound
% hIgG bound
                    Equation 2.2 
Chapter 2: Designed affinity ligands to capture human serum albumin 
- 45 - 
Table 2.1. List of amine compounds used in the triazine library for the solid-phase combinatorial library, with 
the respective chemical name and structure. 
 
2.2.4. On-column binding studies with triazine lead ligands  
Two triazine lead ligands, A3A2 and A6A5, were re-synthesized and 0.5 g of moist functionalized 
agarose (1 ml of 50% (w/v) slurry) was packed into a 3 ml column (0.8 cm x 6.5 cm). The resins were 
regenerated, washed and equilibrated as previously described (see 2.2.3). The equilibration step was 
performed with different binding buffers (Table 2.2): (B1) 10 mM sodium phosphate, 150 mM sodium 
chloride, pH 7.4 at 20-25 ºC, (B2) 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.4 at 0-4 ºC, 
(B3) 10 mM Tris-HCl, 150 mM sodium chloride, pH 8.0, (B4) 50 mM citrate buffer, pH 5.0, (B5) 10 mM Tris-
HCl, 300 mM sodium chloride, pH 8.0 or (B6) 50 mM citrate buffer, 300 mM sodium chloride, pH 5.0. A 0.5 
ml sample of protein solution (0.5 mg/ml HSA or hIgG) in the respective binding buffer was loaded into the 
columns. The flow-through and washes with the corresponding binding buffer (5 x 500 μl) were collected in 
1.5 ml centrifuge tubes under gravitational flow. After screening the resins were washed, regenerated and 
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stored as previously described (see 2.2.3). Total protein quantification of all samples was performed using 
bicinchoninic acid (BCA) assay reagent (Sigma-Aldrich). 
Table 2.2. Selected binding buffers for the optimization of HSA binding towards the triazine-based ligands 
A3A2 and A6A5. 
 
2.2.5. Elution screening with two triazine lead ligands 
The two lead ligands from the triazine-based library (A3A2 and A6A5) were re-synthesized, regenerated, 
equilibrated and a 0.25 mg/ml HSA or hIgG solution in PBS at pH 7.4 was loaded in a 96-well filtration block 
(n=3), as previously described (see 2.2.4). The elution buffers tested were (Table 2.3): (E1) 100 mM glycine-
HCl, pH 3.0, (E2) 25 mM sodium phosphate, 150 mM sodium chloride, 30 mM sodium caprylate, pH 6.0, 
(E3) 10 mM sodium phosphate, 1 M sodium chloride, pH 7.4, (E4) 50 mM sodium phosphate, 1.5 M 
potassium chloride, pH 6.0, (E5) 100 mM glycine-NaOH, pH 10.0, (E6) 150 mM ammonium acetate, 10 mM 
sodium caprylate, pH 6.0, (E7) 10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 in 50% (v/v) 
ethylene glycol, (E8) 10 mM sodium phosphate, 2 M magnesium chloride, pH 7.4, (E9) 25 mM sodium 
phosphate, pH 6.0 and (E10) 25 mM sodium phosphate, 30 mM sodium caprylate, pH 6.0. After screening, 
the resins were washed, regenerated and stored as previously described (see 2.2.3). Total protein 
quantification of all samples was performed using QuantiProTM BCA assay kit (Sigma-Aldrich). The binding 
percentage was calculated according to Equation 2.1. For the elution buffers that interfered with the 
quantification assay (E7 and E8), a previous dialyses step was performed for buffer exchange with PBS. 
2.2.6. On-column purification of HSA from human plasma with A3A2 and A6A5 
ligands 
Adsorbents A3A2 and A6A5 were re-synthesized and 0.5 g of moist functionalized agarose (1 ml of 50% 
(w/v) slurry) was packed into a 3 ml column (0.8 cm x 6.5 cm) (n=3). The resins were regenerated, washed 
and equilibrated as previously described (see 2.2.3). A 0.5 ml sample of human plasma (Sigma-Aldrich) 
with a total protein concentration of 0.7 mg/ml was loaded into the columns. The flow-through, washes with 
the optimized binding buffer (5 x 500 μl) and elution with the optimized elution buffer (5 x 500 μl) were 
collected in 1.5 ml centrifuge tubes under gravitational flow. For ligand A3A2, the optimized binding buffer 
was 10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 at 20-25 ºC and the optimal elution buffer 
Binding buffer Buffer composition 
B1 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4, 20-25 ºC 
B2 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4, 0-4 ºC 
B3 10 mM Tris-HCl, 150 mM sodium chloride, pH 8.0 
B4 50 mM Citrate buffer, pH 5.0 
B5 10 mM Tris-HCl, 300 mM sodium chloride, pH 8.0 
B6 50 mM Citrate buffer, 300 mM sodium chloride, pH 5.0 
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10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 in 50% (v/v) ethylene glycol. For ligand A6A5 
the best binding buffer was 50 mM citrate buffer, 300 mM sodium chloride at pH 5.0 and as elution buffer 
25 mM sodium phosphate, 30 mM sodium caprylate at pH 6.0. The resins were then washed, regenerated 
and stored as previously described (see 2.2.3). The adsorbent A6A5 was re-synthesized and 1.5 g of moist 
functionalized agarose (3 ml of 50% (w/v) slurry) was packed into a 3 ml column (0.8 cm x 6.5 cm) (n=6). 
The resins were regenerated, washed and equilibrated as previously described (see 2.2.3). Samples of 
human plasma (0.25 ml; Sigma-Aldrich), with total protein concentrations of 5 mg/ml and 14 mg/ml, were 
loaded into the columns. The flow-through, washes (5 x 1.5 ml) and elution (5 x 1.5 ml) with the buffers 
described above, were collected in 2 ml centrifuge tubes under gravitational flow. Assays with human 
plasma were performed in triplicates (n=3). The determination of total protein concentration was performed 
using bicinchoninic acid (BCA) assay reagent (Sigma-Aldrich). Sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS–PAGE) was performed to evaluate the samples purity. Samples were applied in a 
12.5% acrylamide gel and ran at 90 mV. Images were acquired with Gel Doc™ XR+ System with Image 
Lab™ software from Bio-Rad and analyzed with ImageJ software. 
Table 2.3. Selected elution buffers for the optimization of HSA elution from the triazine-based ligands A3A2 
and A6A5. 
Elution buffer Buffer composition 
E1 100 mM Glycine-HCl, pH 3.0 
E2 25 mM Sodium phosphate, 150 mM sodium chloride, 30 mM sodium caprylate, pH 6.0 
E3 10 mM Sodium phosphate, 1 M sodium chloride, pH 7.4 
E4 50 mM Sodium phosphate, 1.5 M potassium chloride, pH 6.0 
E5 100 mM Glycine-NaOH, pH 10.0 
E6 150 mM Ammonium acetate, 10 mM sodium caprylate, pH 6.0 
E7 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4 in 50% (v/v) ethylene glycol 
E8 10 mM Sodium phosphate, 2 M magnesium chloride, pH 7.4 
E9 25 mM Sodium phosphate, pH 6.0 
E10 25 mM Sodium phosphate, 30 mM sodium caprylate, pH 6.0 
 
2.2.7. Molecular Docking 
The crystal structure of HSA in complex with warfarin (PDB ID: 2BXD) [115] was selected for molecular 
docking calculations using AutoDock 4.0 [116]. The ligands A6A5 and sulfisoxazole were designed using 
ChemDraw Professional 16.0.1.4, and submitted to the ProDrg server [117] for AutoDock format 
parametrization. Being synthesized in solid-phase, the A6A5 was truncated with a methyl group in the 
triazine amine used to experimentally bind the ligand to the solid support. After visual inspection and 
validation of ligands’ structures and parameters, they were submitted to a docking protocol using Autodock’s 
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Lamarckian Genetic Algorithm with a population of 150 individuals, during 100 runs for 27000 generations, 
and 25 million energy evaluations. Docking results were analyzed with AutodockTools [116]. 
 
2.3. Results and discussion 
2.3.1. Design, synthesis and screening of combinatorial libraries of ligands  
Human serum albumin (HSA) has a globular heart-shape form with three structurally homologous 
domains (I, II and III), each one divided into two sub-domains (A and B). Domains IIA and IIIA are also 
known as Drug site I and II, respectively, since exogenous molecules usually bind in one of these sites 
[118,119]. Drug molecules such as 3,5-diiodosalicylic acid, indomethacin [115], sulfisoxazole [120] and 
aspirin [72] are known to interact with the HSA domain II, whereas ibuprofen, diazepam and propofol interact 
with HSA domain III [115]. 
HSA protein binders including protein H from Streptococcus pyogenes [121], protein G from 
Streptococcal group C or G [122], protein MAG (binding α2-macroglobulin, albumin and IgG) from 
Streptococcus dysgalactiae [123], protein ZAG (binding α2-macroglobulin, albumin and IgG) from 
Streptococcus zooepidemicus [124], and protein PAB (peptostreptococcal albumin-binding) from 
Peptostreptococcus magnus naturally bind to domain II [125]. Protein PAB is known to bind HSA domain II 
though PAB residues Phe27, Leu44, Lys36, Ser25, Tyr28 and Ala31,35 [125]. Neonatal Fc receptor (FcRn), 
is also a natural HSA binder responsible for IgG and HSA regulation in mammalians. This receptor is known 
to bind to domains I and III of HSA in a pH-dependent mode (binding occurs at pH 6.0 and dissociation is 
observed at pH 7.4) [126–128]. Evidence showed that conjugation of HSA or IgG to other proteins or 
peptides with poor bioavailability or exhibiting rapid clearance, can increase their pharmacokinetics due to 
the FcRn mediated recycling and transport [129]. 
A combinatorial library of synthetic ligands based on triazine scaffold was rationally designed focusing 
on the mode of interaction between domain II of HSA and its natural binders, leaving HSA domains I and III 
free for possible interaction with FcRn. As a consequence, eight different amines were selected to 
incorporate into the triazine scaffold. Here, one chlorine is reacted with the aminated solid-phase and the 
remaining two chlorines are replaced by amine compounds in a step-wise temperature dependent process, 
generating bi-substituted ligands. A library of 64 adsorbents was prepared by a mix-and-split combinatorial 
chemistry approach in 96-well filtration blocks. The screening of the solid-phase library towards HSA binding 
was performed by micro-scale chromatography at two distinct pH values, pH 6.0 and 7.4. The idea behind 
these pH values was to ensure the binding of the chosen ligands mimicking HSA domain II natural binders 
at pH 7.4, and concomitantly mimicking the pH-dependent interaction of FcRn with HSA evaluating the 
ligands binding stability at pH 6.0. As such, a synthetic triazine library, able to capture HSA from a complex 
media and to potentially work as a spacer between HSA and a drug to increase its pharmacokinetics 
properties, was rationally designed. Ligands AxAy and AyAx displayed nearly identical screening results for 
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the binding to HSA (in 64 ligands only 3 pairs AxAy/AyAx presented a difference higher than 15%; Figure 
2.1.). This suggests a controlled synthesis of the adsorbents which yielded a symmetric library. 
Figure 2.1. Triazine AxAy/AyAx symmetry plot. Experimental data are in ● and difference of 15% between 
AxAy/AyAx is represented in grey. 
 
The results obtained from the library screening revealed 23 triazine-based ligands with more than 50% 
of HSA bound at both pH values (Figure 2.2. Screening of the combinatorial triazine-based library towards 
HSA binding at (A) pH 6.0 and (B) 7.4.Figure 2.2). These were selected to proceed with further studies.  





The ligands were re-synthetized in 96-well filtration blocks and re-screened for HSA. At this stage, the 
binding of these ligands towards human IgG (hIgG) at pH 7.4 (Figure 2.3) was also assessed as hIgG is the 
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second most abundant protein in the human serum. The re-screening results obtained revealed that lead 
ligands bound with higher percentages to HSA when comparing with hIgG binding.  
 
The lead ligands were then selected having as the basis the following criteria of selection: (i) more than 
50% of HSA bound and (ii) an enrichment factor higher than 1.7 (Figure 2.4), corresponding to half of the 
maximum enrichment factor observed. In this way, 8 putative lead ligands for HSA were selected, of those 
ligands A3A2 and A6A5 were the most promising due to the higher enrichment factor, 3.1 ± 0.4 and 2.2 ± 
0.2 respectively (Figure 2.4B). 
Ligand A3A2 is composed by 3,4-dimethylaniline as amine R1 and isopentylamine, mimicking leucine 
amino acid, as amine R2. Ligand A6A5 is composed by sulfisoxazole as amine R1, a typical drug found to 
bind to HSA, and phenethylamine, mimicking phenylalanine amino acid, as amine R2. Both ligands present 
aromatic ring in their constitution leading to believe that hydrophobic interaction might play a role in HSA-
ligand recognition. 
2.3.2. Optimization studies with lead ligands 
In order to optimize the lead ligands performance as promising adsorbents, the binding and elution 
conditions were optimized. According to the previous screening assays, the binding conditions used were 
PBS (10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4) presenting 99% HSA binding to A3A2 
Figure 2.3. Results for the re-screening of the 23 putative lead ligands for binding (A) HSA and hIgG, and 
(B) enrichment for HSA during the binding process. 
Figure 2.4. Screening of the triazine lead ligands towards HSA and hIgG binding and HSA enrichment, data 
are presented as means ± SEM (n=3). (A) Percentage of bound HSA and hIgG in PBS at pH 7.4 and (B) HSA 
enrichment factor. 
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and 100% to A6A5. Although these binding percentages seemed to be promising, these ligands also 
revealed great binding percentage towards hIgG (59% to A3A2 and 61% to A6A5). In this way, the first 
attempt of optimization was to improve the specificity of these ligands towards HSA. 
The first step dealt with the optimization of the binding buffer to selectively bind HSA, using adsorbent 
comprising ligands A3A2 and A6A5. For the adsorbent A3A2, all binding buffers presented more than 85% 
HSA bound, and binding buffer B3 promoted unspecific interactions as it bound 100% of both HSA and hIgG 
(Figure 2.5A). The temperature showed no impact in the binding specificity (B1 (PBS at 20-25 ºC) vs B2 
(PBS at 0-4 ºC)) and citrate buffer at pH 5.0 (B4) presented lower HSA binding (Figure 2.5A). The results 
are compatible with the hypotheses that hydrophobic interactions play the major role in HSA binding as the 
hydrogen phosphate ion has a more kosmotrope effect than citrate, enhancing hydrophobic interactions. By 
the present study, PBS pH 7.4 at 20-25 ºC was the best binding condition of the HSA-A3A2 ligand pair. 
Using the adsorbent A6A5, all the binding buffers tested presented 100% binding to HSA. Temperature 
showed no impact in the binding specificity (B1 (PBS at 20-25 ºC) vs B2 (PBS at 0-4 ºC)) (Figure 4B and 
S4B). B3 and B4 binding buffers did not provide any selectivity towards HSA (Figure 2.5B). Since 
hydrophobic interactions may play a role in the binding of both proteins to the ligand, the next approach was 
to increase the sodium chloride concentration (buffers B5 and B6). The sodium chloride increment 
decreased hIgG binding by 2-fold when comparing B3 vs B5 and B4 vs B6. By the results, buffers B5 and 





Figure 2.5. Binding buffer optimization for HSA purification using adsorbents (A) A3A2 and (B) A6A5, with 
the respective expected ligand chemical structure. Legend: B1: 10 mM sodium phosphate, 150 mM sodium 
chloride, pH 7.4, 20-25 ºC; B2: 10 mM sodium phosphate, 150 mM sodium chloride, pH 7.4, 0-4 ºC; B3: 10 
mM Tris-HCl, 150 mM sodium chloride, pH 8.0; B4: 50 mM citrate buffer, pH 5.0; B5: 10 mM Tris-HCl, 300 
mM sodium chloride, pH 8.0; B6: 50 mM citrate buffer, 300 mM sodium chloride, pH 5.0. 
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Secondly, the best elution conditions were selected using pure proteins. Considering the structure of the 
ligands, these are expected to promote hydrophobic interactions (due to aromatic compounds) and 
hydrogen bonds. Considering the ligands’ structure and the commercially available HSA triazine-based 
purification schemes, eight different elution buffers were screened for HSA elution. Due to the diversity of 
possible interactions, buffers with different pH, ionic strength and the presence of an organic compound 
were tested. The elution studies were performed for HSA and hIgG, to assess a selective elution profile. 
For both triazine-based ligands A3A2 and A6A5, it was possible to achieve a differential HSA selective 
elution (Figure 2.6). For A3A2, the glycine buffers (E1 and E5) and E2 favored hIgG elution (Figure 5A and 
S5A). The high concentration of salt with monovalent ions (E3, E4 and E6) showed to have no impact in the 
elution profile, whereas a high concentration of a salt with a divalent ion (E8) favored HSA elution. According 
to the Hofmeister cation series, while K+ and Na+ lead to “salting-out” effects that strengthen hydrophobic 
interactions, Mg2+ leads to a “salting-in” effect which weakens hydrophobic interactions (Figure 2.6A). 
Nonetheless, for A3A2 the best elution condition was 10 mM sodium phosphate, 150 mM sodium chloride 
at pH 7.4 in 50% (v/v) ethylene glycol which will likely interfere and disrupt the hydrophobic interactions 
between HSA and A3A2 ligand (Figure 2.6A; Table 2.4). The same elution buffers were tested under the 
same conditions for A6A5 ligand (Figure 2.6B). The high pH glycine-NaOH buffer (pH 10.0) (E5) was the 
only buffer favoring hIgG elution, while a low pH buffer (pH 3.0) (E1) favored HSA elution (Figure 2.6B). 
Regarding the salt effect in the elution profile, the same behavior was observed for A6A5 ligand (Figure 
2.6B). The elution buffer E7, with ethylene glycol, also presented a high percentage of HSA eluted (Figure 
2.6B). However, for A6A5 the best elution condition (54% HSA eluted vs 0% hIgG eluted) was 25 mM 
sodium phosphate, 150 mM sodium chloride, 30 mM sodium caprylate at pH 6.0 (E2) (Figure 2.6B). To 
further improve the elution conditions of A6A5 ligand, an additional optimization of the elution buffer was 
performed for a differential HSA/hIgG elution having as basis 25 mM sodium phosphate, 150 mM sodium 
chloride, 30 mM sodium caprylate at pH 6.0 (E2). Two elution buffers at pH 6 were tested: E9, where sodium 
chloride and sodium caprylate were depleted; and E10, where only the sodium chloride was depleted. When 
using only sodium phosphate, no protein eluted, whereas using sodium phosphate and sodium caprylate 
HSA elution increased and hIgG elution decreased (Table 2.4), showing the importance of caprylate in HSA 
elution step. Caprylic acid is many times used as HSA stabilizing agent used in treatment of 
hypoalbuminemia [130], moreover caprylic acid binds to HSA domain II by hydrogen bonding and 
hydrophobic interactions [131]. Nevertheless, for A6A5, the best results were obtained using as binding 
buffer 50 mM citrate buffer, 300 mM sodium chloride at pH 5.0 (B6) and as elution buffer 25 mM sodium 
phosphate, 30 mM sodium caprylate at pH 6.0 (E10) (Table 2.4). 
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Table 2.4. Percentage of HSA and hIgG bound and eluted from triazine-based ligands A3A2 and A6A5 with 
the respective binding and elution buffers. Highlighted in grey are the best binding and elution conditions 





Binding buffer % 
HSA 
% 
hIgG Elution buffer 
A3A2 
B1: 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4 
E7: 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4 in 50% (v/v) ethylene 
glycol 
99  59 
48 7 
A6A5 
B5: 10 mM Tris-HCl, 300 mM sodium chloride, pH 8.0 
E9: 25 mM Sodium phosphate, pH 6.0 
97 68 
0  2 
B5: 10 mM Tris-HCl, 300 mM sodium chloride, pH 8.0 
E10: 25 mM Sodium phosphate, 30 mM sodium caprylate, pH 6.0 
97 68 
74 2 
B6: 50 mM Citrate buffer, 300 mM sodium chloride, pH 5.0 
E9: 25 mM Sodium phosphate, pH 6.0 
99 96 
0% 0% 
B6: 50 mM Citrate buffer, 300 mM sodium chloride, pH 5.0 
E10: 25 mM Sodium phosphate, 30 mM sodium caprylate, pH 6.0 
99% 96% 
100% 0% 
Figure 2.6. Elution buffer optimization for HSA purification using adsorbents (A) A3A2 and (B) A6A5, with 
the respective expected ligand chemical structure, data are presented as means ± SEM (n=3). Legend:
E1: 100 mM glycine-HCl, pH 3.0; E2: 25 mM sodium phosphate, 150 mM sodium chloride, 30 mM sodium 
caprylate, pH 6.0; E3: 10 mM sodium phosphate, 1 M sodium chloride, pH 7.4; E4: 50 mM sodium 
phosphate, 1.5 M potassium chloride, pH 6.0; E5: 100 mM glycine-NaOH, pH 10.0; E6: 150 mM 
ammonium acetate, 10 mM sodium caprylate, pH 6.0; E7: 10 mM sodium phosphate, 150 mM sodium 
chloride at pH 7.4 in 50% (v/v) ethylene glycol; E8: 10 mM sodium phosphate, 2 M magnesium chloride, 
pH 7.4. 
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2.3.3. HSA purification from human plasma 
Purification of HSA from human plasma was performed using adsorbents modified with both lead ligands, 
A3A2 and A6A5, and the optimized conditions for binding and elution. Firstly, 0.4 mg of total protein were 
loaded in 0.5 g of packed bed adsorbents A3A2 and A6A5. In the elution fractions from A3A2 adsorbent, it 
was observed the co-elution of hIgG with HSA (Figure 2.7A). The adsorbent A6A5 presented a better 
compromise between purity and recovery (Figure 2.7B; Table 2.5) with a recovery yield of 88% and protein 
purity of 93% (estimated by densitometric analysis using ImageJ software). Adsorbents with A6A5 ligand 
(1.5g of resin) were also loaded with higher protein titers (9 mg and 36 mg), increasing in this way the ratio 
total protein loaded/resin. The SDS-PAGE analyses showed selective HSA elution. The best results were 
found for the higher protein loading with 98% purity and 100% recovery (estimated by densitometric analysis 
using ImageJ software) (Figure 2.8; Table 2.6). These results demonstrate the feasibility to use A6A5 
adsorbent for HSA purification from a complex crude extract as human plasma. 
 
Figure 2.7. Purification performance of (A) A3A2 and (B) A6A5 for HSA purification from human plasma. 
Silver stained SDS-PAGE gel (12.5% acrylamide) in reducing conditions. As purification conditions for (A) 
the binding buffer used was 10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 (B1) and as 
elution buffer 10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 in 50% (v/v) ethylene glycol 
(E7) was used, for (B) as binding buffer 50 mM citrate buffer, 300 mM sodium chloride at pH 5.0 (B6) and 
as elution buffer 25 mM sodium phosphate, 30 mM sodium caprylate at pH 6.0 (E10) were used. Lanes ID: 
M: Precision Plus ProteinTM Dual Color Standards (molecular weight in kDa); Load: human plasma; FT: 
flow-through; W1: first wash; W2: second wash; W3: third wash; W4: fourth wash; W5: fifth wash; E1: first 
elution; E2: second elution; E3: third elution; E4: fourth elution; E5: fifth elution (all fractions with the same 
protein quantity (1200 ng/well)). Position of HSA (66 kDa) and hIgG heavy (H) (50 kDa) and light (L) (25 
kDa) chains are indicated in the right side of the gel. 
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Table 2.5. HSA purity assessment from its purification from human plasma with a total protein concentration 




Figure 2.8. Purification performance of HSA from human serum plasma with 8.9 mg (A) and 36 mg (B) total 
protein loading using as binding buffer 50 mM citrate buffer, 300 mM sodium chloride at pH 5.0 (B6) and as 
elution buffer 25 mM sodium phosphate, 30 mM sodium caprylate at pH 6.0 (E10). Coomassie stained SDS-
PAGE gel (12.5% acrylamide) in reducing conditions. Lanes ID: M: Precision Plus ProteinTM Dual Color 
Standards (molecular weight in kDa); Load: human plasma; FT: flow-through; W1: first wash; W2: second 
wash; W3: third wash; W4: fourth wash; W5: fifth wash; E1: first elution; E2: second elution; E3: third 
elution; E4: fourth elution; E5: fifth elution (Load sample diluted 10 times and sample fractions diluted 2 
times). Position of HSA (66 kDa) is indicated in the right side of the gel. 
 
Table 2.6. HSA purity assessment from its purification from human plasma with a total protein concentration 
of 8.9 mg and 36 mg, with triazine-based ligand A6A5 using as binding buffer 50 mM Citrate buffer, 300 mM 
sodium chloride at pH 5.0 and as elution buffer 25 mM Sodium phosphate, 30 mM sodium caprylate at pH 
6.0. 
Ligand 
Binding buffer HSA purity 
(%) 
Recovery 
yield (%) Elution buffer 
A3A2 
B1: 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4 
E7: 10 mM Sodium phosphate, 150 mM sodium chloride, pH 7.4 
in 50% (v/v) ethylene glycol 37 100 
A6A5 
B6: 50 mM Citrate buffer, 300 mM sodium chloride, pH 5.0 
E10: 25 mM Sodium phosphate, 30 mM sodium caprylate, pH 6.0 93 88 
Loading 
(mg total protein) 
mg Total protein 
bound/ g support 








0.4 3.23 ± 0.17 0.31 ± 0.02 89 ± 4.3 98 ± 3.4 1.93 ± 0.19 2.15  
9.0 5.84 ± 0.02 0.53 ± 0.08 92 ± 8.7 93 ± 19 1.74 ± 0.33 1.88  
36 5.88 ± 0.04 1.81 ± 0.34 98 ± 1.2 100 ±10 2.09 ± 0.41
2.13  
a Ratio between final and initial protein purity. As different loadings were used in the several runs the maximum 
purification factor is given after SEM. 
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2.3.4. Modeling of A6A5 binding to HSA 
As sulfisoxazole has an identical allosteric behavior as drugs like warfarin and azapropazone in human 
serum albumin (HSA), it is assumed that it binds to Drug site I (Figure 2.9A), as already described for the 
latter drugs [115,120].  
To analyze the putative binding mode of ligand A6A5 to HSA, molecular docking studies were performed. 
The docking grid covered all domain II residues, including the key residues for PAB protein interaction with 
HSA: Phe228, Ala229, Ala322, Val325, Phe326, and Met329 [125]. As ligand A6A5 has a sulfisoxazole 
substituent in the triazine based compound, the molecular docking of sulfisoxazole was also performed as 
no crystallographic structure for sulfizoxazole bound to albumin has been reported. When comparing 
sulfisoxazole docking position to the crystal structure of HSA-warfarin complex (Figure 2.9B and 8D), similar 
interactions are observed [115]. The Drug Site I residue Lys199, performs a cation-π interaction with six-
carbon aromatic rings in both drugs; His242 also acts as a hydrogen bond donor to the warfarin’s hydroxyl 
group and sulfisoxazole sulfone; and Tyr150 interacts with both ligands donating a hydrogen bond to 
sulfisoxazole and as a hydrogen bond acceptor of the warfarin’s hydroxyl group (Figure 8B; D). Additionally, 
the sulfisoxazole binding mode presents: three extra hydrogen bonds, one with the sidechain of Arg257 and 
two with the sidechain and backbone carbonyl of Ser192; and two residues with hydrophobic interactions, 
Leu260 and Ala291. Overall, the binding mode proposed from the docking calculation for sulfisoxazole is in 
agreement with the canonical residue interactions with described HSA-drug structures [115]. 
The positive docking result for sulfisoxazole for the domain II located in Drug site I, should restrain the 
docking result position for ligand A6A5, as this drug is part of the synthesized affinity ligand. However, the 
increased molecular size with the addition of a triazine ring and the phenethylamine substituent, and the 
fact that the affinity ligand is immobilized, should not allow it to bind to HSA’s Drug Site I, as observed for 
sulfisoxazole alone. Therefore, the position of A6A5 after its docking to HSA’s domain II, is in agreement 
with the presented statements and located outside the Drug Site I, at the end of the surface of domain II in 
the vicinity of domain I, (Figure 2.9A; C). Furthermore, this binding mode presents the anchoring point 
towards the solvent, revealing that ligand A6A5 could be immobilized onto a solid support in that position. 
The main interactions present in A6A5 binding mode to HSA are three hydrogen bonds and hydrophobic 
interactions with two residues. Two triazine substituted amines act as hydrogen bond donors toward the 
side chains of Glu244 and Glu252, the additional hydrogen bond is between His247 side chain and the 
oxygen atom in the isoxazole group of the synthesized ligand. The hydrophobic interactions are close the 
isoxazole methyl group, Leu203, and the phenethylamine’s phenyl group, Leu66 (Figure 2.9C). These 
interactions are in agreement with the best binding condition obtained for A6A5-HSA binding since citrate, 
present in the binding buffer, presents a kosmotropic effect promoting ligand-protein hydrogen bonding as 
well as hydrophobic interactions, both observed in the docking results. 
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Figure 2.9. (A) Location of HSA ligands, warfarine (magenta), A6A5 ligand (blue) and sulfisoxazole (yellow), 
in its 3-dimentional structure. (B) Interaction details of warfarine and HSA from the complex crystallographic 
structure (PDB ID: 2BXD). Binding mode results for the docking of (C) A6A5 and (D) sulfisoxazole in HSA 
crystallographic structure (PDB ID: 2BXD) (hydrogen bonds in dotted green lines, cation-π interactions in 
yellow triangles).  
 
2.4. Conclusion 
HSA is an important biopharmaceutical with a wide variety of applications, ranging from its capacity to 
carry diverse molecules and increase their circulation half-life time, to be a biomarker in many diseases (e.g. 
cancer and rheumatoid arthritis). Due to its high market value, different chromatographic and non-
conventional approaches for HSA purification have been explored. In this work, a library based on the 
triazine skeleton was rationally developed based on amino acids of the PAB protein and synthetic drugs 
known to bind HSA domain II. The triazine scaffold yields ligands with interesting properties for the 
purification of biopharmaceuticals namely potential low toxicity in process leachates [132], and capability to 
generate adsorbents with high resistance to conventional cleaning-in-place and sterilization-in-place 
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procedures [17,133–136]. Of the 64 ligands screened, 2 triazine ligands showed promising results for HSA 
purification, ligands A3A2 and A6A5. After optimization studies for HSA binding and elution, it was possible 
to purify HSA from human plasma with a purity of 98% and 100% of recovery yield using adsorbents 
modified with the triazine ligand A6A5. The best binding and elution conditions for HSA recovery using A6A5 
adsorbent are similar to those reported for commercial kits (AlbuPure® from ProMetic BioSciences). Still, 
the 50 mM ammonium acetate salt used to elute HSA from AlbuPure® were replaced in our case by 25 mM 
sodium phosphate, thus deriving milder and less toxic elution conditions (Table 2.7). 
Our preliminary data show that the binding of A6A5 to HSA is stable at physiological conditions (PBS 
buffer) at pH 7.4 and 6 (100% and 63%, respectively). Moreover, as the present ligand was rationally 
designed to bind HSA domain II (possibility confirmed by docking results), it opens the possibility to improve 
in the future the pharmacokinetics of HSA fusions via FcRn binding. 
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Table 2.7. Comparison of commercial (AlbuPure®) and in-house developed absorbents for HSA purification. N/A: Not available. 
Ligand Structure Binding Elution HSA puritya (%) 
Recovery 
yielda (%) Company 
AlbuPure® N/A 50 mM Sodium citrate, pH 5.5 
50 mM Ammonium acetate, 
10 mM caprylate pH 7 (or) 




















50 mM Citrate buffer, 
300 mM sodium chloride, 
pH 5.0 
25 mM Sodium phosphate, 
30 mM sodium caprylate, 
pH 6.0 













10 mM Sodium 
phosphate, 150 mM 
sodium chloride,  
pH 7.4 
10 mM Sodium phosphate, 
150 mM sodium chloride, 
pH 7.4 in 50% (v/v) 
ethylene glycol 
37b 100b - 
a With a total protein loading of 36 mg from human serum plasma. 
b With a total protein loading of 0.4 mg from human serum plasma. 
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Abstract 
Currently most economical and technological bottlenecks in protein production are placed in the 
downstream processes. With the aim of increasing the efficiency and reducing the associated costs, various 
affinity ligands have been developed. Affitins are small, yet robust and easy to produce, proteins derived 
from the archaeal extremophilic “7 kDa DNA-binding” protein family. By means of combinatorial protein 
engineering and ribosome display selection techniques, Affitins have shown to bind a diversity of targets. In 
this work, two previously developed Affitins (anti-lysozyme and anti-IgG) were immobilized onto magnetic 
particles to assess their potential for protein purification by magnetic fishing. The optimal lysozyme and 
human IgG binding conditions yielded 58 mg lysozyme/g support and 165 mg IgG/g support, respectively. 
The recovery of proteins was possible in high yield (≥ 95%) and with high purity, namely ≥ 95% and 81%, 
when recovering lysozyme from E.coli supernatant and IgG from human plasma, respectively. Static binding 
studies indicated affinity constants of 5.0×104 M-1 and 9.3×105 M-1 for the anti-lysozyme and anti-IgG 
magnetic supports. This work demonstrated that Affitins, which can be virtually evolved for any protein of 
interest, can be coupled onto magnetic particles creating novel affinity adsorbents for purification by 
magnetic fishing.  
 
3.1. Introduction 
Affinity-based separations are extremely efficient tools in protein production. Still, production costs of 
biopharmaceutical proteins are now mostly associated with the downstream processing steps [137], [138]. 
Historically, antibodies were explored as affinity biological ligands in purification as they combine a tailored 
high specificity for a diversity of targets [137]. However, they are prone to degradation, modification, 
aggregation and/or denaturation [137], their complex structure results in high production costs [139] and 
they have low shelf-life [140]. These properties limited their widespread use for cost effective affinity 
purification schemes. 
Alternative biological affinity ligands have been gathering advantages over classical full-length 
monoclonal antibodies, namely enhanced stability and reduced molecular size [139]. These alternative 
ligands include smaller versions of antibodies, as single-chain variable fragments and antigen-binding 
fragments [137,141] or engineered binding proteins based on different scaffolds [142]. An optimal scaffold 
should ideally combine a few key characteristics: it must be small and stable, lack disulfide bridges, be 
easily produced at high levels [143], have low background binding and must be highly soluble in aqueous 
solutions [144]. 
Members from the archaeal “7 kDa DNA binding” protein family [145], such as Sac7d from the 
extremophilic Sulfolobus acidocaldarius [146] were described as alternative scaffolds [143,147] to obtain 
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affinity reagents called Affitins [148]. Using combinatorial libraries and ribosome display selections, Affitins 
were isolated for a diversity of protein targets. Affitins have been shown to be chemically and thermally 
stable and resistant to extreme acidic and alkaline pH [142–144,149]. Among the targeted proteins, CelD 
and lysozyme are two endo-glycosidases, for which Affitins present inhibition constants in the nanomolar 
range. In addition, the structures of the complexes formed have been solved to decipher their modes of 
action [142]. Affitins designed from Sac7d scaffold and engineered in a Sso7d protein scaffold, were also 
targeted against human Immunoglobulin G (IgG) and shown to withstand extreme pH conditions with a 
dissociation constant in the micro to nanomolar range [144,149]. This study has shown that Affitins can 
recognize discontinuous epitopes which could explain why in general Affitins are highly specific of their 
cognate targets [142–144]. This additional property of high specificity of Affitins resulted in potent purification 
tools for affinity chromatography once covalently immobilized on agarose resin [150]. 
Magnetic particles (MPs) are an alternative to standard chromatographic media for protein purification 
[151]. The superparamagnetic properties of MPs allow their easy and selective removal from viscous 
biological solutions [152]. Magnetic particles have highly accessible surface areas and are non-porous 
supports, therefore bioseparations are not limited by pore diffusion [22,151]. Furthermore, magnetic 
separation is easy to use without the need of sophisticated apparatus, enabling operation in a wide range 
of conditions. To be suitable for protein purification, MPs should be hydrophilic and inert, should allow further 
functionalization [22], be stable during binding, elution and regeneration conditions, possess large surface 
areas and be responsive to external magnetic fields [153]. Similarly to chromatographic affinity separations, 
various biological molecules have been used to functionalize magnetic particles [152,153].  
In this work, we explored for the first time the use of magnetic particles functionalized with Affitins for the 
selective capture of proteins. As a proof-of-concept, two Affitins previously evolved against lysozyme and 
IgG were immobilized onto magnetic particles and assessed for protein capture and recovery. Our data 
shows that Affitin-functionalized magnetic particles can be an alternative for protein purification. In addition, 
and considering the versatility of the Affitins platform, new affinity magnetic adsorbents can be developed 
against any target of interest. 
 
3.2. Materials and Methods 
3.2.1. Magnetic particles synthesis, coating and amination 
Bare magnetic particles were synthesized by the co-precipitation method. A solution of 25% ammonium 
hydroxide in deionized water (200 ml) was purged with N2 gas. A freshly prepared iron solution (FeCl3 and 
FeCl2 salts (Sigma) with a molar ratio of Fe2+/Fe3+ of 0.5, 25ml) was added in a dropwise manner. The 
reaction continued for 2h. The resulting MPs were washed with distilled water (10-times) with aid of magnetic 
separation. The particles (10 mg/ml) were sonicated (Elmasoni S30, Elma, 37 kHz) for 15 minutes and a 
solution of sodium metasilicate pentahydrate (Sigma) was added (2.28 g in 80 ml ethanol/water 50%). The 
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mixture was incubated (40°C, 2 hours with orbital shaking (200 RPM)). Afterwards the support was washed 
with distilled water (10-times). The supernatant was removed and the particles were resuspended in 80 ml 
of ethanol/water (5:1). The solution was sonicated for 10 min and 25% ammonium hydroxide (3 ml) and 
tetraethyl orthosilicate (TEOS) (1.5 ml, Sigma) were added dropwise during sonication. The mixture was 
incubated (40°C, 2 hours with orbital shaking, 200 RPM). Afterwards the particles were washed with distilled 
water (10-times). The particles were resuspended in 175 ml of distilled water and sonicated for 10 minutes. 
A solution of dextran (2 g in 25 ml of water) was added dropwise to the particle solution and the mixture was 
incubated (60°C, 2 hours with orbital shaking, 200 RPM). The particle amination protocol has been 
described elsewhere [22]. The amount of amines was assessed by the Kaiser Test as 212.8 ± 17.3 µmol 
NH2/g support. All produced magnetic supports were characterized by dynamic light scattering (DLS) and 
by zeta potential (0.05 mg/ml solution in deionized water, pH 5.80) using a Dynamic Zetasizer NanoZS from 
Malvern instruments. Magnetic particles samples were prepared by evaporating dilute suspensions which 
were grounded and mixed with KBr (1:100). The Fourier Transform Infrared (FT-IR) spectra were recorded 
on a Tensor 27 from Bruker. 
3.2.2. Affitin production 
The sequence of the Affitin H4 (anti-lysozyme) and Affitin D1Sso7d-DM (anti-IgG) have been previously 
reported [142] and [149], respectively. In this study, we inserted a cysteine at the C-terminus by directed 
mutagenesis to allow coupling via thiol chemistry. 
The resulting Affitin H4-Ct has thus the following sequence: 
MRGSHHHHHHGSVKVKFFWNGEEKEVDTSKIVWVKRAGKSVLFIYDDNGKNGYGDVTEKDAPKELLDM
LARAEREKKGC. As for Affitin D1Sso7d-DM-Ct, it has the following sequence: 
MRGSHHHHHHGSATVKFKYKGEELEVDISKIKKVWRDRLAAVFTYDLGGGKTGYGWVFTKDAPKELLQM
LEKQKKLNC. The resulting Affitins were expressed in Escherichia coli DH5α Iq strain and purified by 
immobilized metal ion affinity chromatography and gel filtration as described previously [142]. The Affitins 
were supplied in buffer 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4. 
3.2.3. Optimization of support functionalization  
For the optimization of the functionalization conditions different conditions were varied: (i) magnetic 
particle concentration, (ii) presence of reduction agent and (iii) NH2:Affitin ratio. The compound 
sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) (Pierce Biotechnology) 
was used as an amine-to-sulfhydryl crosslinker. The magnetic support was washed 5-times with conjugation 
buffer (10 mM phosphate, 0.15 M NaCl, 1 mM EDTA, pH 7.2 purged with N2). Five-molar excess of sulfo-
SMCC to the amines of the support in distilled water was added to the support and incubated (30 minutes, 
25°C with orbital shaking, 200 RPM). The support was washed 5-times with conjugation buffer with aid of 
an external magnet. The protein was then added to the mixture and incubated (1 hour, 25°C with orbital 
shaking, 200 RPM). The support was washed with conjugation buffer and supernatants were collected and 
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analyzed for protein content using a microplate reader Tecan Infinite F200 (λexcitation = 280 nm and 
λemission = 340 nm). A solution of 100 mM cysteine was added to the particle slurry and the mixture was 
incubated (1 hour at 25°C, with orbital shaking, 200 RPM) and washed 10-times with conjugation buffer. 
The magnetic support functionalized with affitin anti-lysozyme was named MP-H4-Ct, whereas that 
functionalized with the affitin anti-IgG was named MP-D1Sso7d-DM-Ct. 
3.2.4. Testing magnetic supports with protein samples – optimization of binding 
and elution conditions 
Functionalized and non-functionalized magnetic particles were tested for protein binding. The supports 
were previously washed with 0.2 M NaOH in 50% isopropanol, deionized water and equilibrated with 
phosphate buffer (PBS; 10 mM sodium phosphate, 0.15 M NaCl, pH 7.4). For the optimization of the binding 
conditions the following parameters were varied: (i) magnetic particle concentration (2.5, 5 and 10 mg/ml), 
(ii) incubation temperature (0-8°C and 25°C), and (iii) lysozyme:Affitin molar ratio (1:1, 1:1.5 and 1:3). The 
lysozyme solution (500 μl) was loaded and incubated for 30 minutes with functionalized magnetic support 
(500 μl), for final volume of 1 ml. The supports were washed with PBS by means of centrifugation (5 minutes, 
1850 ×g) and with aid of an external permanent magnet and all supernatants and loading solutions were 
collected and analyzed by fluorescence (λex = 280 nm and λem = 340 nm). 
For the optimization of the elution conditions, 500 μl of magnetic particles (2.5 mg MP-H4-Ct/ml) were 
incubated with 500 μl of lysozyme solution (1:3 lysozyme to Affitin molar ratio), varying: (i) pH, (ii) salt 
concentration and (iii) ethylene glycol percentage of the elution buffer. Target proteins bound to magnetic 
supports, were recovered with the different elution buffers and all supernatants and loading solutions were 
collected and analyzed by fluorescence intensity (λex = 280 nm and λem = 340 nm) using a microplate 
reader (Tecan Infinite F200). Different calibration curves were performed for each elution buffer tested. 
3.2.5. Protein purification from crude extracts 
For lysozyme purification, an E. coli crude extract was spiked with 40% (w/v) lysozyme from chicken egg 
white (Sigma-Aldrich) at a final concentration of 2.1 mg total protein/ml, 500 μl of this solution were incubated 
with 200 μl of 2.5 mg MP-H4-Ct/ml in PBS and incubated for 30 minutes at 0-8°C. Afterwards, the support 
was washed with PBS and the bound protein was eluted with 100 mM glycine-HCl buffer, 0.15 M NaCl, pH 
2.5. Human IgG was purified from human serum samples (Sigma-Aldrich), 250 μl of solution with 1.2 ± 0.2 
mg total protein/ml was loaded into 250 μl of 2.5 mg MP-D1Sso7d-DM-Ct/ml in PBS. The mixture was 
incubated for 30 minutes at 25°C. The weakly bound proteins were washed using PBS and the bound 
proteins were eluted with 100 mM glycine-HCl with 0.15 M NaCl at pH 2.5. The quantification of proteins 
was performed by the Bradford method using bicinchoninic acid (BCA) assay reagent provided by Thermo 
Scientific Pierce. The protein standard used was bovine serum albumin (BSA) from Pierce. Absorbance 
was measured at 562 nm in microplate reader Tecan Infinite F200. Sodium dodecyl sulfate–polyacrylamide 
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gel electrophoresis (SDS–PAGE) was performed to evaluate the samples purity. The buffer sample 
composition was 0.15 M Tris–HCl, pH 6.8, 6% SDS, 0.025% bromophenol blue, 12.5% glycerol and as 
reducing agent β-mercaptoethanol was used. Prior to loading in the gel all the samples were denaturated 
at 100°C for 5 minutes. Samples were applied in a 12% or 15% acrylamide gel, prepared from 41% or 49.5% 
acrylamide/bis stock solution (30:1) from Bio-Rad, respectively, and ran at 90 mV using as running buffer 
192 mM glycine, 25 mM Tris-HCl and 0.1% SDS, pH 8.3. Gels were stained using Bio-Rad silver staining 
kit. Images were acquired with Gel Doc™ XR+ System with Image Lab™ software from Bio-Rad, and 
analyzed with ImageJ software. 
3.2.6. Determination of the binding constants by static partition experiments 
The functionalized supports were regenerated with 0.2 M NaOH in 50% isopropanol and distilled water 
and equilibrated with PBS. Different concentrations of lysozyme (0.5 to 3.4 mg lysozyme/ml) or IgG (0.2 to 
3.5 mg IgG/ml) were incubated with the 2.5 mg/ml of functionalized magnetic particles in a total volume of 
500 μl and 250 μl, respectively. The interaction was promoted over 12 hours at 4°C and 25°C, respectively 
for lysozyme and IgG, to achieve chemical equilibrium. The supernatants were collected and the 
fluorescence intensity was measured. The adsorption phenomenon followed a Langmuir isotherm and the 
experimental data was fitted using OriginPro (v8.5.1). 
 
3.3. Results and Discussion 
3.3.1. Affitin immobilization onto magnetic supports 
The best conditions for Affitin anti-lysozyme functionalization onto magnetic particles were determined 
by (i) tuning magnetic particle concentration, (ii) usage of reduction agent and (iii) ratio of Affitin to amines 
on the support (Figure 3.1). Two different magnetic particle concentrations were tested during the 
immobilization protocol (2.5 and 10 mg/ml) with a 1:0.05 NH2 to Affitin molar ratio. Both conditions yielded 
similar results, and a 2.5 mg/ml concentration of MP was fixed for further studies. The immobilization of 
Affitin was promoted through sulfo-SMCC, a crosslinker between the amine groups of the support and the 
sulfhydryl group of the Affitin H4-Ct. In solution, Affitin molecules can form dimers and potentially decrease 
the immobilization yield. However, pre-incubation with tris(2-carboxyethyl)phosphine (TCEP), a sulfhydryl 
group reducing agent, showed a decrease in the immobilization yield (Figure 3.1A). The results obtained in 
the presence of dithiothreitol (DTT) or with no-reducing agent added were comparable. However, to avoid 
the addition of chemicals and for more reproducible results, no reducing agent was used in the upcoming 
experiments. The ratio between amines in the support and moles of Affitin (NH2:Affitin) was also tested 
(Figure 3.1B). Reducing the molar amount of Affitin contributed to a decrease of the Affitin immobilized 
(Figure 3.1B). However a higher amount of Affitin to the support amines would not be suitable due to the 
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large size difference between the particles and Affitin, which would not allow a 1:1 ratio as usually used with 
peptides [154]. Therefore, and considering that unreacted free amines are further blocked with cysteine 
residues, the intermediate condition was selected. To summarize, the best immobilization conditions have 
been determined as using 2.5 mg/ml of MP, the non-usage of a reducing agent in prior incubation step and 
a ratio of 1:0.1 of NH2:Affitin, resulting in a final immobilization of 14.5 ± 4.1 μmol Affitin H4-Ct/g support 
(101 ± 29 mg Affitin H4-Ct/g support).  
 
3.3.2. Magnetic particles characterization  
To confirm the surface modification of magnetic particles and further immobilization of Affitins, Fourier 
transform infrared (FT-IR) spectroscopy was employed (Figure 3.2A). The FT-IR spectra of Affitin H4-Ct 
alone (Figure 3.2A; spectra a) shows a band at 1620 – 1640 cm-1 that corresponds to amide I (C=O 
stretching) and is centered in the region which has been assigned to β-sheets in protein structures [155]; 
this is correlated with the presence of five β-sheets in the three-dimensional structure of Affitin H4 (PDB ID: 
4CJ2 [142]).  
The FT-IR spectra obtained for the magnetic particle samples before Affitin immobilization (Figure 3.2A; 
spectra c) show bands in the region 400 - 600 cm-1, typical for the Fe-O bond vibrations in the structure of 
magnetite [156]; a signal at 1168 cm-1 typical of tetraethyl orthosilicate [157]; a broad peak at 3434 cm-1 
typical for the hydroxyl stretching vibration of dextran [158]. The main characteristic bands for dextran are 
superimposed in a broader peak at 1020-1146 cm-1 resultant of the deformation vibrations of the CCH and 
HCO bonds and valent vibrations of C-O and C-C bonds [158]. Affitin immobilization is confirmed in the final 
functionalized particles (Figure 3.2A; spectra b) by an extra band at 1550 cm-1.  
The magnetic particles were further analyzed by Dynamic Light Scattering (DLS). The hydrodynamic 
diameter (Figure 3.2B) indicates the formation of 2 μm agglomerates of the bare particles due to low stability 
rendered by the lack of coating [159]. The successive coatings with silica confer stability and hydrophilicity 
to the particles [160], which contribute to a decrease in the hydrodynamic diameter. The coating with the 
Figure 3.1. Optimization of Affitin H4-Ct immobilization (n=3) in 2.5 mg MP/ml using Sulfo-SMCC as cross 
linker agent by changing (A) reduction agent, and (B) ratio NH2 of the support to Affitin. 
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polymer dextran contributed to a smaller hydrodynamic diameter. The amination reagent, (3-
Aminopropyl)triethoxysilane, can crosslink and contribute for the increase of the particles’ diameter. The 
zeta potential values (Figure 3.2C) corroborate the successive surface modification with different 
functionalities. Magnetite displays negative zeta potential values at pH 5.80 and a decrease towards more 
negative values upon silica coating was observed. The neutral polymer dextran contributes for the neutral 
charge of the dextran-coated particles. The zeta potential moves towards positive values after particle 
amination and little difference was observed after Affitin functionalization due to the isoelectric point of 8.8 





Figure 3.2. Sample characterization by (A) FT-IR spectra for (a) Affitin H4-Ct, (b) MP-H4-Ct, (c) MP-SiO3-
TEOS-DEX-NH2 and magnetic particles characterization by (B) DLS and (C) zeta potential (n=3) for (1) MP, 
(2) MP-SiO3, (3) MP-SiO3-TEOS, (4) MP-SiO3-TEOS-DEX, (5) MP-SiO3-TEOS-DEX-NH2, (6) MP-H4-Ct, 
(7) MP-D1Sso7d-DM-Ct. 
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3.3.3. Optimization of binding and elution conditions of anti-lysozyme particles 
Prior to functionalization, aminated magnetic supports were tested for non-specific binding to lysozyme, 
resulting in 7.1 ± 1.8 % of lysozyme bound (when loading 0.5 mg of protein). The dextran coating renders a 
neutral charge to the particle surface (Figure 3.2C) and has hydroxyl functional groups which contribute for 
the non-specific binding, as previously reported in other works [161]. On the other hand, the isoelectric point 
of lysozyme is located at pH 11.0 [162], which makes lysozyme positively charged at pH 7.4 during the 
binding assay. The positive charge of the aminated particles decrease the binding of lysozyme, and 
contribute to low non-specific binding. 
The best conditions for lysozyme binding were determined by tuning (i) magnetic particle concentration, 
(ii) lysozyme to Affitin ratio and (iii) incubation temperature (Figure 3.3). Contrary to what was observed 
during the immobilization step, particle concentration had a high influence on lysozyme binding (Figure 
3.3A). A lower concentration (2.5 mg/ml) of particles contributed to a higher amount of lysozyme binding to 
the support, probably due to lower hindrance, which could allow lysozyme to better interact with the 
immobilized Affitin. A higher molar ratio (1:3) between Affitin and lysozyme contributed to increase the 
binding percentage, as a higher amount of binder increases the probability of lysozyme to bind (Figure 
3.3B). Lower incubation (0-8oC) temperature contributed to increase the percentage of lysozyme bound to 
the support (Figure 3.3B). Therefore the best binding conditions have been determined as follows: a particle 
concentration of 2.5 mg/ml, a ratio of lysozyme to Affitin of 1:3, and an incubation step at lower temperatures, 
which resulted in a final binding of 58.3 ± 12.6 mg lysozyme/g support. 
 The first approach for lysozyme recovery from the magnetic supports was determined by setting the 
phosphate buffer and tuning the pH and NaCl concentration (Figure 3.4A). Varying the salt concentration 
resulted in different elution yields, with higher yields observed at lower NaCl concentration. However, the 
pH of the buffer was the determinant condition for lysozyme elution. A higher elution yield (24.3 ± 5.6 mg/g 
support) was obtained at acidic pH 2.5, as classically observed in affinity chromatography. For example, the 
salt-bridge formed at neutral pH between Asp52 (pKa  = 3.9) and Lys39 of Affitin H4-Ct could be disrupted 
as aspartic acid is no longer negatively charged at low pH [142]. This would contribute to the dissociation 
of the two proteins. Higher lysozyme recoveries from magnetic supports were also observed by Chen et al. 
at lower pH values [163]. Good yields were also obtained at pH 11.0, a value closed to the isoelectric point 
of lysozyme, contributing for the disruption of the interaction between Affitin and lysozyme. For instance, 
the same Lys39 of lysozyme (pKa = 9.74) [142] is no longer protonated at pH 11.0. 
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Figure 3.3. Optimization of lysozyme binding to MP-H4-Ct by changing: (A) MP concentration (mg/ml; 
performed at 0-8 °C), (B) ratio lysozyme to immobilized Affitin (performed at 0-8 °C) and (C) incubation 
temperature (°C). (D) hIgG binding to MP-D1Sso7d-DM-Ct with 2.5 mg/ml MP (performed at 0-8 °C), and a 
1:3 hIgG to Affitin ratio changing the incubation temperature. 
 
Due to its capacity to disrupt hydrophobic interactions, 50% ethylene glycol was also added to the elution 
buffers at pH 2.5 and pH 11.0 (data not shown). It was observed the recovery of 17.6 mg lysozyme/g support 
and 7.1 mg lysozyme/g support at pH 2.5 and pH 11.0, respectively, therefore showing that the presence 
of ethylene glycol decreased the recovery yield. The results suggest that hydrophobic contacts identified 
between lysozyme and the Affitin H4 do not contribute as significantly as hydrogen bonds and salt bridges 
[142] (Figure 3.4A).The best elution condition (0.15 M NaCl, pH 2.5) was tested with a glycine-HCl buffer, 
to study the influence of the buffer composition (Figure 3.4B). This resulted in recovering twice the amount 
of lysozyme than using a phosphate buffer for the same pH, with a total of 55.0 ± 4.1 mg lysozyme eluted/g 
support. Additionally, an SDS-PAGE gel analysis was performed to confirm lysozyme elution, and at the  
same time that the low pH does not promote Affitin leakage from the support as no band corresponding to 
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Figure 3.4. Optimization of lysozyme elution from Affitin-functionalized magnetic particles. (A) Using a 10 mM 
phosphate buffer, varying the pH conditions and NaCl concentration. (B) Comparing lysozyme elution using 10 mM 
phosphate buffer, 0.15 M NaCl, pH 2.5 and 100 mM glycine buffer, 0.15 M NaCl, pH 2.5. (C) Coomassie stained SDS-
PAGE gel (12.5% acrylamide) in reducing conditions of purification fractions collected using pure lysozyme from 
chicken egg white using as purification conditions 2.5 mg/ml MP functionalized, with an incubation period of 30 minutes 
at 4°C, as elution buffer 100 mM glycine buffer, 0.15 M NaCl, pH 2.5 was used. Lanes ID: MM: Precision Plus 
ProteinTM Dual Color Standards (molecular weight in kDa); Loading: pure lysozyme from chicken egg white; W1: first 
wash; W2: second wash; E1: first elution; E2: second elution. 
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3.3.4. Application of the magnetic adsorbent for lysozyme recovery 
The performance of the MP-H4-Ct support for the recovery of lysozyme from an E. coli crude extract was 
tested. A cell-free E. coli supernatant was spiked with 0.8 mg/ml of lysozyme for a total protein concentration 
of 2.1 ± 0.5 mg total protein/ml in 500 μl, and incubated with 500 μl of 2.5 mg MP-H4-Ct/ml for 30 minutes 
at 0-8°C. Afterwards, the support was washed with PBS and the bound protein was eluted with 100 mM 
glycine-HCl buffer, 0.15 M NaCl, pH 2.5. The resultant samples were analyzed by SDS-PAGE (Figure 3.5A). 
It was possible to confirm that most host-cell proteins were present in the flow-through (FT) and first wash, 
and no lysozyme was present after the third wash. The non-specific binding of host cell proteins to the 
magnetic support was negligible even with about seven times more concentrated crude extract proteins. A 
one-step elution was possible with 100 mM glycine-HCl buffer, 0.15 M NaCl, pH 2.5, with a lower 
concentration of lysozyme coming out in the following elution steps. It was possible to achieve a final 
lysozyme purity ≥95%, which is higher than the purity values described for the one-step purification of 
lysozyme from non-diluted egg white [164] although the protein complexity of this kind of sample is much 
lower than an E. coli crude extract. 
3.3.5. Application of the magnetic adsorbent for IgG recovery  
Following the optimization process using MPs functionalized with the anti-lysozyme Affitin, the best 
conditions were applied for the immobilization of Affitin D1Sso7d-DM-Ct (anti-IgG) on MP and for the 
purification of IgG. Regarding the immobilization of Affitin D1Sso7d-DM-Ct on the magnetic support, the 
following optimized conditions were used - 2.5 mg/ml of MP, a 1:0.1 NH2:Affitin ratio, without any reduction 
agent-,  resulting in a final immobilization of 15.1 ± 0.76 µmol Affitin D1Sso7d-DM-Ct/g support (133.5 ± 6.7 
mg Affitin D1Sso7d-DM-Ct/g support). Regarding the optimization of the binding conditions, the MP 
concentration (2.5 mg/ml) and the protein:Affitin ratio (1:3) were maintained constant, changing the 
incubation temperature. The binding was compared at 25°C and 0-8°C, since previous studies showed 
binding of this Affitin to the target protein at room temperature [142,144]. Before functionalization, aminated 
supports were tested for non-specific binding to IgG resulting in 4.7 ± 1.6 % IgG bound (loading 0.25 mg). 
For the functionalized magnetic particles, the results (Figure 3.3B) showed that IgG was able to bind at both 
temperatures after 30 minutes incubation period. However, better results were obtained at 25°C with a 165.8 
± 14.1 mg IgG/g support binding. Bound IgG was eluted using 100 mM glycine-HCl with 0.15 M NaCl at pH 
2.5, resulting in a recovery yield of 165.8 ± 9.3 mg IgG/g support, meaning 100% of the bound IgG was 
eluted in a one-step elution. The interaction between Affitin D1Sso7d-DM-Ct occurs in the Fc region of IgG 
but not in the same recognition sites as for protein A or CD64, two proteins known to bind strongly to IgG. 
One of the Affitin residues strongly involved in IgG recognition is Asp26 (pKa = 3.9) [144]. Hence at low pH 
this negatively charge residue is no longer charged and this could contribute to disrupt the interaction 
between Affitin and IgG. 
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To assess the purification capacity of MP functionalized with anti-IgG Afftin, human serum was used as 
crude extract. In Figure 3.5B, it is possible to confirm the washing of most proteins in the FT fraction, 
although no IgG is present (50 and 25 kDa). This confirms that IgG remains bound to the affinity magnetic 
support. Likewise, no IgG was lost in the two following washes. Three elution steps were performed; 
nonetheless IgG was only eluted in the first elution enabling not only its recovery but also its concentration. 
At the end it was possible to achieve a final purity of 81% with an approximate final concentration of 60 mg 
IgG eluted/g support. Higher final purities have been reported for the isolation of antibodies from CHO cell 
culture (higher than 95%) [21,110,136]. However, our tests were performed with human plasma which 
contains a higher abundance of contaminant proteins (25 mg total protein/mg IgG) when compared to CHO 
cell culture supernatant (1.5 mg host cell protein/mg IgG) [165–167]. In addition, human plasma contains 
all Ig classes, even though it’s known that D1Sso7d-DM-Ct does not interact with IgA [144], its binding to 
other classes in unknown, therefore the extra bands in the elution fraction may also be related to other 





Figure 3.5. Purification performance of H4-Ct and D1Sso7d-DM-Ct for (A) lysozyme and (B) IgG. Silver 
stained SDS-PAGE gel (12.5% acrylamide) in reducing conditions of purification fractions collected using 
crude extracts from (A) E.coli supernatant and (B) human plasma using as purification conditions 2.5 mg/ml 
MP functionalized, with an incubation period of 30minutes at (A) 4°C and (B) 25°C, as elution buffer 100 
mM glycine buffer, 0.15 M NaCl, pH 2.5 was used. Lanes ID: MM: (A) Low molecular weight Protein Marker 
and (B) Precision Plus ProteinTM Dual Color Standards (molecular weight in kDa); Loading: Crude extracts 
loaded: (A) E.coli supernatant and (B) human plasma; FT: flow-through; W1: first wash; W2: second wash; 
W3: third wash; E1: first elution; E2: second elution (all fraction with the same protein concentration (0.06 
mg total protein/ml). Position of IgG heavy (H) (50 kDa) and light (L) (25 kDa) chains are indicated in the 
right side of the gel. 
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3.3.6. Determination of the binding constants by static partition experiments 
The affinity constant (Ka) and Hill coefficient were determined by the application of Hill plot adjusted to 
data obtained from partition equilibrium studies (Figure 3.6A; B), with the maximum binding capacity of the 
supports (Qmax) estimated by the Langmuir model (Figure 3.6C; D). The obtained values are summarized in 
Table 3.1. Considering the estimated static Qmax, the value obtained for MP-H4-Ct (287 ± 41 mg lysozyme 
/g support or 20 ± 3 μmol lysozyme/g support) was significantly higher than the Qmax value obtained for other 
lysozyme magnetic purification systems (e.g. 70 mg lysozyme/g [168] and 138 mg/g [164]), but within the 
range of other works relying on ion-exchange supports with high surface area (209 mg lysozyme/g support 
[169]). As for the MP-D1Sso7d-DM-Ct adsorbent, a lower Qmax was observed (157 ± 13 mg IgG/g support 
or 1.1 ± 0.1 μmol IgG/g support), which might be due to steric hindrance between immobilized Affitin and 
the large IgG molecule. This problem could be surpassed with a longer spacer between the MP and Affitin. 
 
 
Figure 3.6. Binding isotherms for the affinity pair MP-H4-Ct and lysozyme (A and C; ○) and MP-D1Sso7d-
DM-Ct and hIgG (B and D; □). The experimental results (C and D) were fitted to the Langmuir model (q= 
((Qmax × Ka × C) / (1 + Ka ×C)), where q is the bound protein per mass of support (mg/g support) and C 
corresponds to the concentration of unbound protein in equilibrium (mg/ml) [43]. The experimental results (A
and B) were fitted to the Hill plot linearization Log(q/ (Qmax-q)) = Log(Ka) + nH x Log(C), where q is the 
bound protein per mass of support (mg/g support) and C corresponds to the concentration of unbound protein 
in equilibrium (mg/ml) [41]. 
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The Ka obtained for the MP-H4-Ct was lower than that described originally by Correa et al. between the 
free Affitin and lysozyme by isothermal titration calorimetry (5.0×104 M-1 vs 1.1×108 M-1) [142]. It is commonly 
observed that immobilization tends to alter the binding constants due to the influence of the support and 
linker chemistry [170]. Still, the Ka value obtained was within the range considered suitable for purification 
methods (103-109 M-1 [171]), with Ka values between 104 - 105 M-1, considered ideal for reversible 
binding/elution purification schemes. Regarding the MP- D1Sso7d-DM-Ct, the system also presented a Ka 
favorable for purification (9.3 x 105 M-1), and these results are in line with previous reporting a 4 x 106 M-1 
for this Affitin by surface plasma resonance experiments [149]. In both affinity pairs the Hill coefficient 
determined was higher than 1 (n>1), demonstrating a positive cooperative binding in both cases.  
 
Table 3.1. Binding constants determined for both affinity pairs by fitting of the experimental results to 
Langmuir isotherm and Hill. 
 
3.4. Conclusions 
This work reports the first successful immobilization of Affitins on magnetic particles to yield an efficient 
platform for protein purification by magnetic fishing. Here, an optimization study was done in order to 
improve the immobilization, binding and elution conditions, which represent a critical step in any novel 
purification scheme. The optimal lysozyme binding conditions - particle concentration of 2.5 mg/ml, an 
incubation step at low temperature and a 1:3 lysozyme to Affitin ratio- resulted in 58.3 ± 12.6 mg lysozyme 
bound/g support, similar to what was obtained in other studies (e.g. 76.5 mg lysozyme/g support) [168]. On 
the other hand, IgG purification had the best results at room temperature, binding over 165.8 ± 14.1 mg 
IgG/g support, a higher amount than those reported using MP (51 mg IgG/g support [172] or 130 mg IgG/g 
support [22,136]). The binding parameters, Qmax and Ka for both proteins are favorable for the use of MP 





Hill factor (n) R2 
















6.1×104 ± 4.5×104 287 ± 41 - 0.90 11 x 108 [6] 
MP-D1Sso7d-
DM-Ct/hIgG 








5.0×104 ± 1.7×104 287 ± 41 1.4 ± 0.1 0.90 11 x 108 [6] 
MP-D1Sso7d-
DM-Ct/hIgG 
9.3×105 ± 1.8×105 157 ± 13 1.8 ± 0.2 0.92 4 x 106 [12] 
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with Affitins for purification purposes. All these results confirm attractive features observed previously for 
Affitins immobilized on agarose matrix and their use for affinity purification applications [150]. 
The best elution conditions were 100 mM glycine-HCl with 0.15 M NaCl at pH 2.5, allowing the recovery 
of 55.0 ± 4.1 mg lysozyme/g support and 157 mg IgG/g support. Using this elution condition and pure 
proteins, it was possible to recover 100% of lysozyme and IgG in a one-step elution. When performing the 
proteins purification from heterogeneous samples, crude extracts of E.coli for lysozyme separation, and 
human serum for IgG separation, it was possible to have a final purity of 100% for lysozyme and 81% for 
IgG.  
Here we have reported two systems for protein purification using MP functionalized with Affitins. These 
Affitins have been proven to be highly specific for their cognate targets, robust under the extreme acidic or 
alkaline pH generally used for affinity separations, well produced in E. coli and easy to engineer [149]. All 
these properties might contribute to development of cost effective magnetic separation systems not only for 
lysozyme and IgG, but virtually for any protein of interest given the versatility of Affitins. We anticipate Affitin-
MPs might find a broad panel of applications, such as research and diagnostics tools, either to quickly enrich 
a sample for a given target or on the contrary to deplete it from samples, and as an alternative to the 
traditional chromatographic systems. 
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Abstract  
After more than one hundred and thirty thousand protein structures determined by X-ray crystallography, 
the challenge of protein crystallization for 3D structure determination remains. As new additives emerge, 
magnetic particles (MPs) are versatile inorganic materials, easy to use and manipulate in a wide range of 
biological assays. The potential of using MPs as crystallization chaperones for protein crystallization was 
here evaluated. MPs coated with different molecules were rationally designed to promote crystallization by 
affinity-triggered nucleation to enhance protein crystal growth. Hen egg white lysozyme (HEWL), trypsin and 
green fluorescence protein (GFP), were crystallized in the presence of MPs either bare or coated with a 
polysaccharide (chitin), a protein (casein) and a synthetic ligand (A4C7), respectively. The addition of MPs 
was characterized in terms of bound protein to the MPs, crystal morphology, time-lapse of crystal 
emergence, crystallization yield fold change and crystal diffraction quality for structure determination. The 
MPs additives have shown to bind to the respective target protein, promoted nucleation and crystal growth 
and, moreover, crystal morphology did not change in the presence of MPs. On the other hand, MPs addition 
led to faster detectable crystal emergence and an up to 13 times higher crystallization yield. Structure 
determination of the protein crystallized in the presence of MPs revealed that the structural characteristics 
of the protein remained unchanged, as shown by the superposition with PDB annotated proteins. Moreover, 
and unlike most reported cases, it was possible to crystallize trypsin in the absence of its inhibitor 
benzamidine. Instead, functionalized MPs were used to trigger crystallization, showing promising results. 




High-resolution structure determination of macromolecules alone or in complex with ligands is a powerful 
tool in protein engineering and drug design. The structural information about a protein is one of the key 
steps to control or improve its function, by rationally designing small binding molecules [173] (e.g. agonist 
or antagonist drugs), or by engineering mutants with a desirable biological activity [174]. On the other hand, 
the three-dimensional high-resolution structure of molecular complexes can unveil macromolecule-ligand 
interactions enhancing its biotechnological applications in fields such as biocatalysis [175], sensing material 
development [176], macromolecule function redesign [177], or in the downstream processing field [178].  
One of the most powerful tools for high-resolution structure determination is X-ray crystallography, 
providing an atomic resolution 3D structure of a single protein, protein-DNA complex, protein-protein or a 
protein-ligand complex. X-ray crystallography requires high-quality protein crystals for X-ray diffraction. 
However, the major bottleneck still lies in finding the conditions that give rise to diffraction-quality single 
crystals, added to reliable reproducibility. This can be overcome by developing new and more efficient 
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crystallization screening protocols, but also by introducing new additives that can act as nucleation agents 
for protein crystal growth. 
Protein crystallization occurs under saturated conditions, by changing the protein environment until 
protein’s solubility limit is exceeded, leading to nucleation and crystal growth. The supersaturating 
environment is most of the times determined in an empirical manner. Although classical nucleation theory 
and phase diagram plots may enlighten the interactions promoting protein crystallization, the fact is that 
protein crystallization is still a rather empirical process. The formation of a protein crystal starts with the 
nucleation phase in which the protein molecules, in the supersaturated solution, become arranged in a 
specific repetitive pattern, characteristic of the crystalline form. Then, additional protein molecules are 
deposited on the nucleus surface and the crystal grows in progressive layers. To overcome some of the 
protein crystallization challenges, with the prospect of developing a more general and straightforward 
crystallization process, new additives with nucleation properties are frequently tested. An additive for 
crystallization purposes is any compound used to facilitate nucleation events, reduce the crystal solvent 
content or prepare heavy atom derivatives.[179,180]. Traditional additives commonly found in the 
crystallization screening protocols rely mainly on surfactants, organic compounds, mono- and multivalent 
salts, reducing agents, amino acids or monosaccharides. New additives can be of biological source, such 
as DNA origami [181] and cyclic oligosaccharides [182], or of non-biological origin as small synthetic ligands 
[180] or nanoscale materials [59]. In particular, new nanoscale materials, namely nanoparticles made of 
gold, porous silicon or nanodiamonds, as well as carbon nanotubes, have already been successfully used 
as nucleation agents to trigger crystal growth in different protein crystallization studies for 3D structure 
determination [183–187]. 
Magnetic particles with an iron oxide (Fe3O4) core are another class of nanomaterials never used in the 
context of protein crystallization. Among the advantages of magnetic particles, they are low cost, easy to 
produce and handle, and able to be tailored with different coatings and functionalization. In addition, with a 
superparamagnetic core, these particles can be easily separated from a solution by applying an external 
magnetic field and reversibly resuspended back in solution [136,188,189]. 
Here, we aimed to study the potential of magnetic nanoparticles as additives in protein crystallization. 
Three proteins were selected as model case studies: hen egg white lysozyme (HEWL), bovine trypsin and 
green fluorescent protein (GFP) from Aequorea victoria. To promote the selective binding of the target 
protein to the surface of the magnetic nanoparticles, known affinity ligands for HEWL, trypsin and GFP were 
coated to the surface of the particles. The obtained protein single crystals were further evaluated in terms 
of X-ray diffraction quality. Our results indicate that the presence of magnetic particles as crystallization 
additives to improve protein nucleation caused no changes in maximum resolution limits or in unit cell 
parameters, maintaining crystal isomorphism when compared to native conditions. Furthermore, the 
addition of magnetic particles led to the increase of crystallization yield and enabled a reproducible 
crystallization of trypsin in the absence of its inhibitor benzamidine, commonly used in trypsin crystallization 
assays. 
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4.2. Materials and methods 
4.2.1. Reagents and equipment 
All chemicals were at least 98% pure and solvents pro-analysis grade. All produced magnetic supports 
were characterized by Fourier-transform infrared spectroscopy (FT-IR), dynamic light scattering (DLS), zeta 
potential and transmission electron microscopy (TEM). Infrared spectra were measured on a Tensor 27 FT-
IR spectrometer from Bruker with dried MPs grounded and mixed with KBr (1:100). DLS and zeta potential 
(0.05 mg/ml solution in deionized water, pH 5.80, or other solution if otherwise stated) were measured on 
Dynamic Zetasizer NanoZS from Malvern instruments. TEM of magnetic particles samples were collected 
using Hitachi 8100 microscope operated with 200 kV of acceleration voltage with ThermoNoran light 
elements EDS detector and digital image acquisition.  
4.2.2. Preparation iron oxide magnetic particles 
Fe3O4 magnetic particles (MP-Fe3O4) were prepared by the chemical co-precipitation method [190]. 
Briefly, 0.225 M FeCl3 · 6H2O (24.33 g in 400 ml of H2O) and 1.43 M FeCl2 · 4H2O (10.79 g in 45 ml of H2O) 
were mixed under mechanical stirring until homogenization was achieved. A 25% NH4OH solution (75 ml) 
was added to the mixture under constant mechanical stirring (200 RPM). The resulted mixture was 
vigorously stirred for 5 minutes. MP-Fe3O4 were separated by a magnet and washed with distilled water 
several times until pH 7 was reached.  
A suspension of 10 mg/ml MP-Fe3O4 was sonicated for 15 minutes and further coated with a chitin 
suspension (80 mg/ml; 20 mg in 2.5 ml), added dropwise to the MP-Fe3O4 suspension, under sonication. 
The mixture was incubated for 16 hours at 60ºC with vigorous stirring (200 RPM). After this, the Fe3O4-chitin 
magnetic particles (MP-chitin) were separated by a magnet and washed (10 times) with distilled water. 
Chitin adsorption was measured by the anthrone method as previously described [191], with 90% adsorption 
achieved. 
The synthesis of Fe3O4-casein magnetic particles (MP-casein), was adapted from Alves and co-authors 
protocol [192]. A solution of 10 ml of 0.225 M FeCl3 · 6H2O was added to 10 ml 1.43 M FeCl2 · 4H2O and 
next added to a 20 mg/ml casein (from bovine milk powder) solution in 100 mM Tris-HCl at pH 8.0. The 
mixture pH was adjusted to pH 11 using 25% ammonium hydroxide solution. Next, the mixture was 
incubated for 30 minutes at 50ºC under orbital shaking (200 RPM). MP-casein were separated by a magnet 
and washed with distilled water several times until pH 7 was reached. The casein bound to Fe3O4 magnetic 
core was quantified using absorption at 280nm, yielding 80% binding. 
Fe3O4 particle solution (10 mg/ml), synthesized by the co-precipitation method, was sonicated for 15 
minutes, and then added to a solution of sodium metasilicate pentahydrate (from Sigma-Aldrich) in 50% 
(v/v) ethanol/water (28.5 mg/ml). The reaction was stopped after 2 hours at 40ºC with orbital shaking (200 
RPM) and the particles washed with distilled water (10 times). The particles were resuspended in 20% (v/v) 
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ethanol/water (80 ml) and sonicated for 10 min, followed by dropwise addition, still during sonication, of 25% 
ammonium hydroxide (3 ml) and tetraethyl orthosilicate (TEOS) (1.5 ml, Sigma-Aldrich). The reaction was 
stopped after 2 hours at 40ºC with orbital shaking (200 RPM), and the particles washed with distilled water 
(10 times). The particles were resuspended in 175 ml of distilled water and sonicated for 10 minutes and 
further coated with dextran (from Leuconostoc mesenteroides 150 kDa, Sigma-Aldrich). A dextran solution 
(80 mg/ml in distilled water) was added dropwise to the particle solution and the mixture incubated (60°C, 
2 hours with orbital shaking, 200 RPM), after which the particles were washed 5 times with distillated water. 
Magnetic particles coated with dextran were further functionalized with synthetic UGI ligand A4C7 [193] 
(MP-A4C7). Synthetic ligands based on the UGI reaction are obtained from the reaction between the 
aldehyde-functionalized support, an amine, a carboxylic acid and isopropyl isocyanide. The particles were 
firstly aminated using (3-aminopropyl)triethoxysilane (APTES). The amine content was quantified by the 
Kaiser Test yielding 213.3 ± 3.8 µmol NH2/g of dried MP. The aminated particles were resuspended in 5% 
(v/v) glutaraldehyde and 1 M NaOH, sonicated for 5 min and incubated for 1h at 3ºC with orbital shaking 
(200 RPM). After this, the particles were washed with distilled water (5 times). The first substitution was the 
amine (1-pyrenemethylamine hydrochloride) (5 molar excess to the amine content, in methanol). The 
reaction was performed under 60ºC for 2 hours with orbital shaking (200 RPM), followed by addition of the 
carboxylic acid (phenylacetic acid) (5 excess molar to the amines content, in methanol) and isopropyl 
isocyanide (5 excess molar to the amines content), and incubated for 48 hours at 60ºC with orbital shaking 
(200 RPM). The particles were washed with methanol (2 times), 50% (v/v) DMF (N,N-
dimethylformamide)/methanol (2 times), distilled water (1 time), 0.1 M sodium hydroxide with 30% 
isopropanol (2 times), distilled water (5 times). Finally, the particles were resuspended in the appropriated 
volume of water. 
4.2.3. Biological material 
Pure lysozyme from chicken egg white (protein ≥90 %, ≥40,000 units/mg protein, Sigma-Aldrich), pure 
Trypsin from bovine pancreas (PanReac AppliChem) and recombinantly expressed green fluorescent 
protein (GFP) were used in the crystallization assays. For GFP expression, glycerol stocks with transformed 
E. coli cells BL21(DE3) pET-21C plasmid encoding GFP (Geneart) were used as described [194]. The pre-
inoculum samples (glycerol stocks (5 µl)) were incubated in LB medium (5 ml) with ampicillin (100 µl/ml final 
concentration) for 6 hours at 37ºC and 220 RPM. The pre-inoculum (1 ml) was placed in 500 ml shaking 
flask with LB medium (100 ml) and ampicillin (100 µl/ml final concentration) for 16 hours at 37ºC and 220 
RPM. For protein expression, the inoculum (20 ml) was placed in a 5000 ml shaking flask with LB medium 
(2000 ml) and ampicillin (100 µl/ml final concentration) at 37ºC with 220 RPM orbital shaking. At OD600nm= 
0.6-0.8, 3-5 hours after growth, protein expression was induced with the addition of IPTG (1 mM final 
concentration) and culture growth was performed for 22 hours with 220 RPM at 37ºC. Afterwards, cell 
harvest was done by centrifugation (4500 xg, 15 min, 4ºC), and the pellet resuspended in 10 mM Tris-HCl 
at pH 8. The resuspended pellet was subjected to three freeze/thaw cycles and cell lyses carried out in a 
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French Press (four passages at 1000 psi). The resulting lysates were treated with 10% (w/v) DNase I for 15 
min at 4ºC, following a centrifugation (10 000 xg, 30 min, 4ºC) and an ultracentrifugation (22 000 xg, 90 min, 
4ºC). The soluble fraction was further purified having as capture step the multimodal chromatography using 
A4C7 synthetic ligand, as described [193]. The eluted fractions were pooled and dialyzed to 20 mM Tris-
HCl at pH 8. Following, a polishing step using anion exchange chromatography using MonoQ (GE 
Healthcare, Sweden) having as binding buffer 20 mM Tris-HCl at pH 8 and as elution buffer 1 M NaCl in 20 
mM Tris-HCl pH 8. The final soluble crude extract was quantified by fluorescence (λex = 485 nm, λem = 
535 nm, calibration curve [GFP] 106 –101 mg/ml; Evrogen, Russia) and bicinchoninic acid colorimetric assay 
(BCA, calibration curve [BSA] 0.2-1 mg/ml, Sigma–Aldrich). Purity assessment was performed with Sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE). The buffer sample composition was 0.15 
M Tris–HCl at pH 6.8, 6% (w/v) SDS, 0.025% (w/v) bromophenol blue, 12.5% (v/v) glycerol and as reducing 
agent β-mercaptoethanol was used. Prior to loading in the gel, all the samples were denaturated at 100°C 
for 5 minutes. Samples were applied in a 12.5%, prepared from 41% acrylamide/bis stock solution (30:1) 
from Bio-Rad and migrated at 90 mV using as running buffer 192 mM glycine, 25 mM Tris-HCl and 0.1% 
SDS, pH 8.3. Gels were Coomassie stained with the staining solution of 0.5% (w/v) Coomassie Blue R-250, 
7.5% (v/v) acetic acid, 45% (v/v) methanol, for 30 minutes at room temperature with orbital shaking and 
revealed with the distaining solution (7.5% (v/v) acetic acid, 45% (v/v) methanol) until proper protein 
visualization. Images were acquired with Gel Doc™ XR+ System with Image Lab™ software from Bio-Rad 
and analyzed with ImageJ software. 
4.2.4. Static binding capacity 
MP-Fe3O4 (0.5 mg/ml) and MP-chitin (0.5 mg/ml) in 0.5 M NaCl were separately incubated with HEWL 
at different concentrations (0.2 to 5 mg/ml) in 50 mM CH3COONa at pH 4.5. 0.5 mg/ml of MP-Fe3O4 and 
MP-casein in 0.2 M (NH4)2SO4 with 30% (w/v) PEG8000 were separately incubated with trypsin at different 
concentrations (0.2 to 5 mg/ml) in (a) 3 mM CaCl2 with 10 mg/ml benzamidine and (b) 3 mM CaCl2. The 
interaction was promoted over 16 h at 20ºC. The supernatants were collected, and fluorescence intensity 
was measured (λex = 280 nm and λem = 340 nm). The adsorption phenomena followed a Hill isotherm 





1-n                      Equation 4.1 
Where, q is the bound protein per mass of support (mg/g support) and C corresponds to the 
concentration of unbound protein in equilibrium (mg/ml). 
4.2.5. Binding assay 
HEWL (500 μl at 25 mg/ml) in 50 mM CH3COONa at pH 4.5 was incubated with 500 μl of 0.5 mg/ml of 
MP-Fe3O4 and MP-chitin in 0.5 M NaCl for 1 hour at 20ºC with 200 RPM orbital shaking. For trypsin, 500 μl 
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of 60 mg/ml of trypsin in (a) 3 mM CaCl2 with 10 mg/ml benzamidine and (b) 3 mM CaCl2 were incubated 
with 500 μl of 0.5 mg/ml of MP-Fe3O4 and MP-casein in 0.2 M (NH4)2SO4 with 30% (w/v) PEG8000, for 1 
hour at 20ºC with 200 RPM orbital shaking. The supernatants were collected, and fluorescence intensity 
was measured (λex = 280 nm and λem = 340 nm). 
4.2.6. Magnetic crystallization 
Crystallization assays were performed using the hanging drop method in 24-well crystallization plates. 
The crystallization setups were carried out at 20ºC and drop inspections were performed using an optical 
microscope (V81 Stereo Microscope equipped with Camera – AxioCam Erc5s (5 MP), ZEISS). HEWL in 50 
mM CH3COONa at pH 4.5 (25 mg/ml) was crystallized using the following precipitant solutions: (i) 500 μl of 
0.5 M NaCl, (ii) 0.5 mg/ml MP-Fe3O4 in 500 μl of 0.5 M NaCl and (iii) 0.5 mg/ml MP-chitin in 500 μl of 0.5 M 
NaCl, in 4 μl crystallization drops with 1:1 protein-to-precipitant ratio. 60 mg/ml of trypsin from bovine 
pancreas in (a) 3 mM CaCl2 with 10 mg/ml benzamidine and (b) 3 mM CaCl2 were crystallized using the 
following precipitant solutions: (i) 500 μl of 0.2 M (NH4)2SO4 with 30% (w/v) polyethylene glycol 8000 
(PEG8000), (ii) 0.5 mg/ml MP-Fe3O4 in 500 μl of 0.2 M (NH4)2SO4 with 30% (w/v) PEG8000 and (iii) 0.5 
mg/ml MP-casein in 500 μl of 0.2 M (NH4)2SO4 with 30% (w/v) PEG8000, in 4 μl crystallization drops with 
1:1 protein to precipitant ratio. 15 mg/ml of GFP in 10 mM Tris-HCl at pH 8.0 were crystallized using the 
following precipitant solutions: (i) 500 μl of 0.05 M KH2PO4 and 20% (w/v) PEG8000 at pH 3.8, (ii) 0.5 mg/ml 
MP-Fe3O4 in 500 μl of 0.05 M KH2PO4 and 20% (w/v) PEG8000 at pH 3.8 and (iii) 0.5 mg/ml MP-A4C7 in 
500 μl 0.05 M KH2PO4 and 20% (w/v) PEG8000 at pH 3.8, in 4 μl crystallization drops with 1:1 protein to 
precipitant ratio. 
4.2.6.1. Yield fold change 
The crystallized proteins were harvested from the crystallization drops using a crystallization loop, 
washed in harvesting solution (with 10% more of the correspondent precipitant in solution) to avoid crystal 
solubilization and remove precipitated protein adsorbed to the crystal or MPs. Once cleaned, the crystals 
were solubilized in 10 mM phosphate buffer with 150 mM NaCl at pH 7.4 and centrifuged for 10 minutes at 
2000 xg at room temperature. The supernatant was retrieved and compared with the loading sample in 
terms of amount of protein. HEWL and trypsin were quantified by λex = 280 nm and λem = 340 nm, while 
GFP was quantified by λex = 485 nm, λem =535 nm. The fold change in crystallization yield was calculated 
by Equation 4.2. 
Yield fold change= mg of protein recovered from the crystallization drop 
 mg of protein recovered from positive control drop
                     Equation 4.2 
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4.2.7. X-ray diffraction and data processing 
Data collections from all suitable protein crystals grown in the presence of different MP-Fe3O4 were 
carried out at the in-house X-ray diffraction facility using a Bruker D8 Venture Cu Kα X-ray generator coupled 
to a Photon 100 CMOS detector and an Oxford Cryo-Systems nitrogen stream at 100 K. All protein crystals 
were cryo-protected prior to flash-freezing in liquid nitrogen. HEWL and trypsin were cryo-protected using 
20% glycerol added in the harvesting buffer and GFP using paratone. Data were indexed, integrated and 
scaled using PROTEUM3 software pipeline (Bruker AXS 2015) and converted to observed structure factors 
using SCALEPACK2MTZ and TRUNCATE from the CCP4 suite [195]. The structures were solved by 
molecular replacement using PhaserMR [196] within Phenix [197] with previously known structures of the 
proteins as search models (PDB 6F1L for HEWL, PDB 5MNE for trypsin and  PDB 1GFL for GFP). Electron 
density maps were generated and analysed with COOT [198]. The output model was further refined using 
PHENIX.REFINE [199]. Water molecules and ions were also modelled into the structures. 
 
4.3. Results and discussion 
With the aim to overcome the current challenges that structure determination by X-ray crystallography 
faces, namely finding crystallization conditions and reproducing good-quality single crystals, iron oxide core 
magnetic particles (MP-Fe3O4) were used as additives. In this work, three different proteins with already 
known crystallization conditions, were crystallized in the presence of MPs coated or functionalized with the 
respective affinity ligand (Table 4.1), fomenting affinity-triggered magnetic crystallization. 
Table 4.1. Affinity-triggered magnetic crystallization conditions. Proteins reported crystallization conditions 
and respective maximum resolutions of the X-ray crystallography structures, and the affinity ligands used in 
















(PDB 6QWY) 14.4 kDa 
Protein solution: 50 mM CH3COONa at 
pH 4.5  
Precipitant solution: 0.5 M NaCl 
P43212 
a = 77.2 
b = 77.2 
c = 37.1 
1.92 Chitin 
Trypsin 
(PDB 5MNE) 23.3 kDa 
Protein solution: 3 mM CaCl2 with 10 
mg/ml benzamidine 
Precipitant solution: 0.2 M (NH4)2SO4 
with 30% (w/v) PEG8000 
P212121 
a = 54.7 
b = 58.3 
c = 66.9 2.29 Casein 
GFP 
(PDB 5HGE) 27.0 kDa 
Protein solution: 10 mM Tris-HCl at pH 
8.0  
Precipitant solution: 0.05 M KH2PO4 
and 20% (w/v) PEG8000 at pH 3.8 
P212121 
a = 51.2 
b = 62.9 
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4.3.1. The effect of magnetic particles as additives in crystallization 
Prior to the crystallization assays MPs were produced and chemically modified with affinity ligands 
tailoring each of the target proteins, namely MP-chitin for hen egg white lysozyme (HEWL), MP-casein for 
trypsin and MP-A4C7 for green fluorescent protein (GFP) assays. In brief, MPs were characterized by 
Fourier-transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), dynamic light 
scattering (DLS) and zeta potential (Figure 4.1 and Table 4.2). Particles functionalization was confirmed by 
FT-IR spectra (Figure 4.1A), with spherical shape with 5 to 10 nm in diameter confirmed by TEM (Figure 
4.1B). DLS and zeta potential analyses was assessed both in water and in the crystallization conditions of 
the respective target proteins. Overall MP-Fe3O4 present a smaller hydrodynamic diameter when compared 
with the functionalized MPs in water and in the respective crystallization conditions. Regarding the zeta 
potential, MP-Fe3O4 and functionalized MPs present the same range of stability in water and in the 
respective crystallization conditions (Table 4.2). 
 
Figure 4.1. Characterization of iron oxide magnetic particles (1 mg/ml) by (A) FT-IR and (B) Transmission 
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Table 4.2. Characterization of iron oxide magnetic particles (1 mg/ml) characterization by DLS and zeta 
potential in different crystallization conditions 
 
 
Crystal growth and crystallization yield, as in yield fold change (Equation 4.2), were assessed using MP-
Fe3O4 as nucleation agent for HEWL crystallization. Crystal size measurement was impaired by the opacity 
of MPs in the crystallization drop, hence this was not a reliable method to assess the influence of MPs in 
protein crystal growth (Figure 4.2A). Nonetheless, having MP-Fe3O4 as additives enhanced HEWL crystal 
growth in all concentrations tested, from 0.5 mg/ml up to 4 mg/ml of MPs. The yield fold change, always 
having as threshold the HEWL crystallization in the absence of MPs, demonstrated the positive effect 
(crystal yield >1) of MPs as additives by enhancing the mass of protein crystallized per assay (Figure 4.2B). 
The data suggested an association between the concentration of MPs added and an increase in protein 
crystallized. An increase from 1.5 to 1.9 in yield fold change was observed in the presence of 0.5 and 4 g/l 
of MP-Fe3O4, respectively. However, an exponential association was not observed and, for subsequent 
assays, 0.5 mg/ml of MPs were used as standard MPs concentration to facilitate observations at the 
microscope. The effect of the addition of MP-Fe3O4 was also assessed in the crystallization of trypsin and 
GFP. These additives had a notorious effect in the amount of trypsin crystallized, as seen in the major 
difference in yield fold change in the presence and absence of MP-Fe3O4 (Figure 4.2C), with up to 12 times 
more protein crystallized in the presence of MP-casein. The addition of MPs to the GFP crystallization 
conditions did not affect the crystal growth, and marginal change in the yield fold change of GPF 
crystallization was improved by 1.1 fold (Figure 4.2C). 
 
                                           MP 
Condition                                       






Water 100.9  ± 0.1 245.5  ± 0.4 8243.5 ± 1579.6 6482.3 ± 784.9 
0.5 M NaCl  5134.8  ± 651.4 4102.0  ± 709.1 - - 
3 mM CaCl2 with benzamidine  95.99 ± 0.85 - 10665 ± 586 - 
3 mM CaCl2  5446.7 ± 2050.8 - 10556.3 ± 1556.4 - 











) Water -0.6 ± 0.4 -15.8  ± 0.4 -6.9 ± 1.8 -1.5 ± 0.6 
0.5 M NaCl  10.3  ±  2.8 -13.5  ± 2.2 - - 
3 mM CaCl2 with benzamidine  23.1  ± 2.8 - 9.7 ± 1.9 - 
3 mM CaCl2  -0.4  ± 0.3 - 14.1 ± 0.5 - 
20% PEG8000  -54.0 ± 1.9 - - -42.1 ± 3.6 
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Figure 4.2. Effect of MPs in protein crystal growth (n=3). (A) Average crystal longest length of visual 
measurement of HEWL crystals over 7 days in the presence of MP-Fe3O4 at different concentrations: 0 
mg/ml (■); 0.5 mg/ml (●); 1 mg/ml (▲); 2 mg/ml (▼) and 4 mg/ml (◄). (B) HEWL crystallization yield fold 
change between crystals grown in the presence of MP-Fe3O4 at different concentrations (0, 0.5, 1.0, 2.0 
and 4.0 mg/ml). (C) HEWL (25 mg/ml), trypsin (60 mg/ml) and GFP (15 mg/ml) crystallization yield fold 
change between crystals grown in the presence of no MP (light grey); 0.5 mg/ml of MP-Fe3O4 (grey). 
 
4.3.2. The effect of affinity-triggered magnetic crystallization 
As HEWL binds to chitin [200], iron oxide MPs coated with chitin (MP-chitin) were evaluated in terms of 
binding capacity under the HEWL crystallization conditions (Table 4.3). The binding assay of HEWL at 25 
mg/ml to both particles - MP-Fe3O4 and MP-chitin - at 0.5 mg/ml showed yields higher than 50% (Table 4.3). 
In the same line, the static binding capacity data of both isotherms were fitted to the Hill plot, since it was 
the best model to fit the MP-chitin::HEWL binding. The summarized data is shown in Table 4.4. The static 
binding capacity data (Table 4.3 and Table 4.4) suggested that HEWL binds to both MP-Fe3O4 and MP-
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Table 4.3. HEWL adsorption to MP-Fe3O4 and MP-chitin (n=3) and trypsin adsorption to MP-Fe3O4 and MP-
casein in the presence and absence of benzamidine. Binding of 25 mg/ml HEWL in 50 mM CH3COONa at 
pH 4.5 to 0.5 mg/ml of MP-Fe3O4 and MP-chitin in 0.5 M NaCl (n=3). Binding of 60 mg/ml trypsin in 3 mM 
CaCl2 in the presence and absence of benzamidine in the protein solution to 0.5 mg/ml of MP-Fe3O4 and 
MP-casein in 0.2 M (NH4)2SO4, 30% (w/v) PEG8000 (n=3). 
 
Bound protein (g protein/g support) 
MP-Fe3O4 MP-affinity 
Lysozyme 17.8 ± 0.7 22.4 ± 1.1 
Trypsin (without benzamidine) 206.4 ± 1.7 206.88 ± 2.2 
Trypsin (with benzamidine) 127.7 ± 0.5 126.4 ± 2.9 
 
Table 4.4. Affinity data for the fitting of the affinity pairs HEWL::Fe3O4 / HEWL::MP-chitin and trypsin::MP- 
Fe3O4 / trypsin::MP-casein in the presence and absence of benzamidine. The experimental results were 
fitted to the Hill isotherm q = Qmax x Ka x C1-n/(1 + Ka x C1-n), where q is the bound protein per mass of 
support (mg/g support) and C corresponds to the concentration of unbound protein in equilibrium (mg/ml). 
 
HEWL Trypsin 















999.6 ± 86.2 2221.1 ± 
279.1 
















n (Hill coefficient) 1.2 ± 0.4 1.4 ± 0.4 2.1 ± 0.7 2.5 ± 0.7 1.7 ± 0.4 1.7 ± 0.5 
 
A crystallization period of 4 days was recorded to assess if the magnetic (MP-Fe3O4) and affinity-
triggered magnetic (MP-chitin) crystallization had an effect in crystal growth (nucleation time and maximum 
dimensions). As representative, in Figure 4.3 the time course of crystal growth for 3 drops with no MPs, MP-
Fe3O4 and MP-chitin is shown. The affinity-triggered magnetic crystallization led to an earlier visible onset 
of HEWL crystals, almost at its full length by day 2. The presence of MP-Fe3O4 did not cause such fast-
triggering effect in crystal nucleation as MP-chitin, but still the HEWL appeared at day 3, one day earlier 
than under the crystallization conditions without MPs. The condition with no MPs, not only led to a delayed 
crystal visible onset, but at the same time, by day 4 the crystal was 3 times smaller than in the presence of 
MPs (Figure 4.3). 
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Figure 4.3. HEWL (25 mg/ml) crystallization in the absence and presence of MP-Fe3O4 and MP-chitin (0.5 
mg/ml). Visual inspection of days 2, 3 and 4 of crystal growth. Black arrows indicate protein crystal. 
 
Prior work demonstrated the feasibility of purifying trypsin from a complex mixture by magnetic fishing 
with iron oxide core MPs coated with casein [192]. The binding capacity of trypsin to MP-Fe3O4 and MP-
casein was calculated in trypsin’s crystallization conditions, and binding results were best fitted by the Hill 
equation (Table 4.3 and Table 4.4). Overall, the MP-casein performed better for trypsin binding than MP-
Fe3O4 in terms of Ka and Qmax. Once again, the addition of MPs has a notorious effect in the amount of 
protein crystallized, as seen in the major difference in yield fold change in the presence and absence of 
MPs (Figure 4.4A), with up to 13 times more protein crystallized in the presence of MP-casein.  
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Green fluorescent protein (GFP) has been reported as a tag protein to enhance protein crystallization in 
fusion with the target protein [201–203]. Its intrinsic fluorescence brings the additional advantage of easy 
detection of protein crystals in the precipitation solution, by visual inspection under normal light conditions. 
As previously described, the synthetic ligand based on the UGI reaction, named A4C7, was uncovered as 
a new ligand to bind and purify GFP and GFP fusion proteins from complex media [193]. As for the addition 
of MP-Fe3O4, the affinity MPs did not improve or had a great impact in crystal yield (Figure 4.5A), 
nonetheless it did not hamper crystal growth (Figure 4.5B). 
Figure 4.4. Trypsin adsorption to MP-Fe3O4 and MP-casein (n=3). (A) Trypsin (60 mg/ml) crystallization yield fold change 
between crystals grown in the presence of no MP (black); MP-Fe3O4 (grey) and MP-casein (light grey). (B) Trypsin (60 
mg/ml) crystallization in the absence and presence of MP-Fe3O4 and MP-casein (0.5 mg/ml) in the with and without 
benzamidine (10 mg/ml) present in the protein solution. Visual inspection was performed at day 30 of crystal growth. White 
arrow indicates protein crystal. 
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Figure 4.5. GFP adsorption to MP-Fe3O4 and MP-A4C7 (n=3). (A) GFP (15 mg/ml) crystallization yield fold 
change between crystals grown in the presence of; no MP (black); MP-Fe3O4 (grey) and MP-A4C7 (light 
grey). (B) GFP (15 mg/ml) crystallization in the absence and presence of MP-Fe3O4 and MP-A4C7 (0.5 
mg/ml). Visual inspection was performed at day 10 of crystal growth. 
 
4.3.3. Magnetic crystallization for peptidases 
Trypsin, being a peptidase, is many times crystallized in the presence of benzamidine, a competitive 
inhibitor of trypsin, trypsin-like enzymes and serine peptidase. In this work the presence of benzamidine in 
the crystallization conditions was assessed in terms of trypsin’s binding capacity to both MPs. 
The binding capacity of trypsin to MP-Fe3O4 and MP-casein was determined in trypsin’s crystallization 
conditions – in the presence and absence of benzamidine (Table 4.3 and Table 4.4). The presence of 
benzamidine impaired trypsin binding to both MPs (Table 4.3), as it was corroborated by the static binding 
capacity results (Table 4.4). This could be due to benzamidine occupying trypsin’s binding site to the MPs 
or by benzamidine binding to the MPs. The presence of benzamidine led to lower Ka and Qmax, whereas the 
absence of benzamidine led to higher Ka, up to one order of magnitude higher (Table 4.4). The higher Ka 
and Qmax observed in the absence of benzamidine rises the hypothesis that either benzamidine and casein 
bind to the same trypsin residues hampering casein to bind trypsin, or some conformational change in 
trypsin occurs when bound to benzamidine, impeding casein to bind. Overall, the MP-casein performed 
better for trypsin binding than MP-Fe3O4 in terms of Ka and Qmax, (Table 4.4). Once established the effect of 
benzamidine in MPs binding, the effects in trypsin crystallization in the absence of MPs, presence of MP-
Fe3O4 and MP-casein, with and without the addition of benzamidine, were assessed (Figure 4.4B). The 
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presence of benzamidine led to higher nucleation rate and crystal size. In contrast, the lack of benzamidine 
in the crystallization drop led to protein precipitation and therefore, no crystal appearance in the drops 
without MPs and with MP-Fe3O4 (Figure 4.4B). When no inhibitor was added, the only condition in which it 
was possible to achieve protein crystallization was in the presence of MP-casein. The affinity-triggered 
crystallization led to crystal growth in conditions that otherwise would result in protein precipitation. When 
adding MP-casein in crystallization assay without adding the inhibitor, in 2 out of 3 crystallization drops 
crystal growth was observed. 
4.3.4. X-ray diffraction studies 
To assess diffraction quality and isomorphism of the crystals obtained in the presence of MPs, in 
comparison to reported crystallization conditions for HEWL, trypsin and GFP, X-ray diffraction studies were 
performed to completion.  
Primary evaluation of the effect of MPs in crystal morphology was done by comparative analysis of the 
indexed spacegroups, cell parameters and solvent content (Matthews coefficient, VM) for the crystals of 
each protein. In the presence of the correspondent MPs, both GFP and trypsin kept their original P212121 
spacegroup, and the same happened with HEWL, which crystallized in spacegroup P43212, as originally 
reported (see Table 4.1). Unit cell parameters for HEWL in the presence of MPs were a=b=79.0 Å, c=37.0 
Å and α=β=γ=90.0°, with a calculated VM of 1.92 A3/Da. Unit cell parameters for bovine trypsin in the 
presence of MPs were a=54.2 Å, b=58.2 Å, c=66.3 Å and α=β=γ=90.0°, with a VM of 2.29 A3/Da. Finally, 
unit cell parameters for GFP in the presence of MPs were a=51.2 Å, b=62.9 Å, c=65.9 Å and α=β=γ=90.0° 
and the VM was 2.07 A3/Da. All unit cell parameters are within values comparable with the reference 
structures and the same was observed for the calculated VM values (see Table 4.1). After structure solution 
and refinement, the 3D structures were superposed (in PyMol, Cealign) with PDB available structures from 
crystals grown in similar precipitant conditions, but in the absence of the additives under study.  
HEWL structure obtained from crystals grown in the presence of MP-chitin was superposed and fCα 
atoms (Figure 4.6A). The 3D structure of trypsin obtained from a crystal grown in the presence of MP-casein 
and benzamidine was superposed with PDB ID: 5MNG [204], presenting an 0.26 Å r.m.s.d. for 216 Cα 
atoms (Figure 4.6B). The structural superposition of the GFP structure obtained from crystals grown in the 
presence of MPs with PDB ID: 1GFL produced an r.m.s.d. of 0.01 Å for 224 Cα atoms, with no relevant 
structural differences (Figure 4.6C).  
The X-ray crystallography results in this study show that nanoparticles can behave as nucleating agents 
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This is the first report of a rationally-designed crystallography assay based on the addition of magnetic 
particles, coated or functionalized with affinity molecules towards a protein of interest, with the purpose of 
producing single crystals for 3D structure determination. Here, after the successful characterization of all 
MPs – coated and functionalized, three different proteins were used to exemplify and reinforce the 
straightforward approach that magnetic affinity crystallization represents.  
HEWL, is an extensively used protein in the search for innovative crystallization methods, and here also 
elected to investigate the influence of MPs as additives in protein crystallization. However, more than 
demonstrating the feasibility of using MPs and still be able to obtain protein crystals that diffract as optimally 
as the ones grown without the additives, we could witness faster onset of crystals with more protein (in 
mass) crystallized. This was particularly notorious when using affinity-triggered magnetic crystallization with 
MP-chitin.  
Similarly to HEWL, bovine trypsin is also broadly used in crystallization studies as model protein. 
Nonetheless, as a peptidase, it is necessary to add benzamidine as an inhibitor of its proteolytic activity. 
Once added to the crystallization conditions, this inhibitor led to the decrease in the amount of protein bound 
to both MPs and to the decrease of Ka for the same MP. The depletion of benzamidine from the 
crystallization assays led to protein precipitation when no MP and MP-Fe3O4 was used as additive. However, 
when MP-casein was added, in 2 out of 3 crystallization drops, it was possible to achieve protein crystal 
growth without the need of benzamidine. Moreover, the addition of MPs led to a great increase in mass of 
crystallized protein, compared to the absence of MP additives, even in the presence of benzamidine.  
Figure 4.6. Superposition of the 3D structures obtained from crystals grown in the presence of MPs with 
corresponding representative structures available in the PDB (rmsd values were calculated in PyMol
Cealign). (A) HEWL 3D structure from a crystal grown in the presence of MP-chitin and HEWL from PDB ID: 
6F1L, presenting an r.m.s.d. of 0.92 Å for the matching of 120 C atoms. (B) Trypsin 3D structure from a 
crystal grown in presence of MP-casein and trypsin from PDB ID: 5MNG, presenting an r.m.s.d. of 0.26 Å for 
the matching of 126 C atoms. (C) GFP 3D structure from a crystal grown in presence of MP-A4C7 and GFP 
from PDB ID: 1GFL, presenting an r.m.s.d. of 0.01 Å for the matching of 224 C atoms. 
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A similar approach was designed for the crystallization of GFP. The addition of MPs as crystallization 
additives was evaluated in terms of yield fold change and crystal morphology. The crystallization of GFP in 
the presence of MPs additives, led to an increased amount of crystallized protein.  
Overall, the addition of MPs to the crystallization assays led to faster onset and growth of crystals. This 
was more pronounced when adding MPs with affinity towards the target protein. Affinity-triggered magnetic 
crystallization not only reduced the crystallization time, but also enabled the removal of critical additives as 
benzamidine, a trypsin inhibitor, usually necessary to obtain reproducible single crystals of trypsin. In all the 
tested proteins, MP addition did not change the crystal diffraction quality and unit cell parameters. Moreover, 
this work once again reinforces the versatility of MP coating and functionalization, here coated with a 
polysaccharide (chitin), a protein (casein) and a synthetic ligand (A4C7). Furthermore, the use of affinity 
driven MPs, such as MP-casein to crystallize trypsin, allowed to exclude the peptidase inhibitor, enabling 
the possible screening of different inhibitors or competition assays. 
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Antibodies are an important class of proteins used in a wide range of areas from fundamental research 
to clinical therapy. Regardless of their use, antibodies must comply with the need for high purity and 
concentration. The current antibody purification processes are fully dependent on chromatographic 
techniques which are a bottleneck in antibody production. As such, alternative non-chromatographic 
approaches are being explored. Given the difficulty to crystallize antibodies, new additives to the 
crystallization assays can be added to promote crystal nucleation. New additives include magnetic particles 
that already had been successfully used in the purification of antibodies from complex media. With the aim 
to explore the synergy between the crystallization and magnetic fishing techniques for the purification of 
polyclonal and monoclonal antibodies, different crystallization screens were tested for the crystallization of 
both proteins in the presence of magnetic particles. Using this approach, we observed spherulite crystals of 
polyclonal antibodies in the presence of magnetic particles coated with dextran and functionalized with an 
affinity synthetic ligand to capture antibodies in solution. On the other hand, no crystal growth was observed 
for monoclonal antibodies, although some conditions led to the precipitation of the proteins in solution. This 
work demonstrated the possibility of using magnetic particles as additives in antibodies crystallization and 
precipitation, foreseeing the synergetic use of magnetic particles in antibody precipitation for purification.  
 
5.1. Introduction 
With the ability to bind virtually any epitope, antibodies are powerful proteins ubiquitously used across a 
variety of scientific and therapeutic areas [205–207]. Depending on the application, polyclonal (pAbs) or 
monoclonal (mAbs) antibodies can be used. PAbs are able to recognize different epitopes of the same 
antigen, whereas mAbs are only able to recognize one epitope of a given antigen [208]. As for scientific or 
therapeutic applications, these proteins are required to be highly pure and at high concentrations. 
The current downstream pipeline used for antibodies purification and formulation, mainly composed by 
chromatographic steps, comprises the major hold-up in antibody production [209]. New alternatives for 
antibody purification and formulation rely on anything but chromatography strategies, as is the case of 
crystallization [28,207,210,211]. Antibodies have a particular Y shape structure, where the two arms 
correspond to the Fab (fragment antigen binding) while the tail corresponds to the Fc (fragment 
crystallizable) regions, both linked by disulphide and noncovalent bonds, comprising a region rich in proline, 
threonine, and serine residues (hinge region). Such structural features make antibodies very flexible and 
therefore hard to crystallize [208]. Successful crystallization of antibodies for purification purposes has 
already been described, nonetheless it was only possible with previously purified and/or dialysed antibodies 
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samples [27,28,212]. New crystallization approaches depend on the addition of new materials that function 
as crystallization additives to act as nucleation agents in the crystallization process [59,183,213].  
Magnetic particles had already been successfully used in the purification of antibodies by magnetic 
fishing [12,136]. Iron oxide magnetic particles (MPs) have a non-porous surface with a high surface area to 
volume ratio. MPs can be coated and functionalized with different polymers [214], synthetic ligands [136], 
proteins or peptides [12]. The synthetic triazine ligand 22/8, with affinity towards antibodies, has already 
been successfully synthetized on iron oxide magnetic particles for antibody purification [13,215].  
We propose the hypothesis that a different coating and functionalization may foster crystal nucleation by 
promoting different interactions between the coated MPs and the target protein. With the main goal of 
retrieving antibody crystallization conditions for further use in the purification pipeline of antibodies, MPs 
coated with dextran and functionalized with synthetic ligand 22/8 were used as additives in the high 
throughput crystallization of pAbs and mAbs using commercially available crystallization screens. The 
crystallization screens used had polyethylene glycol as the main precipitant, as it has been reviewed as the 
major precipitating agent in antibody crystallization [216], the present work also confirms the role of 
kosmotropic cations as major influents in antibody precipitation. This work can be translated for the 
development of new non-chromatographic methods for antibody purification relying on MPs and selective 
precipitation of target proteins. 
 
5.2. Materials and Methods 
5.2.1. Materials 
All used chemicals were at least 98% pure of analytical or HPLC grade.  
5.2.2. Magnetic particles synthesis and characterization 
Iron oxide magnetic particles were synthesized by the co-precipitation method. A solution of 25% 
ammonium hydroxide (200 ml) was purged with N2 gas, and a newly iron solution (FeCl3 and FeCl2 salts 
(Sigma-Aldrich) with a 0.5 molar ratio of Fe2+/Fe3+, 25 ml) was added in a dropwise manner. The reaction 
was stopped after 2 hours, the particles were washed with distilled water (10 times), using a permanent 
magnet for magnetic particle separation. The particle solution (10 mg/ml) was sonicated for 15 minutes, 
following a solution of sodium metasilicate pentahydrate (Sigma-Aldrich) in 50% (v/v) ethanol/water (28.5 
mg/ml). The reaction was stopped after 2 hours at 40ºC with orbital shaking (200 RPM)) and the particles 
washed with distilled water (10 times). The particles were resuspended in 20% (v/v) ethanol/water (80 ml) 
and sonicated for 10 min. Then, 25% ammonium hydroxide (3 ml) and tetraethyl orthosilicate (TEOS) (1.5 
ml, Sigma-Aldrich) were added dropwise during sonication and the reaction was stopped after 2 hours at 
40ºC with orbital shaking (200 RPM). The particles were washed with distilled water (10 times). The particles 
were resuspended in 175 ml of distilled water, sonicated for 10 minutes, and further coated with dextran 
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(from Leuconostoc mesenteroides 150 kDa, Sigma-Aldrich). A dextran solution (80 mg/ml in distilled water) 
was added dropwise to the particle solution and the mixture incubated (60°C, 2 hours with orbital shaking, 
200 RPM), after which the particles were washed 5 times with distillated water. Magnetic particles coated 
with dextran (MP-dextran) were further functionalized with synthetic triazine ligand 22/8 (MP-22/8).  
MP-dextran functionalization with synthetic ligand 22/8 (MP-22/8) was carried out through a triazine 
scaffold. The particles were firstly aminated using (3-aminopropyl)triethoxysilane (APTES) as previously 
described [22]. The amount of amines was 213.3 ± 3.8 µmol NH2/g of dried MP, assessed by the Kaiser 
Test as described [22]. The aminated particles were washed 2 times with cold distilled water and 2 times 
with 50% (v/v) acetone/distilled water solution and suspended at a 10 mg/ml concentration. The particles 
were let to react with 5 molar excess of cyanuric chloride (in acetone) to the amine content on the support, 
for 1 hour at 0ºC with orbital shaking (200 RPM). The particles were washed with 100% acetone (2 times), 
50% (v/v) acetone/distilled water (3 times) and distilled water (5 times). The first nucleophilic substitution 
was carried out using 3-hydroxyaniline dissolved in 50% (v/v) dimethylformamide (DMF)/distilled water with 
2 molar excess to the amines in the support to a final MP concentration of 10 mg/ml, the reaction was let to 
occur for 24 hours at 30ºC with orbital shaking (200 RPM). Next, the particles were washed with distilled 
water (5 times) and the second nucleophilic substitution was carried out using 5 molar equivalents of 4-
amino-1-naphthol hydrochloride, dissolved in 50% (v/v) DMF/distilled water, to a final MP concentration of 
10 mg/ml. The reaction occurred for 48 hours at 80ºC with orbital shaking (200 RPM). The particles were 
washed with water (2 times), 0.1 M hydrochloric acid (1 time), distilled water (1 time), 0.1 M sodium 
hydroxide with 30% isopropanol (1 time) and distilled water (5 times). In the final step, particles were 
resuspended in the appropriated volume of water.  
All particles were characterized by Fourier transform infrared (FT-IR), dynamic light scattering (DLS), 
zeta potential and transmission electron microscopy (TEM). DLS and zeta potential (0.05 mg/ml solution in 
MilliQ and precipitant solution (20% (w/v) PEG3350 in Tris buffer)) were measured using Dynamic Zetasizer 
Nano ZS from Malvern instruments. FT-IR spectra were recorded on a Spectrum Two™ spectrometer from 
Perkin Elmer. For that, MP samples were prepared by drying the samples overnight at 60ºC, followed by 
grounding and mixing with KBr (1:100) and pressing in a hydraulic press, up to 10 tones force. Analytical 
TEM was done in a Hitachi 8100 microscope with ThermoNoran light elements EDS detector and digital 
image acquisition without staining. 
5.2.3. Biological material 
Human polyclonal antibodies (pAbs) (product name: Gammanorm®) from Octapharma (Lachen, 
Switzerland) and clarified cell culture supernatant from CHO cell lines producing anti-TNFα or anti-HER2 
monoclonal antibodies (mAbs) were kindly provided by João Gonçalves Laboratory from iMed.ULisboa – 
Research Institute for Medicines (Faculty of Pharmacy, University of Lisbon) and produced as in annex 
1. 
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5.2.3.3. mAbs purification  
The produced mAb, present in the cell supernatant was purified by Protein A affinity chromatography 
using 1 ml column MabSelect™ SuRe™ (GE Healthcare Life Sciences, Chicago, Illinois, EUA) in ÄKTA 
Pure 150 system from GE Healthcare Life Sciences. Adsorption was performed in 10 mM phosphate buffer 
saline (PBS) at pH 7.4 and elution in 100 mM glycine-HCl at pH 2. Before injection, the column was 
equilibrated with 5 CVs of adsorption buffer. The feed injection was loaded at 1 mL/min and the unbound or 
weakly bound samples were washed-out with 2 CVs of adsorption buffer. The elution of mAbs was achieved 
by changing the buffer to 100 mM glycine-HCl at pH 2 for 5 CVs. To avoid denaturation of the eluted 
antibodies, 1 M Tris-HCl at pH 8 was added to the elution fractions collected, to adjust the pH to 7. All the 
fractions were analysed by SDS-PAGE. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) was performed to evaluate mAb recovery and purity. The buffer sample composition was 0.15 M 
Tris–HCl at pH 6.8, 6% (w/v) SDS, 0.025% (w/v) bromophenol blue, 12.5% (v/v) glycerol and β-
mercaptoethanol was used as reducing agent. Prior to loading in the gel, all the samples were denatured at 
100°C for 5 minutes. Samples were applied in a 12.5% gel, prepared from 41% acrylamide/bis stock solution 
(30:1) from Bio-Rad (Hercules, California, USA) and migrated at 90 mV using as running buffer 192 mM 
glycine, 25 mM Tris-HCl and 0.1% SDS, pH 8.3. Gels were stained using two methods: (i) Coomassie-
stained with the staining solution of 0.5% (w/v) Coomassie Blue R-250, 7.5% (v/v) acetic acid, 45% (v/v) 
methanol, for 30 min at room temperature with orbital shaking and revealed with the distaining solution 
(7.5% (v/v) acetic acid, 45% (v/v) methanol) until proper protein visualization; or (ii) using Bio-Rad silver 
staining kit. Images were acquired with Gel Doc™ XR+ System with Image Lab™ software from Bio-Rad. 
5.2.4. Crystallization assays 
5.2.4.1. Polyclonal antibodies 
Crystallization assays were performed using the sitting drop method in 96-well 3-drop Swissci plates. 
The crystallization setups were carried out at 20°C and regularly visualised using an optical microscope 
(V81 Stereo Microscope equipped with Camera – AxioCam Erc5s (5 MP), ZEISS). The PEG/Ion Screen™ 
(Molecular Dimensions, United Kingdom) was chosen to perform the crystallization assays. The 
crystallization experiments were performed using the automated nanodrop-dispensing robot Oryx8 
(Douglas Instruments, United Kingdom), to obtain 1 µl drops. Polyclonal antibody (pAb) in 10 mM Tris-HCl 
at pH 7.0 (0.5 µl at 10 mg/ml) was crystallized either in the absence of MP (0.5 µl of precipitant), or in the 
presence of MP-dextran or MP-22/8 (0.1 µl at 1 mg/ml). 
5.2.4.2. Monoclonal antibodies 
Crystallization assays of the monoclonal antibodies (mAbs) were carried out at the High Throughput. 
Crystallization Laboratory (HTX Lab) at EMBL Grenoble, through the iNEXT extended support that enables 
the access to X-rays infrastructures for translational research. With the aim to speed and improve mAbs 
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crystallization, four different screens: (i) JCSG-plus™ HT-96 (Molecular Dimensions), (ii) PACT premier™ 
HT-96 (Molecular Dimensions), (iii) Wizard Classic 1 & 2 (Rigaku) and (iv) PEGs I Suite (Qiagen), were 
used for the screening of mAbs crystallization conditions. Crystallization assays were performed using the 
sitting drop method in CrystalDirect™ 96-well plate from MiTeGen. The crystallization setups were carried 
out at 293.15 K and drop inspections were performed using RockImager (Formulatrix, USA) with visible and 
UV light periodic inspections. The crystallization setups were prepared using the crystallization robot 
Cartesian PixSys 4200 (Genomic Solutions, United Kingdom), to obtain 200 nl drops. mAbs in 10 mM Tris-
HCl at pH 7.0 (100 nl at 20 mg/ml) was crystallized either in the absence of MP (100 nl of precipitant) or in 
the presence of MP-22/8 (20 nl at 1 mg/ml) as additive. 
 
5.3. Results and discussion 
5.3.1. Magnetic particles characterization 
Magnetic particle (MP) surface modifications (Figure 5.1A) including dextran coating (MP-dextran) and 
functionalization with the synthetic triazine ligand 22/8 (MP-22/8) were confirmed by Fourier transform 
infrared (FT-IR) spectroscopy (Figure 5.1B, spectrum a to c respectively). The uncoated MP (MP-Fe3O4) 
(Figure 5.1B, spectra a) present a single band corresponding to the Fe-O bond vibration, typical of 
magnetite, in the 400-600 cm-1 region [156]. The MP-dextran, presented a band in the characteristic peaks 
of dextran at 1146 and 1020 cm-1; at 1146 cm-1 resulting from the valent vibrations of C-O-C and glycosidic 
bond, as for 1020 cm-1, results from the great chain flexibility present in dextran around the glycosidic bonds 
[158] (Figure 5.1B, spectra b). The functionalization of MP with the triazine synthetic ligand 22/8 was 
confirmed by the presence of peaks between 1600 and 1400 cm-1 corresponding to the aromatic C-C 
stretching (Figure 5.1B, spectra c). The MP were further analysed in terms of hydrodynamic diameter by 
dynamic light scattering (DLS) and surface charge by zeta potential in three different solutions – MilliQ 
water, 10 mM Tris-HCl at pH 7 and 20% (w/v) PEG3350 in 10 mM Tris-HCl at pH 7 (Figure 5.1C). The 
stability of MPs, given by DLS and zeta-potential, was evaluated in the presence of Tris-buffer and PEG 
given the literature review [216] in which the PEG role in antibody was evidenced; here, the Tris buffer was 
chosen since it is the solution in which antibodies are before the crystallization assays. DLS results indicate 
that all MPs tend to aggregate in Tris buffer, however, with the addition of 20% (w/v) polyethylene glycol 
(PEG) 3350, the particles have a lower hydrodynamic diameter, as presented in water. The zeta potential 
(Figure 5.1D), as the hydrodynamic diameter, vary with the solution in which the particles are in suspension. 
MP-Fe3O4 presented a higher stability in 20% (w/v) PEG3350 than in water or Tris buffer. MP-dextran 
presented a higher stability in water than in Tris buffer or 20% (w/v) PEG3350. MP-22/8, as MP-dextran, 
also presented a higher stability in water, however, showing an overall zeta potential lower than -20 mV, 
these MPs can be considered to be stable in all of three solutions. Transmission electron microscopy (TEM) 
showed the presence of spherical magnetic cores (Figure 5.1E), and the tendency of MPs, in particular MP-
dextran, to form aggregates, already assessed by DLS.  
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Figure 5.1. Magnetic particles (A) schematic synthesis and characterization by (B) DLS and (C) zeta-
potential for (a) MP-Fe3O4, (b) MP-dextran and (c) MP-22/8 in MilliQ-water (H2O), buffer solution (10 mM 
Tris-HCl at pH 7.0) and precipitant solution (20% PEG3350) in buffer solution (n=3) and (D) FT-IR 
spectroscopy and (E) Transmission electron microscopy analysis of (a) MP-Fe3O4, (b) MP-dextran and (c) 
MP-22/8. 
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5.3.2. Polyclonal antibody crystallization 
As reviewed that PEG plays a major role in antibody crystallization [216], the PEG/Ion Screen™ was 
elected for the attempts to crystallize pAbs in the presence of MP-dextran and MP-22/8 as additives. In the 
PEG/Ion Screen™ different salt compounds are empirically tested, keeping 20% (w/v) PEG3350 as main 
precipitating agent. For the designed assay, crystallization was unsuccessful in the absence of MPs as 
additives, demonstrating that not only PEG but also additives, as MPs, are important for antibodies 
crystallization. Moreover, when MPs are included as additives, crystal growth was only visible in the 
presence of the divalent cations’ magnesium and calcium, with a major effect from magnesium, as more 
crystallization hits were obtained with it. According to the Hofmeister series, both Mg2+ and Ca2+ are 
kosmotropic cations. Kosmotrope cations tend to interact with water in solution decreasing the hydrophobic 
interaction while promoting protein-protein interactions. Out of six crystallization hits (Figure 5.2A and B), 
three are recurring to both MP-dextran and MP-22/8, being the common salts 0.2 M magnesium chloride, 
0.2 M calcium acetate and 0.2 M magnesium bicarbonate all in the presence of the precipitant 20% (w/v) 
PEG3350. On the other hand, in the presence of MP-dextran, two additional hits were uncovered –0.2 M 
magnesium acetate tetrahydrate and 0.2 M magnesium sulfate in the presence of the precipitant 20% (w/v) 
PEG3350. As for the presence of MP-22/8, another hit – 0.2 M magnesium nitrate with 20% (w/v) PEG3350 
was found. 
The crystal growth conditions were monitored for 30 days for all the crystallization conditions. The 
average crystal size varied with the conditions as well as with the MPs used as additives (Figure 5.2C and 
D). Overall crystal growth is faster, and crystals tend to be bigger when MP-dextran are added, when 
compared with MP-22/8.  
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Figure 5.2. Polyclonal antibody (10 mg/ml) crystallization in the presence of MP-dextran and MP-22/8. (A) Visual inspection 
of crystallization day 30 in different crystallization conditions. (B) SDS-PAGE for crystals grown in the presence of MP-
dextran. Lane ID: M: Precision Plus Protein™ Dual Color Standards (from top to bottom: 200, 150, 100, 75, 50, 37, 25 and 
20 KDa)  (C) Average crystal length of visual measurement of polyclonal antibodies crystals over 30 days in the presence of 
MP-dextran  and  (D) MP-22/8 in the presence of different crystallization conditions. 
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5.3.3. Monoclonal antibody crystallization 
For the crystallization of monoclonal antibodies (mAbs), a different strategy was devised. In collaboration 
with the HTX Lab from EMBL (European Molecular Biology Laboratory) at Grenoble, two mAbs: anti-TNFα 
mAb and anti-HER2 mAb, were screened for crystallization conditions using different crystallization screens 
– JCSG-plus™ (Molecular dimensions); PACT premier™ (Molecular dimensions); PEGs I Suite (Qiagen) 
and Wizard Classic 1 & 2 (Rigaku). The crystallization screens were chosen due to their diversity in buffer, 
salt, ion, pH and most of the formulations include PEG as precipitant. As additives to the crystallization 
screens only MP-22/8 was added. Contrary to pAbs, no screened condition produced mAbs crystals, instead 
only protein precipitation was observed. The protein precipitation was visible by UV inspection of the 
crystallization drops (Table 5.1). Out of the four crystallization screens used, only the PEGs I Suite (Qiagen) 
did not retrieve results, either crystal or visible precipitate (Table 5.1). Of the six precipitation conditions, 
four had PEG in their composition, still none produced crystals of the mAb. In the same line, four of the 
crystallization conditions present Zn2+ or sodium citrate in their precipitant composition. Both Zn2+ and 
sodium citrate are in the extreme ends of the Hofmeister series as kosmotropic and chaotropic species, 
respectively. Whole mAbs are well known difficult proteins to crystallize due to the mobility of the interchange 
disulphide bond between the mAbs Fab and Fc regions. Most of the mAb structures in PDB regard the Fab 
region, on which stand the complementarity-determining regions (CDRs), responsible to bind the epitope of 
interest. 
Table 5.1. Monoclonal antibody (20 mg/ml) crystallization in the presence of MP-22/8 with the 
corresponding precipitation condition and respective crystallization screen. UV and visible inspections 
of both mAbs after 90 days.  
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5.4. Conclusion 
Due to antibodies’ size and the flexibility of their hinge region, crystallization of a full-length antibody 
without leaning on stabilizing mutations is still a challenge. With the goal to overcome this difficulty, and 
aiming at finding antibody crystallization (or gentle precipitation) conditions fostered by the presence of MPs 
for purification processes, a new strategy was devised. The addition of MPs to the PEG/Ion™ crystallization 
screen led to the nucleation and growth of pAbs crystals with spherulite morphology. On the other hand, 
when no MPs were used, no crystal growth or protein precipitation was observed, reinforcing the previously 
confirmed role of MPs as potential nucleating agents (Chapter 4). In view of the results from the addition of 
MP-dextran and MP-22/8 to the crystallization conditions, it was possible to infer that kosmotropic cations, 
as Mg2+ and Ca2+, in combination with PEG as precipitant, play a major role in the crystallization of 
antibodies. Previous knowledge supporting polyethyleneglycol as favourable precipitant for antibodies was 
used to choose the trial crystallization screens for mAbs anti-TNFα and anti-HER2, in the presence of MP-
22/8 as additive. Nonetheless, among the different screens tested, no mAb crystals were obtained in the 
conditions tested. This not only confirms the inherent difficulty of crystallizing antibodies, but also that pAbs 
and mAbs do present different behaviours, requiring different approaches. Nonetheless, it was possible to 
retrieve six conditions in which both mAbs formed crystalline precipitate, as seen in the UV inspections of 
the crystallization drops. Here, once again, PEG was seen playing a major role in mAbs precipitation, 
adjuvated by the presence of Zn2+ and sodium citrate, respectively a cation (kosmotrope) and anion 
(chaotrope) from the extreme ends of the Hofmeister series.  
Here, the importance of the Hofmeister series in protein precipitation was demonstrated to be a variant 
for antibody precipitation. Mainly kosmotropic cations are recurrent in the precipitation of pAbs and mAbs, 
alongside with PEG as the precipitating polymer. Further work will be developed to implement, in a criterious 
way, the use of the Hofmeister series in the development of a new methodology for MP-assisted purification 
of antibodies. 
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Chapter 6: Affinity magnetic precipitation: a new method for antibody purification from complex media 





The new trend in downstream processing comprises the use of “anything-but-chromatography” methods 
to overcome the current downfalls of the standard packed-bed chromatography. Precipitation and magnetic 
separation are two techniques already proven to accomplish protein purification from complex media, yet 
never used in synergy. With the aim to capture antibodies directly from crude extracts, a new method 
combining precipitation and magnetic separation was developed – affinity magnetic precipitation. A 
precipitation screen based on the Hofmeister series and a commercial precipitation kit were tested with 
magnetic particles functionalized with a synthetic affinity ligand for antibody capture from human serum and 
clarified cell supernatant. The best results were obtained using PEG3350 as precipitant at 4ºC for 1h with 
200 RPM orbital shaking, reaching 80% purity and 50% recovery of polyclonal antibodies from serum, and 
97% recovery yield and 99% purity from anti-TNFα mAb. The synergic use of precipitation and magnetic 
separation can significantly influence the yield of mAbs purification processes. 
 
6.1. Introduction 
Downstream processing of biological products usually comprises four main steps: recovery, isolation, 
capture and polishing, and accounts for up to 60-80% of the total manufacturing costs [217]. The purification 
of high added value biological drugs, is mostly based on chromatographic methods [218,219]. Monoclonal 
antibodies (mAbs) and derived molecules are the most important players in the biopharmaceutical industry 
[220]. Albeit the advances in antibody engineering, antibody manufacturing still presents challenges. The 
development of new efficient upstream processes producing high volumes and titers (up to g/l), has added 
several limitations to the overall purification process mostly due to the high matrix cost, diffusion limitations 
and limited binding capacity [216]. To overcome these problems, anything but chromatography (ABC) 
approaches emerged as promising alternatives. Although most ABC approaches are not new concepts, 
they are not being re-adapted for the purification of biopharmaceuticals. The now-chromatographic methods 
include membrane separation methods [221], aqueous two-phase systems [13,20,222], magnetic 
separation [12,22,189], precipitation and crystallization [25,62,216,223].  
Within the different methods, precipitation is mainly used for the purification of low value products 
[224,225]. However, this method can cope with high titers and volumes produced upstream, which scales-
up with process volume, whereas chromatographic methods scale stoichiometrically with the reaction 
between molecules in solution [60]. Protein precipitation relies on the supersaturation of a homogenous 
protein solution, however, to exceed the proteins’ saturation limit, changes in its environment must be 
introduced. Even though precipitation is a rather empirical methodology, several additives (e.g. salts or 
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polymers) are known to help exceed a protein’s solubilization limit. However, this effect is dependent on the 
target protein and on the salt or polymer concentration [51]. Protein precipitation by salt addition follows 
frequently the Hofmeister series [52], as it ranks the anions and cations according to their relative effect on 
protein solubility [53,54]. Kosmotropic agents are referred as “water structure makers” that promote the 
salting-out of proteins; chaotropic agents are defined as “water structure breakers” that promote the salting-
in effect. On the other hand, polymers such as polyethylene glycol (PEG), with a molecular weight usually 
higher than 4000 Da, are often associated with protein precipitation. PEG captures the water molecules 
from the proteins’ surface, enabling the establishment of protein-protein interactions that lead to protein 
precipitation [55–57]. Other parameters, mainly pH and temperature, also play a role in protein precipitation 
by interfering in interprotein interactions. Precipitation methods have been attempted for mAbs purification, 
although many times the precipitated crude extract samples were previously conditioned, either purified by 
affinity chromatography or dialyzed in a more suitable buffer for precipitation, nonetheless the recent studies 
prove to be possible to precipitate mAbs maintaining its structural and functional characteristics 
[25,27,28,91]. 
The magnetic separation of proteins directly from crude extracts through the use of magnetic adsorbents 
is another known ABC alternative [12,136,151]. Due to their superparamagnetic properties, iron oxide 
magnetic particles (MPs) can be used in viscous solutions to separate a target protein, presenting a high 
surface area to volume ratio. Given the virtual infinite surface modifications that can be made at the particles 
surface, different coatings and functionalizations can be performed to target a protein from a complex crude 
extract [226]. From the different functionalization strategies, small affinity synthetic ligands rationally 
designed towards a target protein represent a low cost and viable option. For mAbs, the triazine synthetic 
ligand 22/8 was designed to capture antibodies from complex crude extracts [227], and its functionalization 
in MPs accomplished and optimized [136]. There are examples of MPs alone (magnetic fishing) or in 
combination with other unit operations [13,17]. 
Even if many times used in separate, precipitation and magnetic separation were never explored in 
synergy for antibody purification from complex media. The potential to use a hybrid system based on 
precipitation and magnetic fishing with affinity towards protein purification was explored here and enables 
its selective capture and concentration in a single step unit operation. In this work, different extracts – human 
serum and clarified cell supernatant – were used for the capture of antibodies with a new and straightforward 
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6.2. Materials and methods 
6.2.1. Material  
All used chemicals were at least 98% pure of analytical or HPLC grade.  
The 96-well UV-star® half area microplates from Greiner (Kremsmünster, Austria) and 96-well 
transparent microplates flat-bottom from Sarstedt (Nümbrecht, Germany). 
6.2.2. Biological material 
Clarified cell culture supernatant from CHO cell lines producing anti-TNFα or anti-HER2 monoclonal 
antibodies (mAbs) were kindly provided by João Gonçalves laboratory from iMed.ULisboa – Research 
Institute for Medicines (Faculty of Pharmacy, University of Lisbon) and produced as in annex 1. 
6.2.3. Production and characterization of magnetic particles 
Iron oxide magnetic particles were synthesized by the co-precipitation method. A solution of 8% 
ammonium hydroxide (175 ml) was purged with N2 gas, and a freshly prepared iron solution (FeCl3 and 
FeCl2 salts (from Sigma-Aldrich) with a molar ratio of Fe2+/Fe3+ of 0.5, 25 ml) was added in a dropwise 
manner. The reaction was stopped after 2 hours, the particles were washed with distilled water (10 times), 
with a permanent magnet for magnetic particle separation. The particle solution (10 mg/ml) was sonicated 
for 15 minutes, followed by addition of a solution of sodium metasilicate pentahydrate (from Sigma-Aldrich) 
in 50% (v/v) ethanol/water (28.5 mg/ml). The reaction was stopped after 2 hours at 40ºC with orbital shaking 
(200 RPM)) and the particles washed with distilled water (10 times). The particles were resuspended in 20% 
(v/v) ethanol/water (80 ml) and sonicated for 10 minutes. Then, 25% ammonium hydroxide (3 ml) and 
tetraethyl orthosilicate (TEOS) (1.5 ml, Sigma-Aldrich) were added dropwise during sonication. The reaction 
was stopped after 2 hours at 40ºC with orbital shaking (200 RPM)), and the particles were washed with 
distilled water (10 times). The particles were resuspended in 175 ml of distilled water (10 mg/ml), sonicated 
for 10 minutes, and further coated with dextran (from Leuconostoc mesenteroides 150kDa, Sigma-Aldrich). 
A dextran solution (80 mg/ml in distilled water) was added dropwise to the particle solution (10 mg/ml) and 
the mixture was incubated (60°C, 2 hours with orbital agitation, 200 RPM). The particles were then washed 
5 times with distilled water. Magnetic particles coated with dextran (MP-Dextran) were further functionalized 
with synthetic triazine ligand 22/8 (MP-22/8).  
MP-Dextran functionalization with synthetic ligand 22/8 (MP-22/8) was then carried out. The particles 
were firstly aminated using (3-aminopropyl)triethoxysilane (APTES) as previously described [22]. The 
amount of amines was 213.3 ± 3.8 µmol NH2/g of dried MP, assessed by the Kaiser Test [22]. The aminated 
particles were washed 2 times with cold distilled water and 2 times with 50% (v/v) acetone/distilled water 
solution and suspended at a 10 mg/ml concentration. The particles were let to react with 5 molar excess of 
cyanuric chloride (in acetone) to the amine content on the support, for 1 hour at 0ºC with orbital shaking 
Chapter 6: Affinity magnetic precipitation: a new method for antibody purification from complex media 
 - 116 -  
 
(200 RPM). The particles were washed with 100% acetone (2 times), 50% (v/v) acetone/distilled water (3 
times) and distilled water (5 times). The first nucleophilic substitution was carried out using 3-hydroxyaniline 
dissolved in 50% (v/v) dimethylformamide (DMF)/distilled water with 2 molar excess to the amines in the 
support to a final MP concentration of 10 mg/ml, the reaction was left for 24 hours at 30ºC with orbital 
shaking (200 RPM). The particles were then washed with distilled water (5 times) and the second 
nucleophilic substitution was carried out using 5 molar equivalents of 4-amino-1-naphthol hydrochloride, 
dissolved in 50% (v/v) DMF/distilled water, to a final MP concentration of 10 mg/ml. The reaction occurred 
for 48 hours at 80ºC with orbital shaking (200 RPM). The particles were washed with water (2 times), 0.1 M 
hydrochloric acid (1 time), distilled water (1 time), 0.1 M sodium hydroxide with 30% isopropanol (1 time), 
distilled water (5 times). Finally, the particles were resuspended in the appropriated volume of water.  
All particles were characterized by Fourier transform infrared (FT-IR), dynamic light scattering (DLS), 
zeta potential and transmission electron microscopy (TEM). DLS and zeta potential (0.05 mg/ml solution in 
MilliQ and precipitant solution (20% PEG3350)) were measured using Dynamic Zetasizer Nano ZS from 
Malvern Instruments. FT-IR spectra were recorded on a Spectrum Two™ spectrometer from Perkin Elmer. 
MP samples were prepared drying the samples overnight at 60ºC, then grounding and mixing with KBr 
(1:100) and finally pressing in a hydraulic press, up to 10 tones force. Analytical TEM was done in a Hitachi 
8100 microscope with ThermoNoran light elements EDS detector and digital image acquisition without 
staining. 
 
6.2.4. Antibody purification 
6.2.4.1. Precipitation  
A screen of precipitation conditions (Table 6.1) based on the Hofmeister series were tested for antibody 
precipitation using pure human pAb (product name: Gammanorm ®, from Octapharma (Lachen, 
Switzerland)) at 2 and 20 mg/ml and human serum (Sigma-Aldrich) at 0.5 mg/ml of total protein. 
Simultaneously, crystallization experiments using mAbs were carried out at the High Throughput 
Crystallization Laboratory (EMBL Grenoble), using the following crystallization screens PEGs-I (from 
Qiagen), PACT premier™ HT-96 (from Molecular Dimensions), JCSG-plus™ HT-96 (from Molecular 
Dimensions) and Wizard Classic 1 & 2 (from Rigaku). From the conditions tested, two additional 
precipitation conditions for antibody precipitation were unveiled – 20% PEG3350 and 2.5 M NaCl (Table 
6.1). The precipitation assays were carried out at 20ºC for 1h with 200 RPM orbital shaking with a 1:1 crude 
extract to precipitant volumetric ratio, at a 1 ml scale. The separation of supernatant and precipitant was 
performed by centrifugation (5000 xg, 15min at 15ºC). The supernatant was removed, and the precipitate 
solubilized in 10 mM sodium phosphate, 150 mM sodium chloride at pH 7.4 (PBS). Protein quantification of 
pAb supernatant and precipitate for the different precipitant conditions were performed by measuring 
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absorbance at 280 nm in UV-star® half area microplates from Greiner. The pAb precipitation yield was 
calculated as in Equation 6.1: 
 
Precipitation yield (%)= =
μg pAb precipitated
μg pAb loaded
×100                   Equation 6.1 
 
For serum samples, total protein quantification was performed using bicinchoninic acid (BCA) assay 
reagent (Sigma-Aldrich). Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was 
performed to evaluate the samples Immunoglobulin (Ig) recovery and purity. Samples were applied in a 
12.5% acrylamide gel and migrated at 90 mV. Images were acquired with Gel Doc™ XR+ System with 
Image Lab™ software from Bio-Rad and analyzed with ImageJ software. The total protein precipitation yield 
was calculated as in Equation 6.2: 
 
Precipitation yield (%)= =
μg total protein precipitated
μg total protein loaded
×100                   Equation 6.2 
 
Table 6.1. List of the precipitants for antibody precipitation, based on the Hofmeister series, unless 
otherwise stated. All precipitants were used at a 300 mM concentration at its given pH or at pH 7, adjusted 
by 10 mM Tris-HCl pH 8, unless otherwise stated. 
Precipitant Source 
KCl Hofmeister series 
KCl @pH7 Hofmeister series 
K2SO4 Hofmeister series 
NaCl Hofmeister series 
NaCl @pH7 Hofmeister series 
Na2SO4 Hofmeister series 
Na2SO4 @pH7 Hofmeister series 
Na3C6H5O7  Hofmeister series 
Na3C6H5O7 @pH7 Hofmeister series 
LiCl Hofmeister series 
LiCl @pH7 Hofmeister series 
Li2SO4 Hofmeister series 
Li2SO4 @pH7 Hofmeister series 
CaCl2 Hofmeister series 
CaCl2 @pH7 Hofmeister series 
MgCl2 Hofmeister series 
MgCl2 @pH7 Hofmeister series 
MgSO4 Hofmeister series 
MgSO4 @pH7 Hofmeister series 
20% (w/v) PEG3350 HTX Lab@ EMBL Grenoble 
2.5 M NaCl HTX Lab@ EMBL Grenoble 
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6.2.4.2. Affinity magnetic precipitation 
The four best performing precipitant conditions - 300 mM LiSO4, 300 mM CaCl2, 20% PEG3350 and 2.5 
M NaCl - were tested for the affinity magnetic precipitation of antibodies having 0.5 mg/ml MP-Dextran 
(control) or MP-22/8. Affinity magnetic precipitation was carried out at a 1 ml scale with a 1:1 crude extract 
to precipitant volumetric ratio. Prior to incubation with the crude extract, all MP solutions were sonicated and 
homogenized for 10 minutes. The crude extract and magnetic precipitant incubation were optimized in terms 
of orbital shaking (200 vs 0 RPM), temperature (4º vs 20ºC) and time (1h vs 24h). The best incubation 
parameters were 200 RPM at 4ºC for 1h. Crude extract and magnetic precipitant were incubated, and the 
MPs separated by the application of an external magnetic field for 15 min, generating the magnetic 
supernatant and magnetic precipitate. The magnetic supernatant was further centrifuged (5000 xg, 15min 
at 15ºC), the supernatant harvested, and the precipitate resuspended in PBS and the bound proteins eluted. 
MPs were recovered from solution by the application of an external magnetic field for 15 minutes and the 
eluted proteins were harvested in the soluble fraction. The magnetic precipitation yield was calculated as in 
Equation 6.3: 
 
Magnetic precipitation yield (%)= =
μg total protein recovered
μg total protein loaded
×100                   Equation 6.3 
 
This pipeline was performed for antibody capture from human serum (0.5 mg/ml total protein), anti-TNFα 
monoclonal antibody (Infliximab) and anti-HER2 monoclonal antibody (Trastuzumab) (10 mg/ml total 
protein). As controls, the magnetic precipitation was performed with PBS as precipitant with and without 
MP. Total protein quantification was performed using BCA assay reagent (Sigma-Aldrich). SDS–PAGE was 
performed to evaluate the samples Ig recovery and purity. Samples were applied in a 12.5% acrylamide gel 
and migrated at 90 mV. Images were acquired with Gel Doc™ XR+ System with Image Lab™ software from 
Bio-Rad and analyzed with ImageJ software. The antibody recovery yield was calculated by densitometry 
as in Equation 6.4 and purity as in Equation 6.5: 
Antibody recovery yield (%)= =
Area of heavy and light chains of antibody recovered
Area of heavy and light chains of antibody loaded
×100                   Equation 6.4 
 
Antibody purity (%)= =
Area of heavy and light chains of antibody recovered
Area total of protein recovered
×100                                Equation 6.5 
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6.2.5. Analytics 
6.2.5.1. Total protein quantification 
Protein quantification was performed using bicinchoninic acid (BCA) assay reagent (Sigma-Aldrich). The 
protein standard used was bovine serum albumin (BSA) from Sigma-Aldrich. The assay was performed in 
96-well transparent microplates flat-bottom from Sarstedt. Absorbance was measured at 560 nm in Tecan 
Infinite F200 microplate reader. Precipitation yield was determined by dividing the total protein concentration 
in the precipitate fraction by the total protein content in the crude extract. 
6.2.5.2. Protein gel electrophoresis 
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was performed to evaluate 
the samples’ Ig recovery and purity. The buffer sample composition was 0.15 M Tris–HCl at pH 6.8, 6% 
(w/v) SDS, 0.025% (w/v) bromophenol blue, 12.5% (v/v) glycerol and as reducing agent β-mercaptoethanol 
was used. Prior to loading in the gel, all the samples were denatured at 100°C for 5 minutes. Samples were 
applied in a 12.5% gel, prepared from 41% acrylamide/bis stock solution (30:1) from Bio-Rad and migrated 
at 90 mV using as running buffer 192 mM glycine, 25 mM Tris-HCl and 0.1% SDS, pH 8.3. Gels were stained 
using two methods: (i) Coomassie stained with the staining solution of 0.5% (w/v) Coomassie Blue R-250, 
7.5% (v/v) acetic acid, 45% (v/v) methanol, for 30 min at room temperature with orbital shaking and revealed 
with the distaining solution (7.5% (v/v) acetic acid, 45% (v/v) methanol) until proper protein visualization; or 
(ii) using Bio-Rad silver staining kit. Images were acquired with Gel Doc™ XR+ System with Image Lab™ 
software from Bio-Rad and analyzed with ImageJ software. 
6.2.5.3. High performance size-exclusion chromatography 
High performance size-exclusion chromatography was performed to assess IgG aggregation and HPLC 
purity resulting from the precipitation strategy developed for antibody purification. The samples were loaded 
(20 µl) undiluted and migrated in isocratic mode in a Yarra Sec-3000 column (300x7.8 mm, particle size 3 
µm, pore size 290 Å) from Phenomenex at 0.5 mL/min for 30 min with PBS and UV detection at 280 nm. 
The area of antibody aggregation in each precipitation condition was compared with the area of antibody 
aggregation from the crude extract sample. HPLC purity was calculated by the ratio between the IgG peak 
area and the total area of the chromatogram. 
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6.2.5.4. mAb activity 
6.2.5.4.1. Indirect enzyme linked immunosorbent assay – Anti-TNFα mAbs 
To evaluate the biological activity of anti-TNFα monoclonal antibodies after purification by precipitation, 
an indirect enzyme linked immunosorbent assay (ELISA) was performed, 96-well half-area microplates 
(Corning Costar, USA) were coated with human TNFα (200 ng/well) in PBS and incubated overnight at 4ºC. 
The plate was then aspirated and washed once with 150 µl PBST (PBS with 0.05% (v/v) Tween® 20). 
Nonspecific binding sites were blocked with 3% (w/v) BSA in PBST for 1h at 37°C. Afterwards, the plate 
was washed as previously above. 50 µl of the purified anti-TNFα mAb samples (0.1 µl/ml) and calibration 
curve (Infliximab, Remicade® 10 mg/ml at 0; 0.01; 0.03; 0.05; 0.1; 0.2; 0.3 µg/ml in 1% (w/v) BSA in 
PBST) were added and incubated for 1h at 24ºC. Subsequently, the plate was washed 3 times as previously 
described. Detection was performed with the addition of 50 µl of secondary antibody anti-Human Kappa 
Light Chain-horseradish peroxidase antibody from goat (RRID: AB_ 2535630, Invitrogen) diluted 1:50,000 
(0.02 ng/ml) in 1% (w/v) BSA in PBST. The secondary antibody was incubated for 30 min at 24ºC, and the 
plate was washed 3 times as previously described. The reaction was developed with 50 µl TMB (3,3’,5,5’-
Tetramethylbenzidine, Merk, Germany) substrate for 30 min at 24ºC in the dark and stopped with 2 M H2SO4 
(Merck) for 30 min at 24ºC in the dark. Absorbances were registered at 450 nm, on Model 680 microplate 
reader (Bio-Rad, USA). 
6.2.5.4.2. Indirect flow cytometry – Anti-HER2 mAbs 
The activity of anti-HER2 monoclonal antibodies after purification through precipitation was determined 
by flow cytometry analysis. Cells were harvested with dissociation buffer (0.6 nM EDTA in PBS) and 
centrifuged at 300 xg for 5 min and resuspended in ice cold PBS with 3% (w/v) BSA (Sigma) to a final 
concentration of 1 x 106 cells/ml. Cell suspension with 1 x 105 cells were incubated with 0.5 µg of anti-HER2 
mAbs samples for 30 min at 4ºC. Afterwards, the cells were washed twice by centrifugation at 300 xg for 5 
min and resuspended in ice cold PBS with 3% (w/v) BSA. The detection was performed with addition of the 
secondary antibody Goat anti-Human IgG (H+L) Cross-Adsorbed Secondary Antibody conjugated with FITC 
(RRDI: AB_2535589, Invitrogen), diluted to a final concentration of 1:400. The secondary antibody was 
incubated for 30 min at 4ºC in the dark, the cells were then washed by centrifugation as previously described 
and 10 µl of propidium iodide (10 µg/ml, Sigma) added to the stained cells. Assessment of antibody binding 
were performed using Guava easyCyte™ (Merck Millipore). Flow cytometry data was analysed with FlowJo 
software (TreeStar). 
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6.3. Results and discussion 
6.3.1. Screening conditions for antibody precipitation 
Salts have a major effect in protein solubility and propensity to precipitate that many times follows the 
Hofmeister series. The Hofmeister series ranks the salt anions and cations according to their kosmotropic 
and chaotropic character, whether they have a salting-out or salting-in effect on proteins, respectively. An 
initial precipitation screen inspired in the Hofmeister series was designed for the precipitation of pure human 
polyclonal antibody (pAb) at 2 and 20 mg/ml (Figure 6.1A). All tested precipitation conditions lead to pAb 
precipitation, however the majority did exhibit a very low precipitation yield (<20%). In addition, when the 
precipitant concentration was constant, the 10-fold increase in protein concentration did not reflect a 10-fold 
increase in the precipitation yield. The combination of these results may indicate that the precipitant 
concentration is lower for the protein to precipitate in the set conditions. Nonetheless, and since protein-
protein interactions also play a major role in protein precipitation, the same rational was applied to human 
serum, with a total protein concentration of 0.5 mg/ml, with the aim to precipitate and capture the pAb. Two 
additional precipitation conditions were tested – 20% (w/v) PEG3350 and 2.5 M NaCl (Figure 6.1B). Both 
conditions were unveiled by a high throughput precipitation screening in the HTX lab at EMBL Grenoble. Of 
the 21 precipitation conditions tested, 5 presented a precipitation yield higher than 40% – 300 mM LiSO4; 
300 mM CaCl2; 300 mM CaCl2 @pH7; 20% (w/v) PEG3350 and 2.5 M NaCl (Figure 6.1B). However, none 
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Figure 6.1. Precipitation screen for antibody precipitation using 300 mM precipitant, except if otherwise 
specified. Precipitation yield for (A) pure polyclonal antibody at 2 mg/ml (black) and 20 mg/ml (grey) and 
(B) human serum at 0.5 mg/ml total protein with a dashed line at 40% precipitation yield threshold. (C) SDS-
PAGE for the precipitant condition with a precipitation yield higher than 40% with the supernatant and 
precipitation samples for each condition. Lane ID: M: Precious Plus Protein™ Dual Color Standards (from 
top to bottom: 200, 150, 100, 75, 50, 37, 25 and 20 kDa); arrows indicate HSA (66 kDa), Ig  heavy (Ig H; 50 
kDa) and light (Ig L; 25 kDa) chains. 
6.3.2. Affinity magnetic precipitation – pAb capture from human serum 
To provide antibody selectivity, magnetic particles functionalized with the 22/8 triazine (MP-22/8) 
synthetic ligand [227], were used as additives in the precipitant solution. The orbital shaking, temperature 
and incubation time of crude extract and precipitant with MP-22/8 were optimized (Figure 6.2) using human 
serum with a total protein concentration of 0.5 mg/ml. The orbital shaking (200 vs 0 RPM) had a great effect 
in the precipitation yield, however, depending on the precipitant, the orbital shaking had a positive, negative 
or neutral effect. For 300 mM LiSO4 and CaCl2, the lack of orbital shaking had a negative effect in the 
precipitation yield, whereas for 2.5 M NaCl the lack of orbital shaking had a positive effect in the precipitation 
yield. For 20% (w/v) PEG3350 the precipitation yield was not affected by the orbital shaking (Figure 6.2B). 
The orbital shaking at 200 RPM does improve the homogeneous dispersion of MPs in solution, nevertheless 
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both 2.5 M NaCl and 20% (w/v) PEG3350 precipitation conditions were unveiled in static crystallization 
assays. In the case of 20% (w/v) PEG3350, the orbital shaking, or lack of it, did not present any difference 
in the final precipitation yield, mainly due the MPs stability in this solution. On the other hand, in 2.5 M NaCl 
the same did not occur, the orbital shaking led to be a more stable condition to maintain the protein in 
solution, hence a lower precipitation yield (Figure 6.2B).  
Protein-protein interactions mainly occur by weak interactions as hydrophobic interactions, hydrogen 
bonds, salt bridges or van der Walls forces [228]. Since precipitation is dependent on protein-protein 
interactions, and being these interactions temperature-dependent, the precipitation yield was assessed at 
4ºC and 20ºC (Figure 6.2C), at high salt concentration or in the presence of hygroscopic species, such as 
PEG. This effect is more pronounced at lower temperatures, where hydrogen bonds and salt bridges are 
weakened [229], contributing to the destabilization of the proteins in solution. This explains the results 
obtained, since protein precipitation with 20% (w/v) PEG3350 and 2.5 M NaCl showed a greater increase 
in the magnetic precipitation yield from 20ºC to 4ºC. On the other hand, the change in temperature did not 
have a major influence in protein magnetic precipitation yield with 300 mM of LiSO4 and CaCl2. At last, the 
incubation time was optimized, and two time points were checked – 1 h and 24 h. In all conditions, without 
exception, the 24h incubation led to a lower magnetic precipitation yield (Figure 6.2D). This phenomenon 
can be due to the equilibrium that is established between protein in solution and protein precipitated 
Additionally, the lower precipitation yield was not proportional to a higher antibody purity and capture. In this 
way, the best incubation condition was 200 RPM at 4ºC for 1h. For the tested precipitants, the best 
performing one was 20% (w/v) PEG3350, as it was the condition with higher pAb content in the elution 
fraction. Since precipitant concentration does play a major role, three different concentrations of LiSO4, 
CaCl2 (100 mM; 200 mM and 300 mM), PEG3350 (10%; 20% and 30% (w/v)) and NaCl (1.5 M, 2.5 M and 
3.5 M) were tested in the presence of MP-22/8 (Figure 6.3A), MP-Dextran (Figure 6.3B) and in the absence 
of MPs (Figure 6.3C). PEG3350 showed to be the best precipitant condition with higher antibody recovery 
and purity (Figure 6.3).  
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Figure 6.2. Magnetic precipitation optimization with MP-22/8. (A) Schematic representation of the 
Magnetic precipitation assay. (B) Optimization of the precipitation orbital shaking for 1 hour at 20ºC with 
200 RPM (black) and 0 RPM (grey). (C) Optimization of the precipitation temperature for 1 hour at 200 
RPM at 4ºC (black) and 20ºC (grey). (D) Optimization of the precipitation time at 4ºC with 200 RPM for 
1 hour (black) and 24 hours (grey). (E) SDS-PAGE for the Magnetic precipitant at 4ºC for 1 hour at 200 
RPM. Lane ID: M: Precious Plus Protein™ Dual Color Standards (from top to bottom: 200, 150, 100, 75, 
50, 37, 25 and 20 kDa); arrows indicate HSA (66 kDa), Ig  heavy (Ig H; 50 kDa) and light (Ig L; 25 kDa) 
chains. 
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Figure 6.3. Magnetic precipitation of human serum for pAb recovery. In the presence of (A) MP-22/8, (B) 
MP-Dextran and (C) No MP, using the four main precipitants - LiSO4, CaCl2, at 100, 200 and 300 mM; PEG 
3350 at 10, 20 and 30% (w/v) and NaCl at 1.5, 2.5 and 3.5 M. Legend: Total protein precipitate (black), Ig 
recovery (light grey) and Ig purity (grey).  
 
 
Although the MPs were functionalized with a synthetic affinity ligand with a Ka of 7.7 × 105 M-1 in 50 mM 
phosphate buffer at pH 8 [136], the affinity between two molecules is regulated by the interactions 
established between them dependent on the solution conditions, such as ionic strength or pH. The 22/8 
triazine affinity ligand interaction with antibodies, namely IgG, can be done at both the Fc and Fab domains, 
with higher affinity towards the Fc [230]. Nonetheless, affinity interactions are a combination of hydrophobic, 
H-bonding and electrostatic interactions, strongly dependent on the pH and ionic strength [230]. All 
precipitant solutions presented a 5-8 pH range, except LiSO4 that had a 3-4 pH range. Even though 
theoretical and experimental data suggest that pH is the major factor for 22/8-IgG binding, the fact that the 
elution from MP-22/8 was performed with PBS at pH 7.4. This elution condition, suggests that the pH did 
not have the major contribution in the present situation, but the ionic strength of the precipitant solutions 
did, not only due to the elution buffer but also due to the best performing precipitant – 20% (w/v) PEG3350 
– that presented the lower ionic strength. PEG is a polymer known to attract water molecules from the 
protein’s surface increasing its interprotein interactions, leading to protein precipitation. Furthermore, in 
solution, PEG presents a amphiphilic character, exhibiting hydrophilic and hydrophobic characteristics, 
although neglectable PEG-protein interaction can induce protein conformational changes leading to the 
exposure of the protein hydrophobic residues that may interact with other proteins, PEG molecules or small 
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The increasing PEG3350 concentration (from 10% to 30% (w/v)) led to a higher pAb recovery and purity 
in the presence of MP-22/8 as additives, reaching 80% purity and 50% recovery, whereas when MP-Dextran 
was used as additive 43% pAb was recovered with 23% purity. When No MPs were added, similar results 
were obtained with 47% recovery and 32% purity (Figure 6.4A;B). In the absence of PEG, having only PBS 
in solution, no pAb was recovered in the elution fraction (Figure 6.4A;B). Without the presence of PEG, 
having only PBS in solution, no pAb was recovered in the elution fraction (Figure 6.4A;B). The low recovery 
yields obtained were due to the co-elution of human serum albumin (HSA), being the most abundant protein 
in human serum, and, even though most HSA did not precipitate or bind to the MPs (Figure 6.4C), a portion 
of this protein still precipitated and co-eluted with pAb. Nevertheless, at concentrations higher than 20% 
(w/v) PEG3350, pAb was only recovered in the elution fraction (Figure 6.4C). 
 
6.3.3. Affinity magnetic precipitation – mAb capture from CHO clarified 
supernatant  
Affinity magnetic precipitation was tested for the capture of two monoclonal antibodies (mAbs), both 
IgG1– anti-TNFα and anti-HER2 – using PEG3350 as precipitant. The incubation condition was performed 
with 200 RPM at 4ºC for 1h with the respective precipitant solution. As MPs control, an assay with MP-
Dextran and without MPs were conducted; while PBS at pH 7.4 was used as a precipitant control. MP-
Dextran were used as control since they are an intermediate product of the MP-22/8 synthesis and the use 
of high salt solution (> 0.25 M) and PEG may lead to non-specific interactions between the medium proteins 
and the solid matrix [232].  
Figure 6.4. Magnetic Affinity Precipitation of human serum plasma crude extract for pAb purification. (A) pAb recovery 
and (B) pAb purity using MP-22/8, MP-Dextran and No MP with 10 (black), 20 (light grey) and 30% (w/v) (grey) 
PEG3350. (C) SDS-PAGE for the best affinity magnetic precipitation condition tested – MP-22/8 with 10, 20 and 30% 
(w/v). Lane ID: M: Precious Plus Protein™ Dual Color Standards (from top to bottom: 200, 150, 100, 75, 50, 37, 25 and 
20 kDa); arrows indicate HSA (66 kDa), Ig  heavy (Ig H; 50 kDa) and light (Ig L; 25 kDa) chains. 
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 For anti-TNFα mAb capture, three different PEG3350 concentrations were tested – 10%, 20% and 30% 
(w/v) – to assess IgG recovery and purity in the elution fraction (Figure 6.5). The maximum of recovery was 
observed with 20% (w/v) PEG3350. For 10% (w/v) PEG3350, approximately 10% of the mAb did not 
precipitate onto the magnetic particles and was leaked in the supernatant fraction. On the other hand, with 
30% (w/v) PEG3350, 20% of the mAb precipitated without binding to MP-22/8 (Figure 6.5C). Although pure, 
the recovery of this fraction comprises an additional centrifugation step in the downstream pipeline of anti-
TNFα mAb capture. In this way, the best recovery and purity yields were obtained with 20% (w/v) PEG3350 
using MP-22/8, reaching a 97% recovery and 99% purity, as opposed to 31% recovery and 52% recovery 
from MP-Dextran and no MP, respectively, and 10% recovery using PBS (Figure 6.5).  
 
For anti-HER2 mAb, only the best precipitant solution was tested – 20% PEG3350 – with 200 RPM at 
4ºC for 1h and the same MPs controls were established – MP-Dextran and no MP (Figure 6.6). The best 
results were obtained using MP-22/8 with 100% recovery and 63% purity, whereas for MP-Dextran 89% 
recovery and 55% purity was obtained. When no MPs were used, the recovery yield was 87% with 49% 
purity.  
Figure 6.5. Magnetic Affinity Precipitation of anti-TNFα mAb crude extract. (A) mAb recovery and (B) mAb 
purity using MP-22/8, MP-Dextran and No MP with 10, 20 and 30% (w/v) PEG3350. (C) SDS-PAGE for 
the best affinity magnetic precipitation condition tested – MP-22/8 with 10, 20 and 30% (w/v). Lane ID: M: 
Precious Plus Protein™ Dual Color Standards (from top to bottom: 200, 150, 100, 75, 50, 37, 25 and 20 
kDa); arrows indicate IgG heavy (Ig H; 50 kDa) and light (IgG L; 25 kDa) chains. 
Figure 6.6. Magnetic Affinity Precipitation of anti-HER2 mAb crude extract with 20% (w/v) PEG3350. Anti-
HER2 (A) recovery and (B) purity assessment using MP-22/8, MP-Dextran and No MP. (C) SDS-PAGE for 
the precipitant conditions tested. Lane ID: M: Precious Plus Protein™ Dual Color Standards (from top to 
bottom: 200, 150, 100, 75, 50, 37, 25 and 20 kDa); arrows indicate IgG heavy (Ig H; 50 kDa) and light (IgG 
L; 25 kDa) chains. 
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The two mAbs tested were produced in two different types of clarified CHO cell supernatant. While anti-
TNFα mAb was produced in a serum free medium, anti-HER2 mAb was produced in a serum containing 
medium, making this a less pure medium with lower IgG to total protein ratio. Since protein concentration is 
one of the factors for protein precipitation – the higher the target protein concentration, the higher the 
precipitation yield – the ratio IgG to total protein should be as high as possible. On the other hand, if the 
ratio is low, multiple rounds of precipitation can be performed until higher purities are obtained.  
The presence of aggregates and biological activity were evaluated after the antibodies capture by affinity 
magnetic precipitation. Three different techniques were used: (i) HPLC size-exclusion for both mAbs; (ii) 
indirect enzyme-linked immunosorbent assay (ELISA) for anti-TNFα mAbs and (iii) indirect flow cytometry 
for anti-HER2 mAbs, to verify the antibody integrity after capture. 
Size exclusion chromatography was performed in order to evaluate if IgG aggregates were present or 
formed along the purification process. The magnetic precipitation of anti-TNFα mAbs in the presence of MP-
22/8 did not show aggregates formation, presenting 98% HPLC-purity across all PEG3350 concentrations. 
The same behaviour was observed in the presence of MP-dextran, presenting 97% HPLC-purity. When no 
MPs were present, high HPLC-purities of 98% were only possible with 20% and 30% (w/v) PEG3350. For 
anti-HER2 mAb, magnetic precipitation with MP-22/8 showed the presence of possible mAb aggregates, 
representing 30%, being the mAb monomer present with 66% HPLC-purity. On the other hand, when MP-
dextran was present, the aggregates formation was reduced to 3% and the mAb monomer HPLC-purity 
increased to 84%.   
The biological activity of purified anti-TNFα mAb was evaluated by indirect ELISA (Figure 6.7A). The 
elution fractions from the magnetic precipitation using PEG 3350 as precipitant at different concentrations 
in the presence of either 22/8 or dextran-coated MPs were analyzed, as well as the eluted fractions of mAb 
precipitation without the presence of MPs. Magnetic precipitation - MPs in the presence of PEG3350 as 
precipitant - presented higher mAb activity when compared to magnetic fishing - MPs in the presence of 
PBS (Figure 6.7A) - indicating that PEG can stabilize the mAb along the precipitation steps and does not 
diminish nor interfere with the mAb biological activity. In the conditions tested, mAb activity varied depending 
on the MP present. Nonetheless, amongst the different PEG 3350, 10% (w/v) showed to be the best 
precipitant concentration with both MPs. In the presence of MP-22/8 with 10% (w/v) PEG3350 a 60% anti-
TNFα mAb activity was observed. However, the highest mAb activity was achieved in the presence of MP-
dextran with 10% (w/v) PEG3350, achieving 84% activity (Figure 6.7A). 
For anti-HER2 mAb, since its antigen is the transmembrane protein HER2, its activity was evaluated by 
indirect flow cytometry (Figure 6.7B). Anti-HER2 mAb magnetic precipitation was evaluated in the presence 
of MP-22/8, MP-dextran and no MP presence having as precipitant 20% (w/v) PEG3350. For the flow 
cytometry analyses SKBR3 cells were used to evaluate the activity, whereas HeLa cells were used as a 
negative control. Overall, PEG3350 precipitation did not affect mAb activity, except when MP-dextran was 
present for the magnetic precipitation. A summary of mAb yield, purity and activity is reported in Table 6.2. 
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Table 6.2. Summary of paramount parameters for affinity magnetic mAbs precipitation – yield, purity and 
activity at the elution fraction having as precipitant 20% (w/v) PEG3350 in the presence of MP-22/8 and MP-
dextran. 
  Yield Purity Activity 
MP-22/8 MP-dextran MP-22/8 MP-dextran MP-22/8 MP-dextran 
Anti-TNFα mAb * 97% 31% 98% 52% + ++ 
Anti-HER2 mAb * 100%  89% 63% 55% +++ ++ 




The viability of using affinity magnetic precipitation for antibody capture from clarified cell supernatant was 
for the first time demonstrated. Three different antibodies sources were tested: (i) pAbs from human serum, 
(ii) anti-TNFα mAb and (iii) anti-HER2 mAb from clarified CHO cell supernatant. The study comprised the 
discovery of the best precipitant and precipitation conditions using MPs functionalized with the 22/8 triazine 
synthetic ligand previously discovered to have affinity towards antibodies [227]. The addition of MPs was 
demonstrated to be crucial to achieve higher antibody purity and recovery. Nonetheless, the optimization of 
the precipitant and precipitation conditions also revealed to be essential to minimize antibody loss and 
maximize its purity. The best affinity magnetic precipitation condition was using PEG3350 as precipitant 
with varying concentration of 20% and 30% (w/v) for 1h at 4ºC with 200 RPM orbital shaking. For pAbs 
capture from human serum it was possible to reach 80% purity and 50% recovery with 30% (w/v) PEG3350. 
For both mAbs, the best result was accomplished with 20% (w/v) PEG3350 reaching a 97% recovery and 
99% purity for anti-TNFα mAb and 100% recovery and 63% purity for anti-HER2 mAb. The elution was 
always performed using PBS at pH 7.4, this may lead not only to the antibody capture but also to 
conditioning and concentration in one single step. Contrary to the current Protein A affinity chromatography 
Figure 6.7. Activity of anti-TNFα and anti-HER2 mAbs purified by magnetic precipitation. (A) Indirect ELISA 
of the elution fraction of anti-TNFα mAb in the presence of MP-22/8, MP-dextran and No MP at different 
PEG3350 concentration (10%, 20% and 30% (w/v)) and PBS. (B) Indirect flow cytometry of the elution fraction 
of anti-HER2 mAb in the presence of 20% (w/v) PEG3350 and PBS for SKBR3 and HeLa cells. 
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harsh pH denaturing elution condition [219], the combination of the precipitant condition, with PEG, along 
with the elution condition with PBS makes this a biocompatible and mild capture process for mAbs 
purification [231,232].  
In this way, and with the continuous growth of the biosimilar market, the lower costs associated, the 
scalability of precipitation process, and the use of an affinity synthetic ligand to provide selectivity towards 
the target molecule, makes affinity magnetic precipitation a new platform for the capture of high added value 
proteins directly from the complex cell supernatant. 
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General conclusion and Future work 
The biopharmaceutical industry is currently under a great change, mainly due to the development 
and approval of high added value biosimilar molecules. Still, one of the bottlenecks in protein production 
is their downstream processing, namely its purification. The current gold standard in purification of high 
added value biopharmaceuticals rely in packed bed chromatographic strategies. Over the last 15 years, 
several researchers in industry and academy joined efforts in the search for affinity reagents based on 
fully biological or fully synthetic scaffolds for protein purification. Regardless, due to the limitations 
demonstrated by chromatographic techniques to deal with the high titers and volumes produced 
upstream, a new approach relies in Anything But Chromatography (ABC) methodologies. 
In this work, the potential of having a combination of two ABC methods was evaluated for the 
development of a new non-chromatographic platform for biopharmaceutical purification. Inspired in 
protein crystallization, this work focused on developing a new precipitation process triggered by 
magnetic nano- and micro-particles used as additives, creating a new hybrid purification process named 
magnetic precipitation. The research strategy was divided in two sections. Firstly, protocols to develop 
new simpler affinity ligands towards relevant biopharmaceuticals (human serum albumin (HSA)) were 
done, followed by optimization of strategies for ligand attachment onto magnetic particles (MPs). 
Secondly, crystallization of model proteins having affinity driven magnetic particles was evaluated in 
terms of crystal growth and diffraction quality. Lastly, affinity driven magnetic precipitation was assessed 
in the purification of antibodies from complex media.  
Firstly, we evaluated the potential of magnetic particle functionalization with synthetic ligands in a 
triazine-based scaffold that was rationally designed for the affinity purification of a biopharmaceutical 
relevant protein such as HSA. In order to produce stable ligands with a wide variability in binding 
capacities, the triazine-ring scaffold was chosen for the rational approach to define and produce 64 
synthetic ligands to bind HSA domain II. Of the 64 ligands screened, two showed the most promising 
binding capacity to capture HSA from serum crude extract (100% recovery yield), however it was only 
possible to achieve high yield and purity with one triazine synthetic ligand, named A6A5. Once 
established the ability to used synthetic ligands in conventional packed bed chromatography support, 
we here demonstrated the functionalization of magnetic particles with biological ligands with affinity 
towards pharmaceutical relevant proteins, such as antibodies. The functionalization and capture with 
the affinity driven magnetic fishing led to high recovery and purity of polyclonal antibodies from complex 
crude extract as human serum.  
The successful functionalization of two different solid supports and capture with high recovery yield 
and final protein purity led to the challenge to further improve the magnetic fishing method by coupling 
it with the precipitation method. The proof-of-concept was performed with three model proteins (of those, 
two were commercially available, HEWL and trypsin, and one produced in house, GFP), to evaluate the 
performance of magnetic particles in the crystallization of those proteins. The magnetic particles, here 
used as additives, did not hamper the crystallization, moreover crystallization conditions for trypsin were 
altered in the presence of affinity driven magnetic particles, as the usually used inhibitor (benzamidine) 
could be removed from the crystallization conditions without diminishing crystal quality or altering protein 
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structure. This work proved possible to add magnetic particles to a precipitation process maintaining the 
proteins’ quality and enabling its incorporation in the purification pipeline of high added value proteins.  
With the attempt to use magnetic precipitation in the proteins’ purification train, different antibodies 
from different crude extracts were tested using specific precipitation conditions for the target proteins, 
as well as magnetic particles functionalized with a triazine synthetic affinity ligand to target and capture 
antibodies from the crude extract. The new method enabled the purification of antibodies, without any 
previous conditioning, with a final purity up to 99% and a recovery yield up to 97% in a single step. 
This work highlights the synergy of different separation methods to accomplish a high purity and high 
recovery of biopharmaceutical relevant molecules, enabling to overcome the current bottlenecks in the 
conventional downstream processing regarding the high titers and working volumes produced upstream. 
The work developed here can be integrated in the current purification techniques, not with the objective 
of replacing the implemented chromatographic methods, but as an additional strategy to overcome the 
current challenges. Here, this method can cope with the demands from upstream processing enabling 
in step the capture, conditioning and concentration of the target molecule. Afterwards, the 
chromatographic train can be designed to provide a high quality and high purity product. 
 
Although this was not studied in this work, the mechanism through which differently coated MPs 
influence and trigger nucleation and protein crystal growth deserves investigation. The current work was 
focused on a proof-of-concept to study the effect of MPs as additives in the crystallization of model 
proteins for structure determination. Future work will be done to test this technology in difficult-to-
crystallize proteins or to replace required additives in protein crystallization. Furthermore, assays were 
centered in the vapor diffusion method. Although this is currently the most used protein crystallization 
method, it is of interest to evaluate the effect of MPs when used in other methods, such as batch or free 
interface diffusion. 
As for the purification of antibodies, the integration of magnetic precipitation in the current 
downstream pipeline, having same adaptations to reduce costs and time, should be tested. In line with 
this, the scale-up of this method is critical for the hypothesis here raised, as well as working in cGMP 
conditions.  
  
Overall, the work here presented reinforces that magnetic fishing and crystallization/precipitation 
techniques can be used in synergy for protein 3D structure determination and purification. 
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Annexes 
Annex 1 – Monoclonal antibodies production: Anti-TNFα monoclonal antibody 
and anti-HER2 monoclonal antibody  
The anti-tumor necrosis factor alpha (anti-TNFα) mAb and anti-human epidermal growth factor 
receptor 2 (anti-HER2) mAb were produced in FreeStyle™ 293-F cells (Thermo Fisher Scientific, 
Waltham, Massachusetts, USA) transfected using polyethylenimine (PEI) (Polysciences, Warrington, 
Pennsylvania). Cell culture of FreeStyle™ 293-F cells was conducted at 200 RPM (Inova incubator) with 
8% CO2. MAbs were produced in a small (3 ml) scale in Nunc 24-well plate, with round untreated bottom, 
and larger (100 ml) scale in 500 ml culture Erlenmeyer flask. For the small-scale production, 24 hours 
previously to the transfection, cells were inoculated at 0.5 x 106 cells/mL, and in the following day 
transferred to a culture plate at a 1.0 x 106 cells/mL in 3 ml of fresh FreeStyle™ 293 medium (Thermo 
Fisher Scientific), for anti-TNFα mAbs production and in fresh DMEM medium (Dulbecco's Modified 
Eagle's Medium) (Gibco®, Carlsbad, CA) supplemented with 5% FBS (fetal bovine serum) for anti-HER2 
mAbs production. PEI (4.5 μg or 9 μg) and polycistronic mAb DNA plasmid (1.5 μg or 3 μg) for the heavy 
and light chains were separately diluted in fresh FreeStyle™ 293 medium and mixed at a 1:3 ratio of 
DNA to PEI, for a final volume of 300 µl. After 30 min incubation at room temperature, the PEI:DNA 
mixture was added to the cell suspension. Protein expression was evaluated 72 hours after transfection 
by Western Blot. For mAb large scale production, 24 hours before the transfection, 100 ml of 0.5 x 106 
cells/ml were seeded. In the following day, cells at 1.0 x 106 cells/mL were transfected with PEI:DNA 
mixture. DNA plasmid and PEI were separately diluted in fresh FreeStyle™ 293 medium, for anti-TNFα 
mAb production and DMEM medium supplemented with 5% FBS, for anti-HER2 mAbs production, and 
mixed in a 1:3 ratio and incubated for 15 min at room temperature for further cell transfection. The cells 
were harvested after seven days in culture by centrifugation at 300 xg at room temperature for 10 min 
and the supernatant filtrated through a 0.45 μm filter. 
